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In 2019, an estimated 56 million women were living with female genital schistosomiasis (FGS), a 
neglected tropical disease that results when eggs from the waterborne parasite Schistosoma (S.) 
haematobium are deposited in reproductive tissues. FGS has been associated with important sexual 
and reproductive health consequences, including ectopic pregnancy, infertility, and human 
immunodeficiency virus (HIV-1) acquisition. Inflammation in the female genital tract is likewise 
associated with HIV-1 acquisition and non-optimal  cer ico aginal microbiota ha e also been 
associated with adverse reproductive consequences, including pelvic inflammatory disease, 
infections of pregnancy and the post-partum period and HIV-1 acquisition. The cervicovaginal 
environment of women with FGS has not been fully described. The overall aim of this PhD thesis 
was to describe the cervicovaginal microbiota (including STI) and the cervicovaginal immune 
environment, focusing on cytokines and chemokines, in Zambian women with and without FGS 
and to explore the association of FGS with HIV-1 incidence.  
 
Methods:   
This PhD work was nested within the bilharzia and HIV (BILHIV) study, which recruited 
women aged 18-31, sexually active, and not pregnant from the HPTN 071 (PopART) Population 
Cohort, from which longitudinal information on HIV-1 infection status was available. Women 
enrolled in the BILHIV study (n=603) were assessed for FGS through self-collected genital 
swabs and clinic-collected CVL (n=527). For this PhD work, all BILHIV participants with FGS 
(n=30) and all participants with probable FGS (n=25) were selected, and three FGS negative 
participants were selected for every FGS and probable FGS participant using a random number 
 v 
generator, frequency matched by age to participants with FGS. Among selected participants, 
cervicovaginal microbiota and STI were quantified using PCR and the associations of presence, 
median (IQR), and log concentration mean with FGS status were assessed. The concentrations of 
17 soluble cytokines and chemokines were quantified in cervicovaginal lavage (CVL) by a 
multiplex bead-based immunoassay to evaluate the association between FGS and concentration 
of cervicovaginal cytokines and chemokines. To explore the association of FGS with HIV-1 
incidence, the rate of HIV-1 seroconversion was assessed among women who were HIV-1 
negative at enrolment in the HPTN 071 (PopART) Population Cohort (n=492) and associations 
with FGS were evaluated with exact Poisson regression.  
 
Results:  
Of 603 women enrolled in BILHIV, 5.0% (30/603) had FGS, defined as PCR-detected 
Schistosoma DNA in any of three genital specimens (cervical swab, vaginal swab, or CVL). The 
prevalence of schistosome infection in the study population was 5.5% (33/603) by urine 
microscopy and 15.1% (91/601) by urine CAA. The presence and concentration of 
cervicovaginal species did not differ between participants with or without FGS. However, a 
higher proportion of participants with FGS had T. vaginalis compared to FGS negative women 
(p=0.08). An exploratory analysis suggested an association of T. vaginalis presence with FGS 
among omen ith 2 Schistosoma PCR positive genital specimens (50.0%, 8/16) compared 
with FGS negative (21.5% 34/158, p=0.01).  
 
There was no difference in the concentrations of cytokines or chemokines between participants 
with and without FGS. After adjusting for potential confounders, an exploratory analysis of 
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omen ith 2 genital specimens ith detectable Schistosoma DNA (n=15) showed a higher 
Th2 (IL-4, IL-5, and IL-13) and pro-inflammatory (IL-15) expression pattern in comparison to 
FGS negative women. After adjusting for multiple testing, the association between IL-4 
(p=0.037) and IL-5 (p<0.001) and FGS were unlikely to be due to chance.  
 
Incident HIV-1 infections were observed in 4.1% (20/492) participants. Women with FGS were 
twice as likely to seroconvert as women without FGS but with no statistical evidence for a 
difference (aRR 2.16, 95%CI [0.21 12.30], p=0.33). Exploratory analysis suggested a point 
estimate consistent with increased risk of HIV-1 acquisition among omen ith 2 positi e 
genital PCR specimens (RR 6.02, [0.58 34.96]), p=0.13), without statistical evidence of a 
difference after adjusting for potential confounders. 
 
Conclusion: FGS may alter the cervicovaginal environment, particularly in high burden 
infections. There are higher HIV-1 seroconversion rates in women with FGS, although power to 
detect an association was limited in this analysis. The burden of disease should be assessed and 
correlated with outcomes in participants with FGS. Ideally, a longitudinal study would evaluate 
the interaction between FGS, HIV-1, and the cervicovaginal environment to provide additional 
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Chapter 1  Introduction 
 
Schistosomiasis is a Neglected Tropical Disease, caused when human hosts come into contact with 
fresh water contaminated by Schistosoma larvae [1, 2]. The cercarial larvae penetrate intact skin and 
become schistosomula which mate and mature within the host bloodstream [1, 3]. Adult 
Schistosoma (S.) haematobium blood flukes often inhabit the vesicular venous plexus, where the 
venous anastomoses with the female reproductive tract allows parasite eggs access to the urogenital 
organs [4]. Instead of exiting the human host through the urinary tract to continue the life-cycle, 
some S. haematobium eggs become trapped in tissue of the female genital tract, giving rise to 
female genital schistosomiasis (FGS). Eggs that return to fresh-water in human excreta hatch to 
release miracidia. When these miracidia find a suitable snail intermediate host, asexual reproduction 
commences, ultimately releasing cercariae and completing the life-cycle[1]. 
 
Globally, 779 million people are estimated to be at risk for Schistosoma infection [5]. Six species of 
Schistosoma can infect humans: Schistosoma mansoni, Schistosoma haematobium, Schistosoma 
japonicum, Schistosoma mekongi, Schistosoma intercalatum, and S. guineensis [1, 5]. This PhD 
thesis will focus on S. haematobium, which primarily occurs in the Middle East and sub-Saharan 
Africa. S. mansoni, S. intercalatum, S. guineensis and S. mansoni can also be found in sub-Saharan 
Africa and S. mansoni is also present in the Americas [1, 5]. Two species are localised to Asia, with 
S. mekongi along the Mekong River in Laos and Cambodia and S. japonicum primarily in China and 
the Philippines [1, 5]. The global burden of schistosomiasis is estimated at 1.7 -4.5 million 
disability-adjusted life years with morbidities in children including anaemia and stunted growth [5]. 
Thus, the World Health Organization (WHO) recommends preventive chemotherapy to prevent 
morbidity due to schistosome infection. WHO estimates that 290.8 million people required 
preventive chemotherapy for schistosomiasis in 2018, 90% of whom live in Africa [6]. Modelling 
data suggests that 82 million African women are living with Schistosoma infections [7], and urinary 
and genital manifestations are both commonly seen in women. Varied estimates of the population 
prevalence of FGS amongst reproductive age women are available from cross-sectional studies, 
ranging from 32 to 75% (32% (n=263), Tanzania [8]; 46% (n=24), Ghana [9]; 65% (n=51), Malawi 
[10]; 75% (n=61), Niger [11]). Thus, the approximately 10,000 FGS cases reported in the published 
literature are likely to be an underestimate of the true FGS burden in sub-Saharan Africa [12]. 
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In 2019, UNAIDS estimates that 38 million people worldwide are living with HIV-1 infection, 
54.0% (20.7 million) of whom live in Eastern and Southern Africa [13]. In this region, areas of 
Schistosoma endemicity overlap with areas of high HIV-1 prevalence (Figure 1.1) [14]. In 1994, 
Feldmeier et al, published an editorial suggesting that FGS might be a risk factor for HIV-1 
acquisition, hypothesizing biological plausibility for a causal association and ushering in an era of 
FGS research and advocacy [15]. Subsequent modelling studies from sub-Saharan Africa suggested 
that each S. haematobium infection per 100 individuals was associated with a 2.9% increase in HIV-
1 prevalence [16]. Likewise, cross-sectional studies have shown an association between urogenital 
schistosomiasis and HIV-1 [17], though there is evidence both for an against this association [18, 
19]. 
 
Figure 1.1  Overlapping distributions of schistosomiasis and HIV-1 prevalence 
 
Adapted from [14] 
 
1.1 Urogenital schistosomiasis 
 
Autopsy studies in S. haematobium endemic areas suggest that parasite eggs are primarily found in 
the bladder (urinary schistosomiasis) but can also commonly be found in the female genital tract 
with a higher proportions of eggs in the cervix and vagina compared with the Fallopian tubes and 
ovaries [20, 21]. Urinary schistosomiasis and  
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FGS can overlap, with up to 61% of women with biopsy-proven FGS also having urinary S. 
haematobium infection [22, 23]. Recognizing the propensity for urinary and genital schistosomiasis 
to co-exist, the WHO convened an informal working group in 2009 to propose terminology and 
discuss the potential association between FGS and human immunodeficiency virus-1 (HIV-1) [24]. 
FGS as defined as the presence of o a in the female reproducti e organs or a characteristic 
clinical patholog  [24]. In analogy to the French bilharziose urogenitale , a new term for urinary 
S. haematobium infection, urogenital schistosomiasis , was proposed [24]. In the literature, 
urogenital schistosomiasis  is commonly used to refer to women with urinary S. haematobium 
infection.  
 
1.2 Diagnostics - Schistosoma and female genital schistosomiasis 
 
Urinary S. haematobium infection can be diagnosed ith either of t o reference standard  
diagnostics, urine microscopy or circulating anodic antigen (CAA). Currently, however, a 
reference standard  diagnostic does not e ist for genital schistosomiasis. Thus, an FGS evaluation 
is often based on a combination of diagnostic tests including CAA, urine microscopy, colposcopy, 
tissue-based diagnostics [biopsy, Papanicolaou (pap) smear, wet prep], and polymerase chain 
reaction [PCR]) [17, 25, 26].  
 
1.2.1 Colposcopy and visual identification of FGS-related cervicovaginal manifestations 
 
Four primary cervicovaginal clinical manifestations have been associated with FGS: grainy sandy 
patches, homogenous yellow sandy patches, rubbery papules, and abnormal blood vessels (Figure 
1.2) [27, 28]. While abnormal blood vessels are included as an FGS criterion in the WHO Pocket 
Atlas (Figure 1.2), they are less specific than sandy patches (grainy and homogeneous) and rubbery 
papules, primarily due to the association of abnormal cervical blood vessels with cervical dysplasia 
[28]. However, sandy patches (grainy and homogeneous) and rubbery papules also lack specificity. 
Homogeneous yellow sandy patches have been associated with sexually transmitted infections 
(STIs) (human papillomavirus [HPV], herpes simplex virus type 2 [HSV-2], and Chlamydia (C.) 
trachomatis [26]) and rubbery papules can appear similar to non-infectious findings such as 
Nabothian cysts [28].  
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Figure 1.2  Visual findings suggestive of female genital schistosomiasis 
 
adapted from [14, 27]  
 
The WHO definition for FGS includes both the presence of parasite eggs in genital tissue as well as 
a characteristic clinical patholog  [24] which can be identified by a trained medical professional 
and requires the insertion of a vaginal speculum and magnification of the vagina and cervix. For 
clinical purposes, either criterion would suffice to provide a patient with praziquantel treatment. 
However, there may be challenges in research settings when cervicovaginal clinical manifestations 
alone are used to diagnose FGS in the absence of tissue diagnostics or molecular methods. For 
example, the interpretation of FGS cervicovaginal manifestations may not be reproducible across 
reviewers (Bustinduy, A., unpublished data) and the imperfect specificity of FGS cervicovaginal 
manifestations presents the possibility for confounding by STIs and cervical dysplasia [26, 28].  
 
1.2.2 Polymerase chain reaction for the detection of Schistosoma DNA 
 
Early FGS studies employed tissue-based diagnostic techniques (biopsy, wet-prep, pap smear) [10, 
23] to identify S. haematobium eggs in genital tissue. However, FGS researchers have advocated for 
limiting the routine use cervicovaginal biopsy in FGS research due to the theoretical risk of HIV-1 
acquisition at the biopsy site [29]. PCR detection of Schistosoma deoxyribonucleic acid (DNA) has 
been identified as a semi-quantitative and less invasive means to identify the presence of viable 
parasite eggs, compared with biopsy. The sensitivity of Schistosoma PCR is imperfect, as illustrated 
by a Zimbabwean study that evaluated the performance of CVL PCR [29]. However, this may be 
related to the use of visually identified FGS as a reference standard. In the Zimbabwean study, PCR 
for Schistosoma DNA (n=83) was performed on CVL and compared against a composite FGS 
endpoint defined by the results of tissue biopsy (n=6), wet mount (n=25), pap smear (n=74) and 
FGS-related cervicovaginal manifestations (n=83) as the reference standard with a sensitivity of 
 5 
53% and specificity of 70% [29]. The BILHIV study, a cross-sectional study in Zambia reported 
that vaginal or cervical swab Schistosoma PCR had a sensitivity of 80% compared with a composite 
endpoint of any genital PCR positive specimen (CVL, vaginal swab or cervical swab) [25].  
 
1.2.3 Circulating Anodic Antigen 
 
Active infection with the genus Schistosoma can be detected by the presence of CAA, a 
pol saccharide antigen regurgitated from the parasite s gut into the host s bloodstream [30, 31]. 
CAA is partially filtered by the kidneys, making it possible to measure CAA in both serum and 
urine specimens [30, 32]. The concentration of CAA in urine is lower compared with blood, 
requiring a concentration step prior to urine specimen processing [30]. Parasite antigens decline 
after parasite death, making them useful markers of active schistosome infection, as well as 
response to praziquantel treatment [30, 33-35]. CAA has higher sensitivity than urine microscopy, 
and this is particularly evident in areas of low background Schistosoma prevalence, since CAA is 
more likely than urine microscopy to detect low intensity infections [36]. However, while useful in 
detecting active infection, detectable CAA levels do not confirm genital infection status. 
 
1.2.4 Urine Microscopy 
 
S. haematobium eggs are excreted in the urine and traditional microscopy can be used to identify the 
terminal-spined morphology diagnostic of active infection [37]. There are challenges intrinsic in the 
use of traditional microscopy including variable egg excretion based on host circadian rhythm and 
volume status [38], as well as a diminished ability to detect true positive S. haematobium infections 
in low-endemic settings [39]. The intensity of S. haematobium infection can be categorized into 
light (1-49 eggs) and heavy (>=50 eggs) by the number of eggs excreted per 10mL urine [39, 40]. 
Additional infection intensity sub-classes have also been proposed: ultra-light (1-5 eggs) and light 
(11-49 eggs) [39]. Urine microscopy may be appropriate for moderate and heavy S. haematobium 
infections, but this technique is less likely to successfully detect light [36] or ultra-light infections 
[39]. The diminished sensitivity of urine microscopy is particularly important in communities 
targeted for elimination, especially after receiving repeated preventive chemotherapy and treatment 
with praziquantel [41]. Similar to antigen testing, the presence of urinary schistosomiasis does not 





Haematuria is a defining sign of S. haematobium infection and can be microscopic or macroscopic 
[3, 39]. Macroscopic haematuria can be assessed visually in epidemiologic surveys or through 
standardized questionnaires [37]. Macroscopic haematuria often declines in a population after 
preventive chemotherapy or other treatment with praziquantel, and thus may be challenging to 
follow longitudinally [42]. Chemical reagent strips that detect microhaematuria are an inexpensive 
and rapid indirect method of detecting urinary S. haematobium morbidity [42]. Compared to urine 
filtration, testing with chemical reagent strips is less expensive, requires less technical expertise, 
and results are less impacted by parasite circadian rhythms [43]. However, reagent strips do not 
provide estimates of Schistosoma infection intensity or information regarding genital involvement. 
Like many diagnostic tests, the performance characteristics of chemical reagent strips vary by S. 
haematobium prevalence, with lower sensitivity reported in low-intensity infection and previously 
treated populations [39, 42]. As a low-cost alternative for estimating S. haematobium infection, the 
use of chemical reagent strips remains useful in population surveys and for determining community 
and individual level prevalence in high prevalence and pre-preventive chemotherapy settings, but 
may need to be followed by more sensitive testing in low-prevalence and low-intensity settings 
[44].  
 
1.3 Literature review of Schistosoma infection categories and the cervicovaginal 
environment, the cervicovaginal microbiota, HIV-1 prevalence and HIV-1 incidence 
 
In February 2020, prior to the submission of Research Paper 1, I performed a PubMed search with 
the follo ing search terms Schistosomiasis  OR Schistosoma  OR female urogenital 
schistosomiasis  OR genital or urogenital schistosomiasis  AND HIV or human 
immunodeficienc  irus . The references of relevant articles were also used to identify additional 
resources. Thus, Research Paper 1 primarily describes literature evaluating the association between 
FGS and HIV-1 prevalence [14].  
 
The following section of this PhD thesis includes a review of the literature regarding schistosome 
infection and the cervicovaginal cytokines and chemokines, the cervicovaginal microbiota 
(including STIs), HIV-1 prevalence and HIV-1 incidence. In April 2021, I extended the findings 
from Research Paper 1 by performing additional searches to also include manuscripts that reported 
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schistosomiasis infection with HIV-1 incidence, cervicovaginal cytokines and chemokines, or the 
cervicovaginal microbiota (including STI) as outcomes. For the cervicovaginal cytokines and 
chemokines, I searched using the following search terms: ("Schistosomiasis" OR "Schistosoma") 
AND ("cervicovag* or vagina or vaginal or cervix or cervical or genital") AND ("inflamm* or 
cytokine or chemokine or IL"). For the cervicovaginal microbiota, I searched using the following 
search terms ("Schistosomiasis" OR " Schistosoma") AND ("cervicovag* or vagina or vaginal or 
cervix or cervical or genital") AND ("microbiota or microbiome or lactob* or bacteri* or anaerob* 
or atopobium or vaginae or BV or bacterial vaginosis or sexually transmitted infection [STI] or 
(sexual* transmit*)"). Additionally, the search for Research Paper 1 was repeated from February 
2020. 
 
Given the varying definitions of FGS and urogenital schistosomiasis often employed in the 
schistosomiasis literature, and the frequent use of composite endpoints, the following section will 
use specific Schistosoma case definitions to contextualize the current literature regarding 
schistosome infection and HIV-1 incidence, HIV-1 prevalence, cervicovaginal cytokines and 
chemokines, as well as the cervicovaginal microbiota and STIs. This PhD thesis will focus 
primarily on women with S. haematobium infection. However, to provide additional context, a short 
discussion of S. mansoni related literature is included.  
 
For this PhD thesis literature review, six mutually exclusive groups of differing Schistosoma 
infection diagnostic strategies were created: 1) Schistosoma antibody positivity, 2) unspecified, 
mixed, or S. mansoni infection (all schistosomiasis studies with the above specified outcomes that 
do not focus on S. haematobium or FGS), 3) urogenital schistosomiasis (in S. haematobium endemic 
areas or with primary evaluation for S. haematobium), 4) visual FGS, 5) tissue FGS (including 
composite endpoints), and 6) PCR-defined FGS. If a study utilized multiple diagnostic techniques 
and a reference standard was not identified, the study was grouped according to the diagnostic that 
was used to identify active infection (e.g. studies using both antibody status and CAA are grouped 
with the CAA studies [45] and studies using both urine microscopy and antibody status are 
categorised with urogenital schistosomiasis [19]). Identified manuscripts were included if they 
enrolled participants with above Schistosoma case definitions in combination with one of the 
following outcomes: cervicovaginal cytokines and chemokines, the cervicovaginal microbiota/STIs, 
HIV-1 prevalence or HIV-1 incidence.  
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1.3.1 Schistosoma antibody positivity 
 
Since antibody status cannot differentiate active versus prior infection, this Schistosoma diagnostic 
method is not used commonly in endemic areas [46]. I identified two studies which used S. 
haematobium antibody status to evaluate an association with any of the following outcomes: the 
cervicovaginal environment, the cervicovaginal microbiota/STIs, HIV-1 prevalence or HIV-1 
incidence (Figure 1.3) [47, 48]. Both studies showed an association between schistosomiasis 
antibody status and HIV-1 infection, one with prevalent HIV-1 [48] and one with incident HIV-1 
[47].  
 
In the first study, a cohort of heterosexual HIV-1 serodiscordant couples in Lusaka, Zambia was 
followed longitudinally, evaluating baseline HIV-1 prevalence, HIV-1 incidence and STIs [47]. 
HIV-1 seroconverters and a random sample of non-seroconverters were evaluated in a nested case-
control study and plasma and serum samples were tested for schistosome soluble worm antigen 
preparation by ELISA with species-specific antigens used to differentiate S. mansoni and S. 
haematobium by immunoblot. In a sub-group of couples with a HIV-1 positive male partner and a 
HIV-1 negative female partner, women with S. haematobium specific antibodies had an increased 
risk (adjusted hazard ratio [aHR] 1.4, p=0.034) of HIV-1 acquisition [47]. Baseline Schistosoma 
antibody status was not associated with serum HSV-2 antibody or baseline rapid plasma reagin 
(RPR) results [47]. There was no evidence of an association between HIV-1 acquisition in women 
with S. mansoni infection (aHR 1.33 (0.93  1.91, p=0.12) [47]. 
 
In the second, transient elastography was performed to evaluate the prevalence and correlates of 
liver fibrosis in Uganda, comparing HIV-1 positive and negative participants [48]. Schistosoma 
infection was determined by soluble egg antigen ELISA status. There was strong evidence that a 
higher proportion of participants living with HIV-1 had Schistosoma antibodies (14%, 71/500) than 
those who were HIV-1 negative (9%, 46/500) (p=0.014) (Table 1.1a) [48]. 
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Figure 1.3  Schistosoma antibody  positivity and supporting literature describing the 




Abbreviations: Ab  antibody, HSV-2  herpes simplex virus-2, FGS  female genital 
schistosomiasis, RPR  rapid plasma reagin, STI  sexually transmitted infection 
 
1.3.2 Unspecified schistosome, mixed schistosome, or S. mansoni infection  
 
This PhD thesis focuses primarily on S. haematobium. However, a brief review of the literature 
regarding mixed, unspecified, and S. mansoni infection is relevant for context. Thus, I included 
studies in this category which do not primarily report S. haematobium infection. To be included, 
some proportion of the population required a diagnosis of active schistosome infection (defined by 
either positive microscopy or circulating parasite antigens, or both) in the absence of evaluation for 
genital schistosomiasis. Parasite antigens are not species specific [49], and thus studies evaluating 
circulating cathodic antigen (CCA) or CAA in isolation are defined in this PhD thesis as 
unspecified schistosome infection (Table 1.1b). Studies evaluating both S. haematobium and S. 
mansoni b  microscop  are defined as mi ed  infections (Table 1.1c), even if individual 
participants were confirmed to have only one of the two species. I identified thirteen studies in this 
unspecified/mixed/S. mansoni  category: ten evaluating HIV-1 endpoints (Table 1.1b, 1.1c, 1.1d) 
[45, 50-58], one evaluating the cervicovaginal microbiota as an endpoint (Table 1.1e [59], one 
evaluating the cervicovaginal immune environment as an endpoint (Table 1.1f, Figure 1.4) [60] and 
one evaluating STIs as an endpoint [61] (Table 1.1g).  
 
Four studies of unspecified infection  sho ed disparate results with regards to HIV-1 endpoints 
(Table 1.1b). Two studies from fishing communities in Tanzania [58] and Uganda [55] enrolled 
both women and men and did not show an association between schistosome infection and either 
HIV-1  acquisition [55] or prevalent HIV-1 [58] despite analysis by participant sex in the Tanzanian 
study [58]. Two additional Tanzanian studies showed an association between schistosome infection 
and HIV-1, but only among female participants [52, 57]. The first was a cross-sectional study in 
Tanzania which found that schistosome infection was associated with prevalent HIV-1 infection 
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(OR 3.9 (1.3  12.0), p=0.015) [52]. The second was a Tanzanian cohort that assessed schistosome 
infection status at baseline and evaluated HIV-1 acquisition over time, showing that women with a 
positive CAA had increased odds of HIV-1 seroconversion compared to CAA negative women 
(adjusted odds ratio [aOR] 2.8 [1.2  6.6, p=0.019), however this association was not seen among 
men [57] (Figure 1.4). 
 
Three studies of mi ed  S. haematobium and S. mansoni infections did not show an association 
between schistosome infection and prevalent HIV-1 [45, 51, 56] (Table 1.1c, Figure 1.4). One was a 
case-control study nested within a longitudinal cohort that used both Schistosoma species specific 
antibodies and CAA to evaluate active infection but did not show an association between active 
schistosome infection and HIV-1 seroconversion despite subgroup analyses by sex, schistosome 
species, and infection intensity [45]. Cross-sectional studies from Tanzania and Zimbabwe 
evaluated the association between prevalent HIV-1 and schistosomiasis and found no evidence of 
association [51, 56]. However, the Tanzanian study was conducted only in men [56]. Three 
additional studies of S. mansoni infection (using primarily stool microscopy [50, 53, 54], with CAA 
[54] or CCA [50] done only in subgroups) enrolling both men and women did not show an 
association between schistosome infection and prevalent HIV-1 [50, 53, 54], however only one of 
these studies performed sub-analysis by participant sex [54] (Table 1.1d).  
 
Of the thirteen included studies of participants with unspecified/mi ed/S. man oni  infection, one 
manuscript evaluated the cervicovaginal microbiota as a study endpoint (Table 1.1e) [59]. In this 
small longitudinal Tanzanian study, where women were evaluated at baseline and after treatment 
with praziquantel, women with S. haematobium infection (n=17, serum CAA positive and urine 
microscopy positive) were compared with S. haematobium negative women (n=27, CAA and urine 
microscopy negative) and women with S. mansoni infection (n=39, serum CAA positive and stool 
microscopy positive) were compared with S. mansoni negative women (n=52, CAA and stool 
microscopy negative) (Table 1e) [59]. Alpha diversity is a summary statistic which describes within 
sample diversity for one participant, while beta diversity measures similarity between samples. 
Comparing S. haematobium positive and S. haematobium negative women at baseline, alpha 
diversity (1.83 vs. 1.36, p= 0.39) and beta diversity (p = 0.60) were not different between groups. 
However, in participants with high-intensity S. haematobium infections there was strong evidence 
of higher alpha diversity than in S. haematobium negative participants (2.43 vs. 1.37, p=0.016) [59]. 
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Comparing S. mansoni positive and S. mansoni negative women at baseline, alpha diversity (2.03 
vs. 1.88, p= 0.32) and beta diversity (p= 0.515) were not different between groups [59]. 
 
A small longitudinal study in Tanzania evaluated cervicovaginal cytokines as a study endpoint [60]. 
In this study, women with concordant serum CAA and microscopy results (with both urine 
microscopy for S. haematobium and stool for S. mansoni to evaluate for single species infection), 
were enrolled and the concentration of cervicovaginal lavage cytokines was compared in S. 
haematobium positive (n=18) and S. haematobium negative (n=39) women and between S. mansoni 
positive (n=11) and S. mansoni negative (n=29) women (Table 1.1f) [60]. Women with urinary S. 
haematobium infection had lower concentrations of IL-15 than women without S. haematobium 
infection (p=0.013) [60]. No difference in cervicovaginal cytokines was detected in women with 
and without S. mansoni infection. Of note, in this study among a subset of cervical swabs available 
for testing, there were no significant differences in the prevalence of C. trachomatis, N. 
gonorrhoeae, or T. vaginalis between those with and without schistosome infection [60]. 
 
None of the evaluated studies reported an association between unspecified/mi ed/S. man oni  
infection and STIs. Of the thirteen studies of unspecified/mi ed/S. man oni  infection, three 
evaluated STIs as study endpoints [58, 60, 61]. One study evaluating fishing communities in 
Tanzania did not detect an association between STI and unspecified/mi ed/S. man oni  infection 
[58]. Results of a study of Tanzanian women are discussed in the previous paragraph [60]. A study 
of Ugandan women evaluated C. trachomatis, N. gonorrhoeae, or T. vaginalis infection and did not 
find that detection of these STIs as a group was associated with unspecified/mixed/S. man oni  
infection [61]. However, there was weak evidence that C. trachomatis prevalence was associated 
with schistosomiasis (p=0.06) (Table 1.1g). 
 
Although genital infections occur in S. mansoni, egg deposition is primarily in the colon and small 
intestine [62]. Eggs transiting through the intestinal walls undoubtedly cause disruption in the gut 
mucosal barrier, which could allow increased access to HIV-1 virions to submucosal target cells 
[63]. Additionally, S. mansoni infection has been associated with the presence of rectal pro-
inflammatory cytokines, independent of the native microbiota [64]. The inflammatory environment 
may also increase barrier permeability [65]. Indeed, macaque research suggests that primates with 
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systemic S. mansoni infection acquired simian-HIV infection after rectal inoculation at doses that 
were sub-infectious in S. mansoni uninfected hosts [66].  
 
While many hypotheses exist, the exact mechanism of the potential association between S. mansoni 
infection and HIV-1 has not yet been defined. Some mechanistic hypotheses for the association 
between S. mansoni and HIV-1 include Schistosoma-related direct mucosal effects, effects on HIV-
1 target cells, and parasite modulation of the local and systemic immune response [63]. The 
literature describes HIV-1 susceptibility in women with schistosome infection more commonly than 
in men. A Tanzanian series of women with biopsy-proven FGS described that nearly half (47.4%, 
9/19) of participants with biopsy-proven FGS had clinically visible cervical lesions, arguing for a 
role for direct mucosal effects in S. mansoni infection [67].  
 
Additionally, the organs most commonly involved in male genital schistosomiasis are the prostate 
and seminal vesicles [68], internal structures not exposed during sexual contact. Additionally, the 
HIV-1 vulnerability in S. mansoni infection seen in women, but not men [56, 57], may suggest a 
role of the cervicovaginal mucosa in HIV-1 vulnerability associated with this species. In addition to 
the impact on gut inflammation and barrier dysfunction discussed above, an additional hypothesis is 
that S. mansoni may be involved in activation of the common mucosal immune system [69] with 
subsequent CD4+ T cell recruitment to the cervix via integrin 4 7 [70]. This integrin does not 
home to the foreskin, providing a potential mechanism for HIV-1 vulnerability based on sex [63]. 
Additional mechanisms supporting HIV-1 vulnerability include S. mansoni effects on target cells 
and HIV-1 coreceptors. For example, Th17 cells are preferential targets for HIV-1 infection [71] 
and S. mansoni infected Ugandan men were found to have increased Th17 cells in the blood 
compared to uninfected men, suggesting a potential role of increased HIV-1 target cells in S. 
mansoni associated HIV-1 susceptibility [72]. S. mansoni may also increase HIV-1 susceptibility 
through an observed association with higher levels of the HIV-1 co-receptors CCR5 and CXCR4 on 
CD4+ T-cells [73]. Additional mechanisms to consider would be S. mansoni mediated effects on 
cervicovaginal gene expression, microbiota and the immune environment. The literature review of 
unspecified/mi ed/S. man oni  infection identified two studies evaluating the cervicovaginal 
microbiota [59] and the immune environment [60] as study endpoints. While small and hypothesis 
generating, these studies did not detect a difference between S. mansoni infection and baseline alpha 
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or beta diversity or cytokine concentrations [59, 60]. Additionally, cervical gene expression has not 
been shown to differ between S. mansoni infected and uninfected women [60]. 
 
In summary, in the thirteen studies that e aluated mi ed/unspecified/S. man oni  infection but did 
not specifically assess genital involvement, I identified ten studies that evaluated HIV-1 as a study 
endpoint (75.0%, 9/12) (Table 1.1b, 1.1c, 1.1d) [50-58]. Overall, only a minority of studies (16.7%, 
2/12) show an association between schistosome infection and HIV-1, and if present, the association 
was observed in studies evaluating women or sub-groups of women [52]. 
 
Figure 1.4  Unspecified schistosome, mixed schistosome, or S. mansoni infection  and 
supporting literature describing the cervicovaginal environment, the cervicovaginal microbiota, 




Abbreviations: Ab  antibody, Assoc   association, CAA  circulating anodic antigen, diff  
difference, HSV-2  herpes simplex virus-2, IL  interleukin, FGS  female genital schistosomiasis, 
RPR  rapid plasma reagin, Sh  S. haematobium, Sm  S. mansoni, STI  sexually transmitted 
infection 
 
1.3.3 Urogenital schistosomiasis 
 
Included manuscripts for urogenital schistosomiasis , primarily evaluated urinary S. haematobium, 
in the absence of evaluation for genital involvement [18]. Three studies evaluated either prevalent 
HIV-1 or STI endpoints (Table 1.1h, Table 1.1i, Figure 1.5). The studies evaluating HIV-1 as an 
endpoint showed mixed results [18, 19]. One study in Zimbabwean women (n=544) showed some 
evidence of an association between urogenital schistosomiasis  and HIV-1, with women with 
urogenital schistosomiasis  having a higher HIV-1 prevalence (33.3%, 72/216) compared with 
women without urogenital schistosomiasis  (25.6% 84/328, p=0.053) [18]. However, in a sub-
group analysis by age (<35 years), there was evidence of an association between urogenital 
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schistosomiasis  and HIV-1, with women above 35 years of age and urinary S. haematobium having 
a higher HIV-1 prevalence (37.5%, 33/88) compared to S. haematobium negative women (16.8%, 
30/179, p<0.001) [18]. Additionally, a study of men and women in the Democratic Republic of the 
Congo (DRC) (n=895) did not show evidence of a difference in prevalent HIV-1 between 
participants with (3.2%, 5/156) and without (5.9%, 44/739) urinary S. haematobium infection 
(p=0.18) [19]. An analysis to compare outcomes by participant sex was not performed [19].  
 
The study evaluating STI as an endpoint was performed in a pregnant population enrolled in a 
prospective cohort in the DRC [74]. In this cohort 33.3% of women with S. haematobium had any 
STI. After adjusting for potential confounders, women with S. haematobium had increased odds of 
any STIs (C. trachomatis, N. gonorrhoeae, T. vaginalis) (aOR 3.0 (1.5  6.0), and specifically T. 




Figure 1.5 Urogenital schistosomiasis   and supporting literature describing the cervicovaginal 




Abbreviations: Ab  antibody, Assoc   association, CAA  circulating anodic antigen, diff  
difference, HSV-2  herpes simplex virus-2, IL  interleukin, FGS  female genital schistosomiasis, 
RPR  rapid plasma reagin, Sh  S. haematobium, Sm  S. mansoni, STI  sexually transmitted 
infection 
 
Overall, in the studies that aimed to detect Schistosoma infection but did not evaluate for genital 
involvement, sixteen studies evaluated urogenital schistosomiasis  or mixed/unspecified/S. 
mansoni  infection, the majority of which evaluated HIV-1 as a study endpoint (78.6%, 11/14) [18, 
19, 45, 50-61, 74]. Of these, only a minority (25.0%, 3/12) show an association between 
schistosome infection and HIV-1, and if present, the association was observed in studies evaluating 
women, sub-groups of women [18, 52, 57] or in S. haematobium infection [18].  
 
While the mechanism of the association between schistosomiasis and HIV-1 is still largely 
unknown, similar mechanistic hypotheses exist for S. haematobium as for S. mansoni and include 
the effects of mucosal barrier disruption as well as the impact of helminth infection on the local and 
systemic immune responses. S. haematobium infection is associated with a higher mean egg 
concentration in genital tissue compared with S. mansoni [62] a factor which may increase the 
probability of cervicovaginal mucosal manifestations. Additionally, S. haematobium infection may 
modulate the local and systemic immune system through changes in the cytokine environment, 
cervicovaginal microbiota and differential gene expression [59, 60, 75]. Indeed, distinct 
cervicovaginal gene expression profiles have been observed in women with S. haematobium 
infection with proposed involvement of genes relating to the inflammatory response and tissue [60]. 
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Further support for the effect of S. haematobium on the local cervicovaginal immune environment 
comes from histopathology evaluation of biopsies from Malawian women (n=61) showed that 
cervical tissue containing S. haematobium eggs had a higher density of CD4+ T-cells and 
macrophages than non-egg containing tissue [76]. Additionally, a small South African study (n=44) 
reported that compared to FGS negative women, participants with visual FGS had increased 
expression of the CCR5 co-receptor on plasma CD4+ cells and cervical CD14+ monocytes [77]. In a 
small study of Malawian women with S. haematobium on cervicovaginal biopsies compared with 
Norwegian (n=44) and endemic (n=25) controls, tissue containing schistosome eggs was associated 
with increased vascularity compared to non-endemic controls [78]. These small studies support the 
hypothesis that the association between S. haematobium and HIV-1 could be biologically plausible 
with S. haematobium egg deposition beginning an inflammatory cascade that may to mucosal 
disruption and a milieu supportive of HIV-1 infection [14]. 
 
1.3.4 Visual FGS 
 
I defined studies as isual FGS , when the presence of any of the four recognized FGS 
cervicovaginal manifestations was utilized as the diagnostic technique. The following 
cervicovaginal lesions were identified by an expert clinician during a pelvic exam: grainy sandy 
patches, homogenous yellow sandy patches, rubbery papules, and abnormal blood vessels [27]. 
Other diagnostic tests, such as urine microscopy and CVL PCR for Schistosoma DNA could be 
utilized to confirm the status of negative controls [77] or for comparison against visual FGS  as 
the reference standard [26, 79].  
 
Three studies met pre-defined criteria, all of which reported STI outcomes [26, 77, 79] (Figure 1.6). 
A Madagascan study of 118 women ith isual FGS  did not find an association between any of 
the evaluated STIs (Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis, 
Chlamydia trachomatis, Treponema pallidum, HSV-2, or H. ducreyi) and the presence of rubbery 
papules, sandy patches, contact bleeding, or abnormal mucosal vessels [79]. A Zimbabwean study 
of 527 women, 46% (243/527) ith isual FGS , found that while there was weak evidence that 
grainy sandy patches were associated with N. gonorrhoeae (odds ratio [OR] 7.28 (0.75  70.69, 
p=0.09), homogeneous yellow sandy patches were associated with HPV (OR 2.35 (1.20-4.59, 
p=0.012), HSV-2 (OR 1.62 [1.05-2.51], p=0.03) and Chlamydia (C.) trachomatis (OR 5.62 (1.02-
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31.12], p=0.048) [26]. A South African study of 44 women, 43.2% (19/44) of whom had isual 
FGS  found strong evidence that T. vaginalis was associated with sandy patches (42% [8/19] visual 
FGS positive; 5% [1/21] visual FGS negative, p=0.007), although the sample size was small [77]. 
None of the identified studies reported HIV-1 prevalence or incidence outcomes.  
 
Visual FGS  e aluation techniques ma  be similar across studies as the three identified studies of 
isual FGS , albeit performed in different stud  populations, ere all conducted b  the same 
principal investigator. However, each study reported varying evidence against the null hypothesis of 
the association of STIs with visual FGS . This may be related to power, as the Madagascan [79] 
and South African [77] studies had smaller sample sizes than the Zimbabwean study [26]. 
Additionally, the STI diagnostic methods should also be considered. The South African study that 
detected a difference in T. vaginalis proportions bet een omen ith and ithout isual FGS  
utilized molecular methods (PCR) on CVL [77]. However, the Zimbabwean study used culture and 
serology and the Madagascan study used urine PCR, methods all less sensitive than molecular 
methods using vaginal fluid [80, 81]. It may also suggest that the reported associations between 
STIs and visual FGS  are related to chance. 
 
The authors of the identified studies propose that since there asn t strong e idence that grain  
sandy patches were associated with STIs or cervical dysplasia that grainy sandy patches can be 
considered pathognomonic  for FGS [26]. However, the presence of grainy sandy patches in the 
Zimbabwean study was not associated with S. haematobium eggs on biopsy (OR 7.38 [0.79-69.29, 
p=0.80], though grainy sandy patches were associated with finding S. haematobium eggs in any 
genital specimen (OR 4.51 [2.71-7.52], p<0.01) [26]. Though felt to be a strong indicator of isual 
FGS , clinical evidence of grainy sandy patches is not perfectly correlated with the presence of eggs 
on histopathology. In the Madagascan study, of 31 biopsies, 61.3% (19/31) had adequate stroma for 
evaluation and 73.6% (14/19) of these contained parasite eggs, with 28.6% (4/14) of these 
specimens being from grainy sandy patches [79]. Including the small sample size, this study 




Figure 1.6  Visual FGS  and supporting literature describing the cer ico aginal en ironment, the 




Abbreviations: Ab  antibody, Assoc   association, CAA  circulating anodic antigen, Ct  
Chlamydia trachomatis, diff  difference, HPV  human papillomavirus, HSV-2  herpes simplex 
virus-2, HYSP  homogeneous yellow sandy patch, IL  interleukin, FGS  female genital 
schistosomiasis, RPR  rapid plasma reagin, Sh  S. haematobium, Sm  S. mansoni, SP  sandy 
patch, STI  sexually transmitted infection, Tp  Treponema pallidum, Tv  Trichomonas vaginalis 
 
1.3.5 Tissue FGS (including studies using composite endpoints) 
 
Next, I identified studies using a tissue diagnosis as the FGS diagnostic technique. These studies 
also reported an association bet een tissue FGS  and the cervicovaginal environment, the 
cervicovaginal microbiota/STIs, HIV-1 prevalence or HIV-1 incidence as study endpoints. The 
finding of one or more terminal spined eggs in any tissue specimen was defined as a tissue 
diagnosis of FGS, or tissue FGS . Various techniques were implemented across studies in making 
a tissue FGS  diagnosis, including cervical wet mount, pap smear, and cervicovaginal biopsy 
(using either quantitative crushed biopsy technique [QCBT] or histopathology). Studies that had any 
proportion of women with tissue diagnoses were grouped in this category, even if the proportion 
was less than half of participants [17, 82] or used a composite endpoint of urogenital 
schistosomiasis  and tissue FGS . Studies that used biopsy to confirm isual FGS  as a reference 
standard are already described above [26, 79].  
 
Four studies used tissue diagnostics and reported pre-specified outcomes associated with tissue 
FGS  [10, 17, 82, 83]. An additional eight studies of tissue FGS  ere identified but were not 
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included for the following reasons: three studies of tissue FGS  did not investigate pre-specified 
outcomes [8, 11, 22] , three evaluated STIs but did not associate results with tissue FGS  [23, 84, 
85], and two evaluated STIs but associated STI results with the study site rather than tissue FGS  
[9, 86].  
 
Of these four identified studies, two reported STI endpoints in participants ith tissue FGS  [10, 
17] and three reported HIV-1 outcomes [17, 82, 83]. Overall, the included studies did not identify 
an association bet een tissue FGS  and STIs. A small Malawian study (n=51) reported 
cervicovaginal biopsy results for all study participants [10] (Figure 1.7). Participant specimens with 
koilocytosis or positive immunofluorescence on immunohistochemistry were evaluated for HPV 
[10]. In 15 women, there was no difference in HPV by tissue FGS  status (11 with and 4 without 
tissue FGS , p=0.41) [10]. Similarly, in a Tanzanian study, there was no difference in the 
proportion of women with C. albicans, T. vaginalis, BV and T. pallidum with or without tissue 
FGS  [17]. Of note, microscopy was used to identify C. albicans, T. vaginalis, G. vaginalis and this 
technique is less sensitive than molecular methods [80].  
 
Studies e aluating the association bet een tissue FGS  and pre alent HIV-1 have shown 
conflicting results. Of the four studies identified, three evaluated an association between tissue 
FGS  and prevalent HIV-1 [17, 82, 83]. In a Ghanaian study, 331 women had a cervicovaginal 
biopsy performed and there was no association detected between tissue FGS  status and prevalent 
HIV-1, 0.9% of those ith tissue FGS  had HIV-1 and 6.6% of tissue FGS  negati e omen had 
HIV-1 [83]. However, the methods of analysis used by the authors would be more suitable for 
ordered categorical variable data [83]. In the two remaining studies, some proportion of the 
population had evidence of eggs detected in cervicovaginal tissue, 30.4% (7/23) in a Tanzanian 
study and 43.4% (70/445) in a Zimbabwean study [17, 82]. In the Zimbabwean study, the 
proportion of women with HIV-1 was higher in those with S. haematobium ova detected in a tissue-
specimen (23.0% [29/125]) versus those without (13.0% [41/]320) (OR 2.1 [1.2-3.5], p=0.008) [82]. 
Likewise, in the Tanzanian study, the proportion of women with HIV-1 was higher in those with S. 
haematobium ova detected in a composite endpoint of urogenital schistosomiasis  or tissue-
specimen (17.4% [4/23]) versus those without (5.3% [23/434]) (OR 4.0 [1.2-13.5, p=0.024) [17]. 
The reason for discordant results in the association between HIV-1 prevalence and tissue FGS  
between the Ghanaian versus the Tanzanian and Zimbabwean studies is unclear but may be related 
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to a form of selection bias. Only the Ghanaian study biopsied all study participants and standardized 
the biopsy location to the anterior lip of the cervix, in the absence of suggestive clinical 
manifestations [83]. However, the Tanzanian and Zimbabwean studies performed cervical biopsy 
only in the setting of clinical indications [82] or abnormal cervical lesions [17] and thus they may 
represent an inherently different patient population. Additionally, the biopsy methods in these 
studies are not well-described, and thus there may be substantial heterogeneity in technique [17, 82, 
83]. Background S. haematobium prevalence and test sensitivity can affect the number of true 
positive test results, and the Ghanaian stud  doesn t report baseline urinar  S. haematobium 
prevalence, which was 10.8% (13/120) in the Tanzanian study and 39.4% (177/449) in the 
Zimbabwean study [17, 29, 83]. Additionally, differences in sampling methods could be considered 
(Ghana  quantitative compressed biopsy technique [QCBT], Tanzania  cervical smear or QCBT, 
Zimbabwe  cervical smear, wet mount, or biopsy (histology and QCBT)). S. haematobium eggs are 
not evenly distributed in cervicovaginal tissue and can cluster together [87] and are also found 
primarily in the stroma and are less likely to be found in the epithelium [23], so it is possible that S. 
haematobium cases might have been missed if biopsy technique was not optimal. No estimate of 
biopsy quality is provided in the Ghanaian study, however QCBT has been shown to identify more 
tissue FGS  cases than standard histopatholog  [83, 87] . Despite their limitations, the 
Zimbabwean and Tanzanian studies represent what is considered in the field to be the best available 
evidence for the association between FGS and prevalent HIV-1 and are cited for their effect sizes 
and the strong evidence of an association with prevalent HIV-1, despite the small sample sizes and 
use of sub-groups of the larger study populations. While the effect sizes are moderate to high in the 
Zimbabwean and Tanzanian studies respectively, they should be considered in the context of the 




Figure 1.7  Tissue FGS  and supporting literature describing the cervicovaginal environment, the 




Abbreviations: Ab  antibody, Assoc   association, Ca  Candida albicans, CAA  circulating 
anodic antigen, Ct  Chlamydia trachomatis, BV  bacterial vaginosis, diff  difference, HPV  
human papillomavirus, HSV-2  herpes simplex virus-2, HYSP  homogeneous yellow sandy 
patch, IL  interleukin, FGS  female genital schistosomiasis, RPR  rapid plasma reagin, Sh  S. 
haematobium, Sm  S. mansoni, SP  sandy patch, STI  sexually transmitted infection, Tp  
Treponema pallidum, Tv  Trichomonas vaginalis 
 
1.3.6 PCR-defined FGS  
 
Finally, studies that used PCR as the reference standard to detect Schistosoma DNA in genital 
specimens were evaluated if they assessed the following endpoints: the cervicovaginal environment, 
the cervicovaginal microbiota/STIs, HIV-1 prevalence, or HIV-1 incidence. Six studies 
implemented PCR for FGS diagnosis [25, 29, 79, 88-90]. One study used Schistosoma PCR results 
to validate findings with visual diagnosis as the reference standard and was thus reported above 
under isual FGS  [79]. Four identified studies did not report the pre-specified endpoints [25, 88-
90] (Figure 1.8). Thus, only one study reported independent PCR outcomes and their association 
with HIV-1, hilst also using isual FGS  as a reference standard for calculating the sensiti it  of 
PCR [29]. In this Zimbabwean study, 83 CVL specimens (18%, 83/557 of the original specimens) 
were processed retrospectively for Schistosoma DNA by PCR. In this cohort, 36.1% (30/83) of 
samples had Schistosoma DNA detected and 30 women had sandy patches, with 56% (17/30) 
having both detectable Schistosoma DNA and sandy patches [29]. While this study suggests that 
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PCR detection of Schistosoma DNA is a useful diagnostic strategy for FGS, this cohort did not 
identify an association between prevalent HIV-1 and Schistosoma DNA detection (p=0.97) [29]. 
Additionally, six studies implemented PCR, but did not utilize this semi-quantitative molecular 
method as a reference standard. This research gap will be further addressed by this PhD thesis.  
 
Figure 1.8  PCR-defined FGS  and supporting literature describing the cervicovaginal 




Abbreviations: Ab  antibody, Assoc   association, Ca  Candida albicans, CAA  circulating 
anodic antigen, Ct  Chlamydia trachomatis, BV  bacterial vaginosis, diff  difference, HPV  
human papillomavirus, HSV-2  herpes simplex virus-2, HYSP  homogeneous yellow sandy 
patch, IL  interleukin, FGS  female genital schistosomiasis, RPR  rapid plasma reagin, Sh  S. 
haematobium, Sm  S. mansoni, SP  sandy patch, STI  sexually transmitted infection, Tp  
Treponema pallidum, Tv  Trichomonas vaginalis 
 
1.4 The pathogenesis of HIV-1 acquisition: the role of STIs, vaginal microbiota, and 
FGS  
 
HIV-1 acquisition after sexual contact occurs primarily at mucosal surfaces where an intact 
cervicovaginal epithelium provides the first line of defence against pathogens [91, 92]. Both 
ulcerative and non-ulcerative STIs have been associated with increased odds of HIV-1 
seroconversion [93, 94] suggesting that the pathophysiology of HIV-1 vulnerability extends beyond 
physical breaches to the cervicovaginal barrier. Indeed, STIs are associated with increased risk of 
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HIV-1 acquisition through a number of mechanisms, including breaches in the epithelium (e.g. 
lesions) and through cervicovaginal inflammation [95]. Both viral and bacterial pathogens can 
activate host cytokine and chemokine cascades. While these cascades are an important component 
of pathogen clearance, they can also result in tissue damage [96]. Thus, vaginal inflammation, or the 
STI-related expression of cervicovaginal cytokines and chemokines, is important in HIV-1 
pathogenesis [97] because it mediates the recruitment and activation of target cells [95, 97] and is 
associated with increased permeability of the cervicovaginal barrier [65]. The influx of HIV-1 target 
cells and a damaged cervicovaginal barrier set the stage for increased HIV-1 vulnerability, but 
relatively little is known regarding the nature of the epithelial disruption in FGS [76, 78]. HIV-1 
infection can impair cervicovaginal barrier function [65], but more research is needed to understand 
if epithelial disruption in FGS is associated with HIV-1 acquisition. Additionally, while the 
recruitment of activated HIV-1 target cells to the cervicovaginal epithelium may be associated with 
HIV-1 susceptibility [91, 97, 98], and acute HIV-1 infection [99], the role of FGS in the recruitment 
and activation of cervicovaginal HIV-1 target cells has not been well-defined [77].  
 
Similar to STI, cervicovaginal microbiota and bacterial vaginosis (BV) may also act as a risk factor 
in HIV-1 acquisition [100, 101]. BV is an e ample of non-optimal  microbiota, hich is 
characterized by a shift from lactobacilli dominance to an increase in more diverse anaerobic 
species [102]. In contrast, mucosal surfaces ha e been described as optimal  hen the  pro ide an 
intact barrier against pathogens [102]. In the cervicovaginal environment, protection is mediated by 
acid producing bacteria, most commonly lactobacilli species. These commensal microorganisms 
adhere to an intact vaginal squamous epithelium [102, 103], protecting against pathogens by 
acidifying the vagina and producing antimicrobial substances such as bacteriocins [103]. Similar to 
STI, more diverse bacterial communities have been associated with elevated levels of activated 
HIV-1 target cells and vaginal cytokines and chemokines [104]. FGS has been proposed as a risk 
factor for HIV-1 acquisition, though evidence both supports and refutes this hypothesis [17, 82, 83]. 
Well-known HIV-1 acquisition risk factors, such as STI and BV, and potential risk factors, such as 
FGS, are potentially modifiable.  
 
In this PhD thesis, I present a causal framework describing how FGS may potentially be associated 
with mechanisms that influence HIV-1 acquisition. This causal framework suggests that FGS may 
be associated with conditions such as epithelial disruption, STI, vaginal inflammation, HIV-1 target 
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cell recruitment, or non-optimal  cervicovaginal microbiota that have a well-described association 
with HIV-1. If present, these associations may mediate some of the FGS-related HIV-1 
susceptibility (Figure 1.9). STI, vaginal inflammation and the cervicovaginal microbiota have not 
been well-defined in women with PCR-defined FGS and this PhD thesis aims to address these 
research gaps.  
 
Figure 1.9  Conceptual pathway describing the potential association of FGS with epithelial 
disruption, STI, aginal inflammation and non-optimal  cer ico aginal microbiota, and HIV-1 




*adapted from [14] 
 
1.5 Knowledge gaps and PhD thesis rationale  
 
This chapter identifies a number of research gaps. Little is known about the cervicovaginal 
environment or cervicovaginal microbiota in women with schistosome infection, and a notable gap 
includes the lack of data on women with genital schistosomiasis (Figure 1.10). I did not identify any 
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studies reporting the prevalence and association of the cervicovaginal immune proteins, microbiota, 
or STIs with PCR-defined FGS  (Figure 1.10). Additionally, while conflicting measures of incident 
HIV-1 have been put forward from women with evidence of S. haematobium by antibody testing, or 
antibody testing combined with CAA, to date there are no studies measuring HIV-1 incidence in 
PCR-defined FGS  (Figure 1.10). While man  studies ha e used PCR to confirm isual FGS , this 
chapter illustrates that PCR-defined FGS  has been underutili ed as a semi-quantitative diagnostic 
method and as an independent reference standard. Thus, the overall objectives of this PhD thesis are 
relevant and include: to describe the cervicovaginal microbiota (including STIs) and the 
cervicovaginal immune environment in Zambian women with and without PCR-defined FGS  and 
to explore the association of PCR-defined FGS  with HIV-1 incidence.  
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Figure 1.10  Schistosoma infection categories and supporting literature describing the cervicovaginal environment, the 







References 3, 5, and 16  C. trachomatis, N. gonorrhoeae, T. vaginalis; (reference 5, weak evidence of an association between S. 
mansoni and C. trachomatis (p=0.06)) 
Reference 4  diagnosis of STI in the past 12 months  
Reference 21  C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium, T. pallidum, H. ducreyi, and HSV-2 
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trachomatis, BV  bacterial vaginosis, diff  difference, HPV  human papillomavirus, HSV-2  herpes simplex virus-2, HYSP  
homogeneous yellow sandy patch, IL  interleukin, FGS  female genital schistosomiasis, RPR  rapid plasma reagin, Sh  S. 
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Table 1.1a Literature describing HIV-1 prevalence or HIV-1 incidence in participants with Schistosoma antibody detected  
 















Proportion with Schistosome  
Infection  













HIV (+) 38 
(31-44) 
 










Schistosoma antibody (+)  
% 11.7 (117/1000)  
 
Schistosome infection prevalence higher 
in HIV (+) 14·0% (71/500)  

















































Schistosoma antibody (+)  
% 58.8 (1261/2145)  
 
There were no differences in the 
distribution of the ELISA results when 
stratifying by sex and HIV-1 status 
simultaneously. 
 
S. haematobium specific antibodies (aHR 
1.4, p=0.034) increased the risk of HIV 
acquisition in women, while S. mansoni 
specific antibodies also increased the risk 
of HIV-1 acquisition, though not 




Table 1.1b Literature describing HIV-1 prevalence or HIV-1 incidence in unspecified schistosome infection 
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Infection  



























 CAA (+)  
53·6% (185/345) 
 
CAA ( ) 
46·4% (160/345) 
 
Among CAA (+) women, HIV-1 
infection was 9·2% (17/185) compared 
with 2·5% (4/160) in CAA ( ) (adjusted 
OR = 6·2 




















3 stool samples  
KK or FME 
 
Stored serum for 
CAA @ 6, 12, 
18 months. 
(+) serum CAA 







CAA (+) at cohort enrolment 
 51% (102/200)  
 
CAA (+) 
at other timepoints: 
6 months - 48·0% (96/200) 
12 months - 52·0% (104/200)  
18 months - 52·0% (104/200) 
 
HIV-1 infection 49·0% (24/50) of cases 
and 52·0% (78/150) of controls had S. 
mansoni (CAA (+) infection prior to 
HIV-1 seroconversion (or a similar study 
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blood spots 
before 
















Men CAA (+)  
35·8%  
(47/131) 
Women: 44·0% (20/45) HIV-1 
seroconverters were CAA (+) compared 
to 30·0% (48/162) HIV-1 ( ) controls 
(OR=2·8 [95% CI, 1·2-6·6], p=0·01) 
 
Men: 29·0% (8/28) HIV-1 seroconverters 
were CAA (+) compared to 38·0% 



















Recreational facility workers 
(100% female)  
77.3% (71.9-82.1) 
214/286 
Schistosome infection (all): 15.0% 
(66/434) HIV (+) and highl  positi e  
(CAA) compared to 12.0% (22/190) 
(OR=1.37 [95% CI, 0.82-2.29], p=0.49) 
 
There was not strong evidence of a 
difference by participant sex 
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Fisherman or boat crew 











Table 1.1c Literature describing HIV-1 prevalence or HIV-1 incidence in mixed schistosome infection 
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Any Schistosome infection (by 
urine or stool) 43·4% 
(670/1545) 
 
No Schistosome infection  
56·6% (875/1545) 
 
Urine (+) (S. haematobium) 
infection only 27·6% 
(426/1545) 
 
Stool (+) (S. mansoni) infection 
only 7·8% (121/1545) 
 
Urine and stool (+) (S. 
haematobium and S. mansoni) 
infection 8·0% (123/1545) 
 
Among 407 HIV-1 (+) participants, 222 
(54·5%) were Schistosoma uninfected, 
110 (27·0%) had S. haematobium 
infection only, 40 (9·8%) had S. mansoni 
infection only, and 35 (8·6%) were 
infected with both S. haematobium and S. 
mansoni 
 
Corresponding figures among 1138 HIV-
1  
( ) participants were 653 (57·4%), 316 
(27·8%), 81 (7·1%) and 88 (7·7%), 
respectively 
 
Overall p-value for association between 


















 10mL urine 
 
 1 stool sample  
5 KK slides 
(41.7mg/slide) 
 





 S. mansoni 
infection: eggs in 
stool or CAA (+) 







 CAA (+) or  
Egg (+) 
 63·6% (429/674) 
 
S. mansoni (Stool (+) or serum 
CAA (+) with Urine ( )) 
49·9% (336/674) 
 
S. haematobium (Urine (+) or 
serum CAA (+) with Stool ( ))  
14·1% (95/674) 
 




In HIV-1 (+), 68·4% (26/38) had any 
schistosome infection (CAA (+) or egg 
(+)) compared with 63·4% (403/636) 
among HIV-1 ( ) (OR=1·3 [0·6-2·5, 
p=0·53]) 
 
In HIV (+), 5·3% (2/38) were S. 
haematobium egg (+) compared with 
5·5% (35/636) among HIV-1 ( ) (OR not 
calculated due to small numbers, p=1·0) 
 
In HIV (+), 29·0% (11/38) were S. 
mansoni egg (+) compared with 34·8% 
(221/636) among HIV-1 ( ) (OR=0·8; 




eggs in urine 
 
S. haematobium 
infection: eggs in 
urine or CAA (+) 
with no S. 
mansoni eggs in 
stool 
 
S. haematobium Urine (+) 










































































Serodiscordant couple cohort, 
32% (305/958) were 
antischistosomal (SEA) 
antibody positive  
 
64% (194/305) tested positive 
for schistosome antigens 
(CAA) 
 
Female sex worker (FSW) 
cohort, 34% (439/1292) were 
SEA antibody positive 
 
66% (290/439) tested antigen 
positive 
No association between schistosomiasis 
and HIV-1 acquisition risk in males (aOR 
0.99, 95% CI 0.59-1.67) or females (aOR 
1.21, 95% CI 0.64-2.30) in serodiscordant 
couples. 
 
No association between schistosomiasis 
and HIV-1 acquisition risk in female sex 
workers aIRR 1.11, 95% CI 0.83-1.50) 
 
There was no association between HIV-1 
acquisition risk and S. mansoni 
(serodiscordant couples: aOR=0.90, 95% 
CI 0.56-1.44; FSW aIRR=0.83, 95% CI 
0.53-1.20)  or S. haematobium 
(serodiscordant couples: aOR 1.06, 95% 





Table 1.1d Literature describing HIV-1 prevalence or HIV-1 incidence in S. mansoni infection 
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Infection  





















performed in a 
subset (n=287). 








Stool (+) (S. mansoni) 
31·4% adjusted prevalence 
(358/1239)  
 
Urine CCA (+) 
49·8% (143/287) 
 
Schistosome infection equally prevalent 
among HIV ( ) 31·6% (348/1187)  



























Stool (+) (S. mansoni) 
47·9% 
 (854/1785)  
In HIV-1 ( ) the prevalence of S. mansoni 
(+) was 48·1% (804/1660) 
compared with HIV-1 (+) individuals 
39·5% (50/125) (aPR 1·01, [95% CI 






























Stool (+) (S. mansoni) 




 In Stool (+) 16·1% (116/719) were HIV-
1 (+) compared with 17·8% (96/538) in 
Stool ( ) (aOR=1·04; [95% CI 0·74 - 
1·47], p=0·81)  
 
In CAA (+) 20·7% (99/478) were HIV-1 
(+) compared with 18·0% (31/172) who 






Table 1.1e  Studies investigating the association of unspecified/mixed/S. mansoni infection with cervicovaginal microbiota outcomes 
 
Reference Location Study Design Sample Size Sex Age (years) Per participant method of 
Schistosome diagnosis * 




Tanzania Longitudinal 44 (S. haematobium 














1 stool sample - Kato Katz x5 
At baseline, alpha diversity (1.83 vs 
1.36, p=0.39) and beta diversity 
(p=0.60) were not different between S. 
haematobium infected and uninfected 
women. However, in women with 
high-intensity S. haematobium 
infections, there was strong evidence 
of higher alpha diversity than in S. 
haematobium negative participants 




Tanzania Longitudinal 91 (S. mansoni 




S. mansoni infected 
29 (23-37) 
 
S. mansoni uninfected 





1 stool sample - Kato Katz x5 
Comparing S. mansoni and S. mansoni 
negative women at baseline, alpha 
diversity (2.03 vs 1.88, p=0.32) and 
beta diversity (p=0.515) were not 
different between groups. 
 
Table 1.1f  Studies investigating the association of unspecified/mixed/S. mansoni infection with cervicovaginal cytokines and 
chemokines 
 
Reference Location Study Design Sample Size Sex Age (years) Per participant method of 
Schistosome diagnosis * 




Tanzania Longitudinal 57 (S. haematobium 














1 stool sample - Kato Katz x5 
Decreased IL-15 in women with 
urogenital S. haematobium compared 




Tanzania Longitudinal 40 (S. mansoni 




S. mansoni infected 
29 (27-35) 
 
S. mansoni uninfected 





1 stool sample - Kato Katz x5 
No difference in cervicovaginal 
cytokines in women with and without 
S. mansoni infection. 
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Table 1.1g Literature describing the association of unspecified/mixed/S. mansoni infection with sexually transmitted infection 
 
Reference Location Study Design Sample Size Sex Age (years) Per participant method of 










Mean (range) 27.5 
(23.8  32.0) 
CCA urine 
 
Stored plasma for SEA 
 
Detection of any classical STI 
(defined as Ng, Ct or Tv) was not associated 
with schistosomiasis, all 5 Ct-infected 
participants were co-infected with 




Tanzania Longitudinal 57 (S. 
haematobium [n= 














1 stool sample - Kato Katz x5 
Among a subset of cervical 
swab specimens available for testing, there were no 
significant differences in the prevalence of 
chlamydia, gonorrhea, or trichomoniasis between 










>=18 Stored serum for CAA  Schistosome infection was not significantly 
associated with a history of genital discharge, 
genital sore or a diagnosis of STI in the past 12 
months. 
 
Table 1.1h  Literature describing HIV-1 prevalence or HIV-1 incidence in urogenital schistosomiasis 
 














Proportion with Schistosome  
Infection  














10 mL urine.  
If urine ( ), then 
AWA-TCA 
serology (titre 






Urine (+) S. haematobium 
17·4% (156/895) 
 
Urine ( ) Serology (+) 
20·6% (185/895) 
 
Urine (+) or Serology (+) 
38·1% (341/895) 
 
Urine ( ) Serology ( ) 
 61·9% (554/895) 
In those with Urine (+) 
HIV-1 infection was 3.2% (5/156) 
compared with Urine ( ) 
5·9% (44/739), p=0·18 *** 
 
In those with 
Serology (+) HIV-1 infection was 
3·8% (7/185) compared with  
Serology ( ) 6·7%, (37/554), p=0·1*** 
 
In those with Urine (+) and 
Serology (+) HIV-1 infection was 
 38 
3·5%, (12/34) compared with Urine ( ) 










15-49 Urine samples 
collected 3 
consecutive days 






Urine (+) S. haematobium 
39.7%  216/544 
 
Urine ( ) S. haematobium 
60.3% 328/544 
 
In those with Urine (+) HIV-1 infection 
was 33.3% (72/216) compared with Urine 
( ) 25.6% (84/328), p=0.053 
 
In those older than 35 years, those with 
Urine (+) HIV-1 infection was % 37.5 





Table 1.1i Literature describing the association of urogenital schistosomiasis with sexually transmitted infection 
 
Reference Location Study Design Sample Size Sex Age (years) Per participant method of 













18 years or older Three urine samples over 
three days 
32.0% of women with an STI had S. h infection. 
33.3% of women with S. haematobium had an 
STI.  
 
After adjusting for potential confounders, 
women with S. haematobium had increased odds 
of any STI (Ct, Ng, Tv) (aOR 3.0 (1.5  6.0) 
 
Women with S. haematobium had increased 
odds of T. vaginalis 
 
 
Table adapted from [25] 
**samples collected are per participant 
***No difference when analyzed by sex (p  value not given) 
 Stool (+) prevalence was adjusted for the survey design, but for Urine (+), unadjusted prevalence is presented since no adjusted 
estimates were reported  
 Participants were selected as cases and controls on the basis of their HIV-1 status 
# Threshold for positivity not reported 
 39 
Abbreviations: aOR  (adjusted odds ratio), AWA-TCA  trichloroacetic-acid-soluble fraction of the adult worm antigen (contains 
approximately 3% CCA, Ct  Chlamydia trachomatis, CCA  circulating cathodic antigen, FGS  female genital schistosomiasis, 
FUS  female urogenital schistosomiasis, HIV  human immunodeficiency virus, KK  Kato Katz, MFE  modified formol-ether 
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Vaginal or cervicovaginal microbiota
Sexually transmitted infection
Vaginal or cervicovaginal inflammation
A B S T R A C T
Female genital schistosomiasis (FGS) results from egg-deposition in the female reproductive tract primarily by
the waterborne parasite Schistosoma (S.) haematobium, and less commonly by Schistosoma (S.) mansoni. FGS
a!ects an estimated 20-56 million women worldwide, mostly in sub-Saharan Africa. There is cross-sectional
evidence of increased HIV-1 prevalence in schistosomiasis-infected women, but a causal relationship between
FGS and either HIV-1 acquisition or transmission has not been fully established. Beyond the pathognomonic
breach in the cervicovaginal barrier caused by FGS, this narrative review explores potential mechanisms for a
synergistic relationship between S. haematobium infection, FGS, and HIV-1 acquisition through vaginal in-
flammation and target cell recruitment.
1. Introduction
There are an estimated 82 million African women living with
Schistosoma infections (Lai et al., 2015). Though the risk factors for
human immunodeficiency virus-1 (HIV-1) and Schistosoma haematobium
are di!erent, these two conditions share a substantial geographic
overlap (Figure 1A and 1B). Worldwide, 53% of people living with HIV-
1 reside in Eastern and Southern Africa, where the HIV-1 epidemic
disproportionately a!ects young women (UNAIDS 2018). In 2017, 52%
of the 36.9 million people living with HIV-1 were women aged 15 years
and over (UNAIDS 2018). The synergy of many co-factors present in
Africa increases the risk of heterosexual HIV-1 acquisition, namely high
prevalence of bacterial vaginosis and sexually transmitted infection
(STI) (Cohen et al., 2012), low uptake of circumcision in adult men
(Kaul et al., 2015), baseline immune activation, and endemic co-in-
fections (Modjarrad, 2010). In addition, schistosome infection in
women (Downs et al., 2012), and more specifically, female genital
schistosomiasis (FGS), has been associated with prevalent HIV-1 in-
fection (Kjetland et al., 2006; Downs et al., 2011).
This review will focus on FGS and its causative agent, the parasite S.
haematobium, which requires an aquatic environment and a freshwater
snail vector to complete its life-cycle (Colley et al., 2014). When ferti-
lized S. haematobium eggs are shed in human urine and enter fresh
water, the miracidia hatch and penetrate a snail host. After 4-6 weeks,
cercariae penetrate human skin and enter the bloodstream
(Colley et al., 2014). S. haematobium eggs are often laid in the vesicular
plexus where proximity to the pelvis’ venous drainage provides circu-
lating eggs access to male and female urogenital tissues. FGS occurs
when circulating S. haematobium eggs lodge in the reproductive organs.
FGS has been associated with poor reproductive health outcomes in-
cluding ectopic pregnancy (Helling-Giese et al., 1996), abortion
(Helling-Giese et al., 1996), and infertility (Kjetland et al., 2010), likely
as a consequence of parasite egg deposition and inflammation in re-
productive tissues. It is hypothesized that the relationship between FGS
and HIV-1 acquisition is causal, with the mucosal breach caused by FGS
allowing HIV-1 access to susceptible submucosal target cells. However,
there have been no longitudinal studies investigating the mechanistic
links between FGS and HIV-1 acquisition. This review explores poten-
tial mechanisms for the relationship between S. haematobium, FGS, and
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the use of terms “Schistosomiasis” OR “Schistosoma” OR “Female
Urogenital Schistosomiasis” OR “Genital or Urogenital Schistosomiasis”
OR “Genital or Cervicovaginal Inflammation”, AND “HIV or Human
Immunodeficiency Virus”. The references of relevant articles were also
used to identify additional sources. No language restrictions were ap-
plied.
2.2. Selection Criteria
To be eligible for this narrative review (Gasparyan et al., 2011),
studies must have included some proportion of women who had a de-
finitive diagnosis of FGS, including either detection of Schistosoma (S.)
DNA by molecular methods or through histopathologic diagnosis (eggs
of either S. haematobium or S. mansoni detected in genital tissue). Stu-
dies were also eligible for inclusion if they contained a comparator
group for both prevalent HIV-1 and FGS and were prospective
(randomized or non-randomized) or cross-sectional studies in African
populations. Initially, we searched for studies that evaluated the asso-
ciation between prevalent HIV-1 and FGS, but only identified two stu-
dies that fit these criteria (Supplementary Table 1). We therefore added
an additional question regarding the association of non-genital schisto-
somiasis with prevalent HIV-1 in African populations, with analogous
inclusion criteria to the first study question; however, with the re-
quirement that some proportion of the study population have a measure
of active schistosome infection (defined by positive microscopy or
parasite circulating anodic antigen (CAA) or circulating cathodic an-
tigen. We identified ten studies with relevant information on this
question (Supplementary Table 2).
Beyond the study questions discussed above, where studies focusing
on FGS were not identified, we include findings from publications re-
porting S. haematobium infection or urogenital schistosomiasis as a
narrative synthesis. In circumstances where S. haematobium data were
Figure 1. Overlapping geographical distributions of schistosomiasis infection, HIV-1 prevalence, reported cases of FGS, and infertility. (A) Prevalence of S. hae-
matobium infection in school-aged children in Sub-Saharan Africa from 2000 onwards (from (Lai et al., 2015)); (B) HIV prevalence in African adults (15-49) (from
(UNAIDS 2018)); (C) African countries with published reports of FGS (adapted from (Christinet et al., 2016)), FGS cases have been published by countries shaded in
red; (D) Secondary infertility in Sub-Saharan Africa (from (Larsen 2000)).
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not available, we reference literature relating to S. mansoni.
2.3. Data Extraction & Synthesis
One reviewer identified the eligible articles (A.S.) and two re-
viewers (A.S. and E.W.) extracted relevant data. We extracted study
location, study design, participant ages, the author's definition of FGS,
proportions of study participants with FGS/schistosome infection,
proportion of study participants with HIV-1, method of Schistosoma egg
detection, and the association between FGS/schistosome infection and
HIV-1. Studies relating to our primary question of the association of
FGS with HIV-1 are shown in Supplementary Table 1. Studies relating
to the association of non-genital schistosome infection with HIV-1 are
shown in Supplementary Table 2. Other articles identified in the search
are referenced herein.
3. Female Genital Schistosomiasis – Definition, Clinical
Presentation & Impact
3.1. Urinary schistosomiasis, genital schistosomiasis and their overlap
A working group from the World Health Organization coined the
term “urogenital schistosomiasis” in 2009 to describe the frequent co-
existence of S. haematobium ova in the urinary tract (urinary schisto-
somiasis) and the female genital tract (genital schistosomiasis)
(World Health Organization 2009). Female Genital Schistosomiasis
(FGS) refers therefore, to the presence of S. haematobium eggs, DNA, or
characteristic clinical changes specifically in the genital tract (Figure 2),
regardless of whether or not these are present in the urinary tract
(Kjetland et al., 1996; Kjetland et al., 2005). Female Urogenital Schis-
tosomiasis (FUS) refers more broadly to the deposition of schistosome
eggs in either the female urinary or genital tracts, or both. FGS is caused
most frequently by the parasite S. haematobium. S. mansoni eggs have,
albeit rarely, also been found in genital tissue (Downs et al., 2011).
3.2. The burden of Female Genital Schistosomiasis
With up to 163 million Africans infected with S. haematobium or S.
mansoni (Lai et al., 2015), schistosomiasis morbidity is an under-
estimated public health problem in many parts of sub-Saharan Africa
(World Health Organization 2017). In the 2017 Global Burden of Dis-
ease Study, schistosomiasis was estimated to cause the loss of 1,440
million disability-adjusted life years (DALYs) (Global Burden of Disease
DALYs and Hale Collaborators 2018). Many women acquired S. hae-
matobium infection in childhood, and 30 to 75% of infected women may
develop FGS (Leutscher et al., 1998; Kjetland et al., 2005). A study in
Tanzania reported that 43% (53/122) of women with urinary schisto-
somiasis had concurrent FGS (diagnosed by cervical biopsy)
(Poggensee et al., 1998). A cross-sectional study of girls aged 10-12 in
KwaZulu-Natal, South Africa reported that significantly more girls with
urinary S. haematobium infection reported gynecologic symptoms
(bloody or foul-smelling vaginal discharge) and genital discomfort
(prior to sexual debut and menstruation in 98.6% and 93.0%, respec-
tively) (Hegertun et al., 2013). To our knowledge no clinical studies
have evaluated cervicovaginal physical exam findings in school-aged
girls. However, this study suggested that girls with urinary S. haema-
tobium infection may develop the genital changes associated with FGS
prior to sexual debut or the onset of menstruation. Since FGS may de-
velop in childhood, it is surprising that with the prevalence of S. hae-
matobium estimated at up to 25% in a survey of school-age children in a
majority of sub-Saharan African countries (Lai et al., 2015), less than
half of the countries (shaded red in Figure 1C) have formally published
FGS case estimates. No population prevalence studies have been per-
formed but best estimates are that 20 - 56 million women in sub-Sa-
haran Africa may be living with FGS (World Health Organization 2017).
3.3. FGS morbidity and clinical presentation
Studies of FGS histopathology reported that women ultimately di-
agnosed with FGS initially sought care for vaginal bleeding, abdominal
pain, or infertility (Swai et al., 2006). Frequently associated, but not
Figure 2. The anatomy of female genital and female urogenital schistosomiasis.
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pathognomonic, symptoms included haematuria, dyspareunia, and
post-coital bleeding (Kjetland et al., 1996). FGS has characteristic
clinical findings: grainy sandy patches (representing ova near the mu-
cosal surface) (Kjetland et al., 1996), homogenous yellow sandy patches
(Kjetland et al., 2005), and rubbery papules (Figure 3). These lesions
are associated with neovascularization (Kjetland et al., 1996; Kjetland
et al., 2005) and contact bleeding (Kjetland et al., 1996; Kjetland et al.,
2005). Common sites for egg visualization in adult females were the
cervix (Kjetland et al., 2005), vagina (Kjetland et al., 2005), and vulva
(Kjetland et al., 1996) while women under the age of 20 commonly
presented with vulvar lesions (Helling-Giese et al., 1996; Swai et al.,
2006). The di!erence in presentation may be related to anatomic,
hormonal, and vascular changes associated with puberty (Helling-
Giese et al., 1996).
3.4. Treatment of S. haematobium infection and FGS with praziquantel
Currently the World Health Organization (WHO) recommends pra-
ziquantel (PZQ) mass drug administration (MDA) to control S. haema-
tobium disease and reduce morbidity. Data on the e!ect of PZQ on FGS
lesion reversibility are scarce and subject to limitations. To date, three
studies of adult women with FGS followed after treatment with PZQ
have been conducted in Zimbabwe (n=338), Tanzania (n=33), and
Malawi (n=9). All three suggested that, following treatment with at
least 40mg/kg of PZQ, a proportion of cervicovaginal lesions are irre-
versible with variation by lesion type, duration of follow-up, and pra-
ziquantel dose provided (Richter et al., 1996; Kjetland et al., 2006;
Downs et al., 2013). Data from Zimbabwe suggested that women
treated for schistosomiasis prior to the age of 20 had significantly lower
prevalence of sandy patches and contact bleeding than untreated
women (Kjetland et al., 2008). PZQ administration prior to the age of
21 has also been associated with lower rates of sub-fertility (Miller-
Fellows et al., 2017). Thus, it is critical that schistosomiasis treatment
occurs early, prior to the development of FGS lesions. Further well-
designed clinical trials are required to investigate this question.
In addition to its role in schistosomiasis morbidity reduction,
mathematical modelling suggests that PZQ treatment of women and
school-aged children in S. haematobium high-risk communities could
reduce HIV-1 prevalence (Gibson et al., 2010; Mushayabasa and Bhunu
2011; Nde!o Mbah et al., 2013; Nde!o Mbah et al., 2014). This finding
highlights the need for further research into the use of PZQ for HIV-1
prevention. Other e!ective HIV-1 prevention methods include anti-
retroviral therapy and pre-exposure prophylaxis (PrEP). However, even
with the use of linkage strategies, PrEP (Mugwanya, 2018) and ART
uptake (Bor et al., 2018) and coverage are substantially less than 100%
(Granich et al., 2015), and PrEP adherence in both men and women is
imperfect (Koss et al., 2017). These limitations outline the need for a
comprehensive approach to HIV-1 prevention, and further research is
needed to evaluate praziquantel's role.
3.5. The impact of FGS on reproductive health
Due to its ability to a!ect both the upper and lower female re-
productive tract, FGS has been implicated in poor reproductive health
outcomes. However, data are mostly limited to pathology and case re-
ports. Pathology reports described the presence of severe scarring
(Swai et al., 2006) and inflammation (Wright et al., 1982; Swai et al.,
2006) in the fallopian tubes related to the presence of S. haematobium
eggs. Case reports described poor pregnancy outcomes in FGS, in-
cluding stillbirth (Helling-Giese et al., 1996), ectopic pregnancy
(Helling-Giese et al., 1996; Odubamowo et al., 2014) and spontaneous
abortion (Helling-Giese et al., 1996; Friedman et al., 2007). The ne-
gative impact of FGS on reproductive health is most likely mediated
through the histologic and mechanical e!ect of tissue destruction
caused by schistosome eggs (Kjetland et al., 2010), but more research is
urgently needed to understand the detrimental implications of FGS for a
woman's sexual and reproductive health. Additional adverse outcomes
attributed to S. haematobium infection in pregnancy include anemia,
preterm labor, intrauterine growth restriction, and low birth weight
(Friedman et al., 2007).
Infertility, a known consequence of upper reproductive tract pa-
thology, is another reproductive health outcome that is associated with
S. haematobium (Woodall and Kramer 2018). A 44% prevalence of sub-
fertility (higher than worldwide averages of 8-12%) has been reported
in women living in an area of high S. haematobium endemicity (60-85%
prevalence in school-age children) (Miller-Fellows et al., 2017). FGS,
defined in this study as the finding of S. haematobium ova in Papani-
colau smears, was associated with primary infertility, defined as the
inability to conceive after four years of regular sexual activity (OR 3.6;
1.0 – 12.0, p=0.04) (Kjetland et al., 2010). The distribution of sec-
ondary infertility (infertility after giving birth to a child) overlaps
substantially with the distribution of FGS in sub-Saharan Africa
(Figure 1A and 1D).
4. Female Genital Schistosomiasis and HIV-1 co-infection
4.1. S. haematobium and HIV-1 – epidemiology and an ecological
association
In addition to biologic plausibility supporting the association be-
tween an entity that causes cervicovaginal barrier disruption and HIV-1
acquisition, ecological associations have been reported between S.
haematobium and HIV-1 (Mbah et al., 2013; Brodish and Singh 2016).
The epidemiology of both schistosomiasis and HIV-1 may be influenced
by interactions between the two infections, but individual studies have
reported disparate conclusions regarding egg excretion, infection in-
tensity, and association of schistosome infection with HIV-1. Ten stu-
dies that evaluated the association of non-genital schistosomiasis with
HIV-1 met our inclusion criteria. Four studies with varied methodolo-
gies suggested an association between schistosome infection (genital
Figure 3. Visual findings suggestive of Female Genital Schistosomiasis, from World Health Organization (2015).
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infection status was not reported) and HIV-1 (N'Zoukoudi-
N'Doundou et al., 1995; Ndhlovu et al., 2007; Downs et al., 2012;
Downs et al., 2017) albeit the association in two studies was only seen
within sub-groups (Ndhlovu et al., 2007; Downs et al., 2017). Of note
two of the studies found an association with HIV-1 evaluate S. haema-
tobium (N'Zoukoudi-N'Doundou et al., 1995; Ndhlovu et al., 2007) and
two studies measured CAA (Downs et al., 2012; Downs et al., 2017),
which suggests active schistosome infection but cannot di!erentiate
between S. haematobium or S. mansoni species. Conversely, six cross-
sectional or case-control studies identified in our search evaluated the
association between schistosome infection and HIV-1 did not show an
association between schistosome and HIV-1 infection (Fontanet et al.,
2000; Kallestrup et al., 2005; Mazigo et al., 2014; Sanya et al., 2015;
Ssetaala et al., 2015; Downs et al., 2017), of note, none of these studies
described FGS or S. haematobium infection in isolation. Meaningful
comparison across studies was limited by variations in diagnostic
methods and definitions of schistosome infection and many studies did
not report analyses stratified by sex. In those that did, associations
between schistosome infection and HIV-1 prevalence (Downs et al.,
2012), increased acquisition (Downs et al., 2017), or transmission
(Wall et al., 2018) were commonly (although not universally) seen in
females but not in males. In females, cervicovaginal schistosome egg-
containing tissue is exposed to semen containing HIV-1. The prostate
and seminal vesicles are commonly a!ected by S. haematobium in men
(Kayuni et al., 2019), internal structures that are not exposed during
sexual contact. Authors finding a di!erence in the association between
schistosomiasis and HIV-1 infection by sex hypothesize that this may be
due to di!erential contact of egg-containing tissues in female versus
male genital tissues during sexual contact (Downs et al., 2017).
4.2. FGS as a risk factor for the heterosexual acquisition of HIV-1
While the majority of studies examine the association between
schistosome infection and HIV-1, our search identified only two studies
that evaluate a definition of FGS that includes egg deposition in genital
tissue, and its association with prevalent HIV-1 (Supplementary
Table 1). Data from these two cross-sectional studies suggested that
women with FGS have increased odds of having HIV-1 (Kjetland et al.,
2006). One study performed in rural Zimbabwe, found that 41% (29/
70) of women with FGS (diagnosed by S. haematobium eggs in Papa-
nicolaou, wet smear, or genital biopsy) were HIV-1 positive, compared
with 26% (96/375) in the egg negative group (OR 2.1, 95% CI 1.2-3.5;
p=0.008) (Kjetland et al., 2006). A study in Tanzania investigated HIV-
1 prevalence among women with FUS (defined as either urinary S.
haematobium egg excretion (16/23 participants) or egg detection in
genital tissue (7/23 participants)), found that of the 23 women with
FUS, 4 (17.4%) were HIV-1 infected compared with 23 (5.3%) of 434
women without FUS (OR 4.0, 95% CI 1.2–13.5) (Downs et al., 2011).
This study was limited by small numbers, a low number of women with
eggs detected in genital tissue, and the use of a broad FUS definition.
4.3. Schistosomiasis as a risk factor for HIV-1 incidence and transmission
To our knowledge, published data evaluating the association of FGS
with HIV-1 incidence or transmission are lacking, although a small
number of studies have evaluated the association of schistosome in-
fection with HIV-1 (but genital infection status was not reported in
these studies) (Downs et al., 2017; Wall et al., 2018). A retrospective
analysis of a longitudinal cohort study of HIV-1 incidence in anti-ret-
roviral therapy (ART) naïve, heterosexual HIV-1 serodiscordant couples
in Zambia examined the association of baseline schistosome antibody
status (as a proxy for previous or current infection) with incident HIV-1
acquisition and transmission (Wall et al., 2018). The presence of S.
haematobium antibodies in 482 HIV-1 negative women was associated
with increased risk of HIV-1 acquisition (Wall et al., 2018). However,
limitations include the absence of information on the timing of the
index partner's HIV-1 infection, the use of Schistosoma serology, which
does not di!erentiate between past or present infection, and missing
data on ART initiation. Research is needed to evaluate the association of
FGS with HIV-1 incidence and transmission in the era of universal ART.
4.4. The intersection of FGS and host HIV-1 susceptibility
S. haematobium egg deposition in the female reproductive tract leads
to a histological microenvironment that may enhance HIV-1 vulner-
ability. HIV-1 susceptibility is influenced by multiple factors but ulti-
mately requires the presence of susceptible host cells (commonly in the
vagina or cervix) (Kaul et al., 2015). HIV-1 fusion with and entry into
susceptible target cells (T-lymphocytes, monocyte/macrophages or
dendritic/Langerhans cells) requires the expression of the principal CD4
receptor and a chemokine co-receptor (CCR5 or CXCR4) (Kaul et al.,
2015). These target cells and their chemokine co-receptors are found in
the human genital tract (Kaul et al., 2015). HIV-1 susceptibility in the
host is influenced by the overall number (Secor et al., 2003), density,
and expression of the chemokine co-receptors on target cells that can be
utilized by HIV-1 for cellular entry (Kaul et al., 2015). Certain CD4+
subsets are more susceptible to HIV-1 infection (McKinnon et al., 2011)
and thus the availability, activation status, and phenotype of mucosal
target cells influence HIV-1 susceptibility (Secor et al., 2003;
McKinnon and Kaul 2012). In women with FGS, cervical tissue con-
taining S. haematobium eggs has an increased density of CD4+ lym-
phocytes and macrophages compared to cervical tissue not containing
eggs (Jourdan et al., 2011). On a histological level, cervical tissue
containing S. haematobium eggs is also more vascularized (Jourdan
et al., 2011) potentially allowing increased vascular access to HIV-1
target cells. Thus, the granuloma environment in S. haematobium in-
fection theoretically encourages a milieu of cellular populations ne-
cessary to establish HIV-1 infection.
Compared to egg negative men, egg-positive S. mansoni infection in
Kenyan males was associated with a higher density of CCR5 and CXCR4
co-receptors in the peripheral blood (Secor et al., 2003). Such data are
not available in S. haematobium infection and are hypothesis-generating
regarding the association between schistosome infection and HIV-1
status. Limited data exist regarding the influence of FGS on co-receptor
expression. A small study conducted in KwaZulu-Natal, South Africa
followed 14 women aged 15 – 23 years with FGS (defined by a sug-
gestive clinical exam) for 8 months (Kleppa et al., 2014). Flow-cyto-
metry was performed from peripheral blood and cervical cytobrush
samples before and after praziquantel treatment. Compared to FGS
negative women, participants with FGS had increased expression of the
CCR5 co-receptor on plasma CD4 cells and vaginal CD14+ monocytes
and increased frequencies of systemic monocytes (Kleppa et al., 2014).
Increased frequencies of HIV-1 target cells and co-receptor expression
are plausible mechanisms for increased HIV-1 vulnerability in women
with FGS, but given the small sample size and the lack of histologic or
laboratory diagnosis of FGS, additional research is needed.
5. Does FGS behave like an STI or bacterial vaginosis in
heterosexual HIV-1 acquisition? Mechanistic hypotheses for the
role of FGS in HIV-1 vulnerability
Although the association between FGS and HIV-1 has been hy-
pothesized to be a direct result of FGS-associated lesions in the female
genital tract (Feldmeier et al., 1994; Kjetland et al., 2005), the me-
chanism of the HIV-1 vulnerability has not been fully described. In
ulcerative STIs (e.g. syphilis or herpes simplex virus (HSV)), damage to
the protective cervicovaginal barrier is associated with increased risk of
HIV-1 transmission (Gray et al., 2001) and acquisition (McKinnon and
Kaul 2012). In this section we put forth several hypotheses (Figure 4)
for how FGS may influence mechanisms associated with HIV-1 acqui-
sition. In addition to causing barrier dysfunction, STIs, and perhaps also
FGS, increase the risk of HIV-1 transmission through their contribution
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to genital HIV-1 replication (Cohen et al., 1997) and HIV-1 acquisition
through genital inflammation (Masson et al., 2014; Masson et al., 2015)
and HIV-1 target cell recruitment (Masson et al., 2014).
5.1. Impaired cervicovaginal barrier function
In the female genital tract, the cervicovaginal immune defences are
physical and immunological (Selhorst et al., 2017). An intact vaginal
mucus layer, antimicrobial peptides, an acidic pH, and optimal vaginal
microbiota combined with a preserved cervicovaginal epithelium pro-
vide an e!ective barrier, the first defence against HIV-1 acquisition
(Selhorst et al., 2017). STIs are a classic example of how compromised
cervicovaginal barriers increase susceptibility to HIV-1 acquisition. Like
STIs, the characteristic lesions of FGS represent a breach in the intact
cervicovaginal mucosal barrier and are hypothesized to be an entry
point for HIV-1 (Feldmeier et al., 1995). At a population level, non-
ulcerative STIs may be more important given their higher incidence and
prevalence. And unlike many bacterial STIs which resolve with ap-
propriate treatment, a proportion of FGS genital lesions may persist
despite treatment with praziquantel (see section 3.4) (Downs et al.,
2013). Further research is needed to evaluate if, similar to HSV ulcers,
healed FGS lesions are associated with persistent localized inflamma-
tion, including HIV-1 target cells (Zhu et al., 2009).
5.2. The role of vaginal inflammation in HIV-1 acquisition. Could FGS
contribute?
Inflammation and immune activation are central to HIV-1 patho-
genesis and acquisition. Biological mechanisms that are influenced by
vaginal inflammation and contribute to male-to-female heterosexual
HIV-1 acquisition include mucosal target cell recruitment
(McKinnon and Kaul 2012) and impaired cervicovaginal barrier func-
tion (Arnold et al., 2016). Initiation of the inflammatory cascade
functions to recruit immunologic cellular mediators. In an escalating
onward cascade, the presence of vaginal inflammation recruits the very
cells needed to establish HIV-1 infection (Arnold et al., 2016). HIV-1
can infect T-lymphocytes, macrophages, and dendritic cells present in
the cervicovaginal tissue (McKinnon and Kaul 2012). Elevated genital
cytokines a!ect the expression of proteins associated with the cervi-
covaginal epithelium's integrity (Arnold et al., 2016). Compromise of
this physical barrier occurs in FGS and provides a rich supply of acti-
vated and available subepithelial HIV-1 target cells.
S. haematobium infection has been associated with altered levels of
systemic (Lyke et al., 2006; Erikstrup et al., 2008), seminal fluid
(Leutscher et al., 2005), and vaginal cytokines (Dupnik et al., 2018).
Raised vaginal concentrations of chemotactic (Morrison et al., 2014)
and inflammatory cytokines are a risk factor for HIV-1 acquisition
(Masson et al., 2015). In a study of 58 female HIV-1 seroconverters in
South Africa, women with elevation of more than 5 out of 9 in-
flammatory cytokines had increased odds of HIV-1 acquisition (OR 3.2,
95% CI 1.3-7.9) (Masson et al., 2015). Mechanistically, the association
has biological plausibility, as the production of inflammatory cytokines
can influence expression of biomarkers of tissue remodelling and in-
tegrity (Arnold et al., 2016), modulate HIV-1 replication through
transcription factor expression (Masson et al., 2014), or indirectly in-
fluence the di!erentiation, proliferation, and activation of HIV-1 target
cells (Masson et al., 2014). Further research is needed to evaluate if FGS
is associated with the genital inflammatory cytokines that are also as-
sociated with HIV-1 infection (Masson et al., 2015).
5.3. HIV-1 RNA concentrations, schistosomiasis, and HIV-1 transmission
Treatment of bacterial STI with antibiotics significantly decreases
the concentration of HIV-1 RNA in seminal plasma (Cohen et al., 1997).
Similarly, African men with genital schistosomiasis showed a decline in
the concentration of HIV-1 RNA in seminal plasma after treatment with
praziquantel (Midzi et al., 2017). Immunologically, egg-positive schis-
tosome infection induces a strong Th2 bias (Pearce et al., 1991). Lim-
ited data suggest that HIV-1 replicates preferentially in activated CD4
Th0/Th2 cells (Maggi et al., 1994). Thus, there is immunologic plau-
sibility to a hypothesis linking schistosomiasis with HIV-1 transmission.
Practically, this may manifest as altered plasma and genital HIV-1 RNA
concentrations among those who are dually infected with HIV-1 and
schistosomiasis. Understanding the e!ect of schistosome infection on
HIV-1 viral loads is critical given that schistosome infection in both
women and men has been associated with HIV-1 transmission
(Wall et al., 2018). However, the data regarding the association of
schistosomiasis with elevated plasma viral loads are conflicting (Downs
et al., 2017; Colombe et al., 2018; Bochner et al., 2019) and there may
be a species-specific e!ect of Schistosoma on viral load (Bochner et al.,
2019). In a study of HIV-1 seroconversion, participants with S. hae-
matobium had higher set point plasma viral loads (+0.33 log10 copies,
95%CI -0.07-0.73, p=0.11) compared to uninfected individuals, while
participants with S. mansoni had lower set point HIV-1 viral loads (-0.34
log10 copies, 95% CI -0.58 to -0.09,p=0.007) (Bochner et al., 2019).
Recent longitudinal studies report both increased (Downs et al., 2017)
and decreased (Colombe et al., 2018; Bochner et al., 2019) HIV-1 viral
load set points in participants co-infected with HIV-1 and S. mansoni. Of
note, FGS status was not evaluated in these studies (Downs et al., 2017;
Colombe et al., 2018; Bochner et al., 2019). Di!erences in the results
Figure 4. Conceptual pathway describing the potential contribution of FGS to vaginal inflammation and the association of FGS with sexually transmitted infection
and “non-optimal” cervicovaginal microbiota (McKinnon et al., 2019).
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highlight the need to adjust for ART use and duration of HIV-1 infection
when evaluating HIV-1 viral load in the context of schistosomiasis
(Downs et al., 2017; Colombe et al., 2018; Bochner et al., 2019).
An elevated genital HIV-1 viral load is a known risk factor for HIV-1
transmission (Baeten et al., 2011). An analysis of four prospective co-
hort studies in HIV negative persons in Kenya or Uganda who experi-
enced HIV-1 seroconversion provided data regarding the association of
schistosome infection with altered genital HIV-1 RNA concentrations.
After adjusting for age, year of HIV-1 acquisition, and log10 plasma viral
load, 8 women with S. haematobium infection who acquired HIV-1 were
found to have lower cervical (ß=-0.59 [-1.11- -0.06], p=0.029) and
similar vaginal (ß =-0.09 (-0.65-0.46), p=0.74) HIV-1 viral loads
compared with participants who did not have schistosomiasis
(Bochner et al., 2019). However, since the numbers were small, the
estimates were not adjusted for multiple comparisons, and genital
schistosomiasis status was not assessed, further research is needed to
describe the association of FGS with genital HIV-1 RNA concentrations.
5.4. Vaginal microbiota in S. haematobium endemic countries and the risk
of HIV-1 acquisition
Optimal vaginal microbiota are characterized by the presence of
lactic acid and hydrogen-peroxide producing bacteria, often
Lactobacilli. “Non-optimal” cervicovaginal microbiota (McKinnon et al.,
2019) is not dominated by Lactobacilli. Bacterial vaginosis (BV) is one
condition within this category (Cohen et al., 2012). BV involves the
replacement of lactic acid producing bacteria by anaerobes, with bac-
terial species often clustering into distinct communities
(McKinnon et al., 2019). Prevalence of BV is estimated to be high
among women in sub-Saharan Africa (Cohen et al., 2012) and women
of African descent. Although BV is seldom associated with clinically
visible inflammation (McKinnon et al., 2019), it is consistently asso-
ciated with elevated concentrations of pro-inflammatory immune pro-
teins (Masson et al., 2014) and poor sexual and reproductive health
outcomes, such as preterm delivery, miscarriage, pelvic inflammatory
disease, and HIV-1 acquisition (Atashili et al., 2008). A meta-analysis of
HIV-1 incidence studies reported that the presence of BV resulted in a
60% increased risk of HIV-1 acquisition (Atashili et al., 2008). Potential
factors contributing to this increased risk include an increase in vaginal
pH and upregulation of cytokines that promote HIV-1 replication
(Masson et al., 2014). As a chronic and recurrent disruption of the
genital tract environment, BV contributes a substantial population at-
tributable fraction (PAF) of HIV-1 acquisition (Masese et al., 2015).
Given the substantial risk for HIV-1 acquisition that BV poses in sub-
Saharan Africa, it is critical to evaluate if FGS might also be associated
with changes in the cervicovaginal microbiota. Since the cervicovaginal
presence of FGS likely persists over time, FGS may, like BV, contribute a
high PAF for HIV-1 acquisition.
Research on the role of the gut microbiota in persons with urinary S.
haematobium suggested that the e!ect of urinary S. haematobium in-
fection may be manifest in body compartments distinct from the loca-
tion of egg deposition (Kay et al., 2015). The di!erential detection of
microbes based on Schistosoma infection status extended into the ur-
inary microbiota as well (Adebayo et al., 2017). That S. haematobium
infection is associated with alteration in the gut and urinary microbiota
lends plausibility to the hypothesis that FGS may alter the cervi-
covaginal microbiota. The composition of the vaginal microbiota
played a role in HIV-1 acquisition, as demonstrated by a study of 236
South African women, 31 of whom acquired HIV-1 after a median 335
days of follow-up. This study illustrated that compared with Lactoba-
cillus crispatus dominance, high-diversity vaginal bacterial communities
with low Lactobacillus abundance was associated with HIV-1 acquisition
(Gosmann et al., 2017), however FGS or schistosome infection was not
evaluated. Women with anaerobic dominance were also found to have
increased genital CD4+ T-cell numbers, concentrations of cytokines
produced by activated CD4+ cells (Gosmann et al., 2017), and
cytokines that have been associated with HIV-1 acquisition
(Masson et al., 2015). Further research is needed to evaluate the po-
tential mechanistic connection between the vaginal microbiota and
FGS.
6. Female Genital Schistosomiasis – research priorities
This review highlights gaps in the literature and the need for revised
research priorities that evaluate the mechanistic links between FGS and
HIV-1 acquisition and transmission. Research regarding additional
biological mechanisms for HIV-1 vulnerability in FGS is urgently
needed and future research must explore the association of FGS with: 1)
cervicovaginal HIV-1 concentrations 2) cytokines and chemokines as-
sociated with HIV-1 acquisition, and 3) vaginal microbial community
composition.
7. Conclusion
FGS is a neglected gynaecological disease of poverty, a!ecting
vulnerable women in sub-Saharan Africa. FGS may be an unmeasured
regional risk factor that compounds biological and cultural covariates
in a population at risk for HIV-1 acquisition and transmission. The
clinical cervicovaginal findings of FGS demonstrate a breach in the
physical epithelial barrier. This mechanical mucosal defect may allow
greater access to the HIV-1 target cells in the sub-mucosa. However, the
hypothesis that cervicovaginal barrier dysfunction in FGS is the sole
mechanism linking FGS and HIV-1 acquisition is likely incomplete. The
experience of STI and BV and their association with HIV-1 vulnerability
includes consideration of additional co-factors: target cell recruitment,
vaginal inflammation, and HIV-1 RNA concentrations. A more complete
understanding of the association of FGS with HIV-1 will advance the
research agenda on diagnostic, therapeutic and prevention strategies
for this disabling disease, and its synergistic role in the HIV-1 epidemic.
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pap smear  












S. haematobium eggs in 
Papanicolau smear 
6·0% (26/433); wet 
smear from the genital 
mucosa 40·0% (41/88); 
biopsy from genital 
tissue 57·7% (15/26); 
urine 39·4% (177/449). 
Any genital specimen 
43·4% (70/445). 
 
Of the 70 women with 
FGS, 29 (41·0%) were 
HIV infected, 
compared with 96 
(26·0%) in the 
schistosome ova 
negative group. HIV 
was associated with 
FGS (OR 2·1; 95% CI 
































S. haematobium in 
urine 69·5% (16/23); S. 
haematobium in a 
genital specimen 
26·1% (6/23); S. 
mansoni in cervical 
smear 4·3% (1/23) 
Of the 23 women with 
FUS, 4 (17·4%) were 
HIV infected 
compared with 23 
(5·3%) of 434 women 
without FGS. HIV was 
associated with FGS 
(OR 4·0; 95% CI 1·2 
– 13·5, p=0·024). 
 
* All women ages 20-49 years of age were invited to take part in this study, women were not required to consent to taking part in 
study procedures. Not all women consented to Papanicolau smears. Biopsies were only performed if malignancy was suspected. Wet 
smears from genital mucosa were performed only in the presence of mucosal bleeding. 
** Data restricted to women who lived in the study area for more than 3 years 
 
Abbreviations: FGS – female genital schistosomiasis, FUS – female urogenital schistosomiasis, HIV – human immunodeficiency 
virus 
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Urine (+) (S. haematobium) 
17·4% (156/895) 
 
Urine ( ) Serology (+) 
20·6% (185/895) 
 
Urine (+) or Serology (+) 
38·1% (341/895) 
 
Urine ( ) Serology ( ) 
 61·9% (554/895) 
In those with Urine (+) 
HIV-1 infection was 3.2% (5/156) 
compared with Urine ( ) 
5·9% (44/739), p=0·18 ** 
 
In those with 
Serology (+) HIV-1 infection was 
3·8% (7/185) compared with  
Serology ( ) 6·7%, (37/554), p=0·1** 
 
In those with Urine (+) and 
Serology (+) HIV-1 infection was 
3·5%, (12/34) compared with Urine ( ) 





















performed in a 
subset (n=287). 








Stool (+) (S. mansoni) 
31·4% adjusted prevalence 
(358/1239)  
 
Urine CCA (+) 
49·8% (143/287) 
 
Schistosome infection equally prevalent 
among HIV ( ) 31·6% (348/1187)  






















 One stool 
sample/MFE (1g 
stool)  




Any Schistosome infection (by 
urine or stool) 43·4% 
(670/1545) 
 
No Schistosome infection  
56·6% (875/1545) 
 
Among 407 HIV-1 (+) participants, 222 
(54·5%) were Schistosoma uninfected, 
110 (27·0%) had S. haematobium 
infection only, 40 (9·8%) had S. mansoni 
infection only, and 35 (8·6%) were 
infected with both S. haematobium and S. 
mansoni 
 
 Studies Investigating the Association of Non-Genital Schistosomiasis with HIV-1 Infection in African Populations  
 
 
Urine (+) (S. haematobium) 
infection only 27·6% 
(426/1545) 
 
Stool (+) (S. mansoni) infection 
only 7·8% (121/1545) 
 
Urine and stool (+) (S. 
haematobium and S. mansoni) 
infection 8·0% (123/1545) 
 
Corresponding figures among 1138 HIV-
1  
(±) participants were 653 (57·4%), 316 
(27·8%), 81 (7·1%) and 88 (7·7%), 
respectively 
 
Overall p-value for association between 




















Urine (+) (S. haematobium) 
infection 39·7% (216/544) 
Among 156 HIV-1 (+) participants, 84 
(25·6%) were S. haematobium uninfected 
and 72 (33·3%) had S. haematobium 
infection (p=0.053), PR 1.30. 
 
In a sub-group of women t35 years of 
age, among 63 HIV-1 (+) participants, 30 
(16.8%) were S. haematobium uninfected 
and 33 (37·5%) had S. haematobium 































Among CAA (+) women, HIV-1 
infection was 9·2% (17/185) compared 
with 2·5% (4/160) in CAA (±) (adjusted 
OR = 6·2 

























Stool (+) (S. mansoni) 
47·9% 
 (854/1785)  
In HIV-1 (±) the prevalence of S. mansoni 
(+) was 48·1% (804/1660) 
compared with HIV-1 (+) individuals 
39·5% (50/125) (aPR 1·01, [95% CI 






























Stool (+) (S. mansoni) 




 In Stool (+) 16·1% (116/719) were HIV-
1 (+) compared with 17·8% (96/538) in 
Stool (±) (aOR=1·04; [95% CI 0·74 - 
1·47], p=0·81)  
 
In CAA (+) 20·7% (99/478) were HIV-1 
(+) compared with 18·0% (31/172) who 
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Stored serum for 
CAA @ 6, 12, 
18 months. 
(+) serum CAA 







CAA (+) at cohort enrollment 
 51% (102/200)  
 
CAA (+) 
at other timepoints: 
6 months - 48·0% (96/200) 
12 months - 52·0% (104/200)  
18 months - 52·0% (104/200) 
 
HIV-1 infection 49·0% (24/50) of cases 
and 52·0% (78/150) of controls had S. 
mansoni (CAA (+) infection prior to 
HIV-1 seroconversion (or a similar study 
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 1 stool sample  
5 KK slides 
(41.7mg/slide) 
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CAA (positive 
30 / ) 
 
Definitions: 
 S. mansoni 
infection: eggs in 
stool or CAA (+) 
with no S. 
haematobium 
eggs in urine 
 
S. haematobium 
infection: eggs in 
urine or CAA (+) 
with no S. 









 CAA (+) or  
Egg (+) 
 63·6% (429/674) 
 
S. mansoni (Stool (+) or serum 
CAA (+) with Urine ( )) 
49·9% (336/674) 
 
S. haematobium (Urine (+) or 
serum CAA (+) with Stool ( ))  
14·1% (95/674) 
 




S. haematobium Urine (+) 
 5·5% (37/674)  
 
 
In HIV-1 (+), 68·4% (26/38) had any 
schistosome infection (CAA (+) or egg 
(+)) compared with 63·4% (403/636) 
among HIV-1 ( ) (OR=1·3 [0·6-2·5, 
p=0·53]) 
 
In HIV (+), 5·3% (2/38) were S. 
haematobium egg (+) compared with 
5·5% (35/636) among HIV-1 ( ) (OR not 
calculated due to small numbers, p=1·0) 
 
In HIV (+), 29·0% (11/38) were S. 
mansoni egg (+) compared with 34·8% 
(221/636) among HIV-1 ( ) (OR=0·8; 
















Total CAA (+)  
34·0% 
(115/338) 
Overall: 38% (28/73) HIV-1 
seroconverters were CAA (+) compared 

































Men CAA (+)  
35·8%  
(47/131) 
to 32.0% (87/265) HIV-1 (-) controls 
(p=0.43) 
 
Women: 44·0% (20/45) HIV-1 
seroconverters were CAA (+) compared 
to 30·0% (48/162) HIV-1 (±) controls 
(OR=2·8 [95% CI, 1·2-6·6], p=0·01) 
 
Men: 29·0% (8/28) HIV-1 seroconverters 
were CAA (+) compared to 38·0% 
(39/103) HIV-1 (±) controls (OR 0·7 
[0·3-1·8], p=0·42) 
*samples collected are per participant 
**No difference when analyzed by sex (p ± value not given) 
 Stool (+) prevalence was adjusted for the survey design, but for Urine (+), unadjusted prevalence is presented since no adjusted estimates were reported  
 Participants were selected as cases and controls on the basis of their HIV-1 status 
# Threshold for positivity not reported 
 
Abbreviations: aOR ± (adjusted odds ratio), AWA-TCA ± trichloroacetic-acid-soluble fraction of the adult worm antigen (contains approximately 3% CCA, 
CCA ± circulating cathodic antigen, FGS ± female genital schistosomiasis, FUS ± female urogenital schistosomiasis, HIV ± human immunodeficiency virus, KK 
± Kato Katz, MFE ± modified formol-ether concentration, OR ± odds ratio, PR ± prevalence ratio 
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Chapter 3  P D      ibution 
 
Chapters 1 and 2 define FGS, describe the burden of FGS in sub-Saharan Africa, discuss the 
pathophysiology of HIV-1 acquisition, examine the role of the cervicovaginal environment, 
and identify knowledge gaps. Additionally, Chapter 2 describes potential mechanisms for 
HIV-1 vulnerability in FGS. This PhD thesis aims to address knowledge gaps in our 
understanding of HIV-1 incidence and the cervicovaginal environment in women with PCR-
defined FGS . This chapter describes an overview of the PhD thesis, presents the primary aim, 
key thesis objectives and hypotheses, outlines the contents of each chapter and describes the 
candidate s role in this ork. 
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3.1 Thesis aim 
 
The overall aim of this PhD thesis was to describe the cervicovaginal microbiota (including 
STIs) and the cervicovaginal immune environment, focusing on cytokines and chemokines, in 
Zambian women with and without PCR-defined FGS  and to explore the association of PCR-
defined FGS  with HIV-1 incidence.  
 
3.2 Thesis objectives and hypotheses 
 
1. FGS and the Vaginal Microbiota: To describe the association of PCR-defined FGS  
with the concentration of vaginal Lactobacilli, as well as describing the presence and 
concentrations of other key vaginal microbiota in women with and without PCR-
defined FGS . 
x Hypothesis: FGS will be associated with cer ico aginal microbiota in their non-
optimal  state. 
2. FGS and Sexually Transmitted Infections: To describe the association of PCR-
defined FGS with sexually transmitted infections. 
x Hypothesis: FGS will be associated with PCR-defined STIs. 
 
3.  FGS and the Cervicovaginal Immune Environment: To assess the association 
between FGS and the vaginal microenvironment by comparing: 
a. the concentration of selected HIV-acquisition-associated inflammatory markers 
in the cervicovaginal fluid of Zambian women with and without FGS. 
b. the cervicovaginal inflammatory signature in women with and without FGS 
with a focus on the t-helper type 1 (Th1) and t-helper type 2 (Th2) immune 
responses.  
x Hypothesis: FGS acts as a risk factor for HIV-1 acquisition by promoting elevated 
concentrations of chemokines associated with HIV-1 acquisition and contributing 
to genital inflammation. 
 
4.  FGS and HIV-1 Incidence: To compare HIV-1 incidence rates in Zambian women 
with and without FGS.  
x Hypothesis: FGS is associated with incident HIV-1 infection in Zambian women.  
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3.3 Thesis design 
 
This PhD thesis is comprised of the results from three sub-studies using specimens and data 
collected in a cross-sectional study conducted in Livingstone, Zambia as well as a narrative 
review. The narrative review assesses literature published regarding the association of 
schistosomiasis and FGS with HIV-1. This PhD thesis uses data and specimens collected in 
the cross-sectional BILHIV study (Appendix 1). The primary aim of the BILHIV study was 
to validate home-based genital self-testing for Schistosoma DNA by PCR versus clinic-based 
testing (Appendix 1). I utilized specimens collected in the BILHIV study to perform two 
independent studies, described in this PhD thesis. The first study utilized quantitative PCR to 
characterize the cervicovaginal microbiota in Zambian women with and without FGS. The 
second study evaluated cytokine and chemokine concentrations in women with and without 
FGS (Figure 3.1). One of the BILHIV study objectives was to evaluate HIV-1 incidence in 
women with and without FGS and I further developed the project for this PhD thesis.  
 





3.4 Thesis structure 
 
Chapter 1: The initial chapter presents background on FGS and introduces the knowledge 
gaps this PhD thesis seeks to fill. 
 
Chapter 2: This chapter presents a published manuscript entitled Beyond the barrier: 
Female genital schistosomiasis as a potential risk factor for HIV-1 acquisition . The narrative 
review is Research Paper 1  and further expands on concepts introduced in Chapter 1, 
including FGS morbidity, clinical presentation, treatment, and reproductive health impact. 
The narrative review also provides a summary of the epidemiology of HIV-1 and 
schistosomiasis co-infection and puts forward hypotheses for how FGS may influence 
mechanisms associated with HIV-1 acquisition, transmission, and host HIV-1 susceptibility. 
Chapter 2 also proposes a mechanistic hypothesis for the role of FGS in HIV-1 vulnerability, 
discussing barrier function, vaginal inflammation, HIV-1 RNA concentrations and the 
cervicovaginal microbiota. 
 
Chapter 3: This chapter summarizes the PhD thesis objectives, hypotheses and introduces the 
thesis structure and the candidate s role. 
 
Chapter 4: This chapter includes the methods used to address PhD thesis objectives outlined 
above (Section 3.2). 
 
Chapter 5: This chapter contains Research Paper 2  and includes a submitted manuscript 
entitled Associations of female genital schistosomiasis with the cervicovaginal microbiota 
and reproductive tract infections in Zambian women . This manuscript corresponds with PhD 
thesis objectives 1 and 2 (Section 3.2). 
Chapter 6: This chapter contains Research Paper 3  and includes a published manuscript 
entitled Cervicovaginal immune activation in Zambian women with female genital 
schistosomiasis . This manuscript corresponds ith PhD thesis objective 3 (Section 3.2). 
 
Chapter 7: This chapter contains Research Paper 4  and includes a submitted manuscript 
entitled Female genital schistosomiasis and HIV-1 incidence in Zambian women: a 




Chapter 8: This chapter summarizes the findings from Chapters 5-7 with a discussion of their 
implications in relationship to the current literature, study strengths and limitations, and 
priorities for future work. 
 
This PhD thesis follo s the guidance for a research paper  st le thesis with the presentation 
of four original manuscripts. Rather than presenting chapters in the temporal order of 
publication, the chapters are organized to create a cohesive flow of ideas. 
 
Appendices contain relevant publications not included in this PhD thesis. 
 
3.5 The c  role in the BILHIV study 
 
January  August 2017: As a volunteer, I was responsible for developing study documents for 
the parent study, the BILHIV study. I developed the BILHIV study protocol, information 
sheets, consent forms, study questionnaires, clinic review forms and standard operating 
procedures together with my supervisor. I formatted the study questionnaires and uploaded 
them to the study tablet computers. Participant data from the study questionnaires was uploaded 
directly into the LSHTM server, comprising the study database. I was responsible for drafting 
the ethical approval for both London School of Hygiene and Tropical Medicine (LSHTM) and 
Zambia and was also responsible for renewals and amendments. I applied for tablet computers 
and maintained these device subscriptions through the LSHTM Device Library. I also 
established and maintained Open Data Kit (ODK) server access, as hosted at LSHTM, and was 
one of the server data administrators. I also sourced equipment and supplies to be used in the 
BILHIV study. 
 
September 2017: I officially entered the PhD program at LSHTM 
 
January - August 2018: During the BILHIV Study enrolment, I was one of two study managers 
and assisted with study oversight, performing administrative duties related to the study, data 
management and cleaning. Additionally, I analysed the data and contributed substantially to 
the manuscripts for two peer-reviewed publications not included in this PhD thesis (Appendix 
1 and Appendix 2). 
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September 2018  Present: I was the data manager for the BILHIV study and was responsible 
for cleaning and analysing BILHIV study data.  
 
3.6 T   ndependent PhD work 
 
Research paper 1  Beyond the barrier: female genital schistosomiasis as a potential risk 
factor for HIV-1 acquisition  
x I performed the literature search, retrieved relevant studies, and extracted data 
from relevant studies together with my supervisor. 
x I created data tables together with my supervisor. 
x I assembled three of the four figures in the manuscript. 
 
Research paper 2  Associations of female genital schistosomiasis with the cervicovaginal 
microbiota and reproductive tract infections in Zambian women  
x I selected the microbiota and STIs included in this study with the support of my 
supervisors and collaborators. 
x I learned DNA extraction and PCR methods with the support of collaborators. 
x I wrote the data analysis plan and performed the statistical analysis with support from 
my supervisor. 
 
Research paper 3  Cervicovaginal immune activation in Zambian women with female 
genital schistosomiasis  
x I selected the cytokines and chemokines included in this study with the support of my 
supervisors and collaborators. 
x Together with my supervisors, I applied for funding and received a small grant to cover 
the costs of the bead-based assays. 
x I learned bead-based assay techniques at the LSHTM prior to the experiments. I then 
performed the bead-based assays together with technician Catriona Patterson at 
LSHTM. 
x I wrote the data analysis plan and performed the statistical analysis with support from 
my supervisor. 
 
Research paper 4  Female genital schistosomiasis and HIV-1 incidence in Zambian women: 
a retrospecti e cohort stud . 
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x I applied to Statistical Center for HIV/AIDS Research and Prevention (SCHARP) to 
obtain access to the HPTN 071 (PopART) Population Cohort HIV-1 data. 
x I wrote the data analysis plan, merged the SCHARP database together with the BILHIV 
database, evaluated data completeness, and performed the statistical analysis with 
support from my supervisor. 
 
For all four research papers, I wrote the first draft of the manuscript and revised the manuscripts 
according to supervisor and co-author input. I submitted the final version of each manuscript 
for peer review and, together with co-authors, responded to comments from peer reviewers. 
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Chapter 4  Methods 
 
4.1 The HPTN 071 (PopART) trial 
 
HPTN 071 (PopART) is a trial to measure the impact of an HIV combination prevention 
package, including universal HIV-1 test and treat, on HIV-1 incidence [105]. Twenty-one 
communities in Zambia and South Africa were selected and were grouped into triplets based 
on location and HIV-1 prevalence. The three communities in each triplet were randomly 
assigned to one of three trial arms: arm A (combination prevention plus universal anti-retroviral 
therapy [ART]), arm B (combination prevention plus ART provided based on local guidelines), 
and arm C (standard care). The combination prevention package was provided by trained 
community workers and included HIV-1 counselling and testing with linkage to HIV-1 care 
for ART initiation as well as adherence support. The community workers also screened 
participants for tuberculosis, referred male participants for circumcision and connected 
pregnant participants to clinical services for the prevention of mother-to-child-transmission 
[105]. The primary outcome for HPTN 071 (PopART) was HIV-1 incidence during the three-
year intervention period, measured in a Population Cohort (PC). The PC included one 
randomly selected adult 18 to 44 years of age from a random sample of households in each 
community [105]. 
 
4.2 The BILHIV study 
 
4.2.1 BILHIV study site and subjects 
 
Between January and August 2018, participants from the PC of HPTN 071 (PopART), were 
recruited to participate in the cross-sectional bilharzia and HIV-1 (BILHIV) study. Women 
were eligible to participate if they were 18-31 years old, non-pregnant, sexually active, and 
resident in one of the two communities (designated Community-A and Community-B) that 
participated in HPTN 071 (PopART) in Livingstone, Zambia. Central Livingstone is located 
within 5-10 kilometres of the Zambezi River, with a tributary flowing in close proximity to 
Community A. BILHIV study participants were selected as a consecutive sample from the 
HPTN 071 (PopART) Population Cohort who completed their three-year PC study visit prior 
to or during BILHIV study enrolment (January  August 2018). A 2013 survey of school 
aged children in Livingstone reported prevalence ranges for urinary S. haematobium infection 
between 3.3% and 73.3% (median 15.0%, mean 23.3%) [106].  
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4.2.2 BILHIV study home-based sample collection 
 
Trained community workers provided home visits to women who ga e an e pression of 
interest  in the BILHIV stud  at the HPTN 071 (PopART) PC 36-month visit. The home visit 
included assessment of eligibility, a questionnaire, genital self-sampling (cervical and 
vaginal), and a single urine specimen. Trained field workers provided study information in 
the participant s preferred language (English, Tonga, Bemba, Lozi, or Nyanja). Following 
written informed consent, a questionnaire containing questions regarding demographics, 
water contact, sexual behaviour, and genital symptoms, was administered. There were no 
restrictions on the timing of urine sample self-collection, and 69.5% (419/603) were 
performed between 9:00 and 14:00. The community worker provided participating women 
with instructions for urine collection and cervical and vaginal self-sampling. Participants 
were instructed to hold a 6-inch PrimeSwab (Longhorn Diagnostics, Texas, USA) at the 2 
3/8-inch score mark, insert the swab vaginally until their fingers touched the labia minora, 
and rotate the swab against the vaginal walls (minimum 15 repetitions) (Figure 4.1). 
Similarly, for the cervical swab, participants were instructed to hold a 6 3/4-inch flocked 
swab (Miraclean, Shenzen, China) with a quadrilateral kite-shaped tip at the non-flocked end, 
insert the swab until their fingers touched the labia minora and/or encountered resistance, and 
rotate the swab against the place of resistance (minimum 15 repetitions). Each flocked swab 
head was placed in individual screw cap microtubes (STARLAB, Hamburg, Germany) by the 
participant after the swab shaft was broken. Both swab specimens and urine were placed in 
cool boxes for transportation to the laboratory at -80qC for further processing.  
 
Women with evidence of active schistosome infection, defined by any positive urine 
examination (microscopy, CAA or PCR), or women with clinical evidence of FGS as 
determined b  the mid ife s clinical e amination [27], were treated free of charge with 40 
mg/kg praziquantel, either at the clinic visit, or via community workers. 
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Figure 4.1  Genital self-sampling technique utilized in the BILHIV study 
 
 
4.2.3 BILHIV study clinic-based sample collection 
 
Enrolled women who were not currently menstruating were invited to attend Livingstone 
Central Hospital cervical cancer screening clinic, where one of two trained midwives 
performed cervicovaginal lavage (CVL), which was used for Schistosoma PCR. After 
speculum insertion, a bulb syringe was used to flush normal saline (10 mL) continuously 
across the cervix and vaginal walls for one minute. CVL fluid was collected from the 
posterior fornixes and stored temporarily in a refrigerator (4qC) on ice until transfer to the 
laboratory. Protease inhibitor (Cocktail Set I, Calbiochem, Merck Millipore, Darmstadt, 
Germany) was added to one 1.5 ml aliquot for cytokine and chemokine testing and stored at 
80 C until shipment, as pre iousl  described [107].  
 
The urine aliquots and swab specimens were immediately stored at -80qC after arrival at the 
laboratory. All samples were transported frozen to the Netherlands for further testing at 
Leiden University Medical Center (LUMC). All laboratory analysis was performed blinded 
to any other participant data. Vaginal and cervical swab specimens were used for PCR 
detection of Schistosoma species; cervical swabs were used for detection of microbiota and 
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STIs by PCR; urine was used for CAA microscopic evaluation of the urine for S. 
haematobium eggs. 
 
4.2.4 BILHIV study clinic-based portable colposcopy 
 
Cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, 
Israel) and were evaluated by an expert collaborator (EFK) for the presence of any of the four 
recognized FGS cervicovaginal manifestations: grainy sandy patches, homogenous yellow 
sandy patches, rubbery papules, and abnormal blood vessels [27]. Testing for STI was not 
performed at the point-of-care and participants with suspected STIs were offered syndromic 
management, as per local guidelines [108].  
 
4.2.5 Urine microscopy 
 
Urine aliquoting for quantification of CAA and urinalysis were performed on the day of 
specimen arrival at the laboratory. The remaining urine, up to 60mL per participant, was 
centrifuged in 15mL aliquots and examined by microscopy within 24 hours. The pellet from 
each 15mL urine aliquot (5 maximum) was evaluated for S. haematobium eggs. When a 
pellet contained at least one terminal-spined ovum, the participant was considered positive 
and the total number of counted eggs in the pellet was reported. Review of all positive and 
10% of the negative specimens was conducted blinded by an expert for quality control. 
Dipsticks were used for analysis of haematuria and proteinuria (Multistix, Siemens, 
Germany).  
 
4.2.6 Circulating anodic antigen  
 
A lateral flow assay utilizing up-converting reporter particles for the quantification of CAA 
was performed on urine samples at LUMC [25, 31]. CAA is excreted from the gut of live 
schistosome orms into the host s bloodstream during acti e infection. CAA levels reflect 
the burden of live schistosomes and decline after successful treatment with praziquantel [49, 
109]. Analysing the equivalent of 417 PL urine (wet reagent, UCAAhT417), a CAA value of 
>0.6 pg/mL was considered positive [109]. 
 
An up-converting reporter particle (UCP) lateral flow (LF) assay for the quantification of 
CAA in urine (0.4 mL) was performed at LUMC [31]. Urine CAA antigen levels are known 
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to reflect adult worm burden and decline after successful treatment with praziquantel [30, 
49]. CAA comprises repetitive carbohydrate epitopes that efficiently bind the UCP reporter 
and the test-line on the LF strip via a CAA specific mouse monoclonal antibody. Interfering 
proteins were removed with a trichloroacetic acid (TCA) extraction by mixing 400 PL urine 
with 100 PL 12% (wt/vol) TCA. A centrifugation step removed the precipitate and 500 PL of 
the resulting clear TCA supernatant was concentrated to 20 PL using an 0.5 mL Amicon 
filtration device (Merck Inc.). Subsequently, the concentrate was mixed with a high salt 
lateral flow buffer containing the UCP reporter conjugated with monoclonal mouse anti-CAA 
antibody and incubated at 37qC for one hour. The same monoclonal mouse anti-CAA 
antibody is immobilized on a test line on a nitrocellulose membrane of an LF strip. These LF 
strips, comprised of a glass fibre sample pad, a nitrocellulose membrane, and an absorbent 
pad are inserted into microtiter plate wells with specimen for immunochromatography [31]. 
UCP technology uses a luminescent reporter particle that emits light upon excitation with 980 
nm infrared light. Finally, LF strips are read with a modified Packard Fluorocount microtiter 
plate reader suited for IR excitation and LF strips. Measured signals are compared to a 
standard series with known amounts of CAA. For this assay, analysing the equivalent of 417 
PL urine, a CAA value of 0.6 pg/mL was considered positive based on a series of negative 
controls (highest value plus 2 SDs). 
 
4.2.7 Polymerase Chain Reaction for Schistosoma spp. 
 
The internal transcribed spacer 2 based real-time PCR was performed for the detection of 
Schistosoma DNA in the clinical samples [110]. This PCR, using schistosome primers 
Ssp48F and Ssp124R and the double labelled probe Ssp78T, has been validated on its 
specificity [79, 90]. Appropriate positive and negative controls were included at each PCR 
run and, in addition, an internal control (Phocin herpes virus 1 (PhHV-1),103 plaque forming 
unit (PFU)/mL)) was added to each sample reaction for detection of potential inhibition of 
amplification [110]. For all specimens, DNA amplification and detection were performed 
with the CFX96 Real Time PCR Detection System (BioRad, California, USA). The output in 
threshold cycles (Ct) was analysed using BioRad CFX software.  
 
Genital PCR was performed at the LUMC Department of Parasitology. After thawing, 1.5 
mL of PBS was added to each tube containing a swab. After being vortexed for 10 seconds, 
the swabs were left at room temperature for another hour, after which the fluids were 
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processed similar to the cervicovaginal lavage fluid. DNA extraction and PCR set up was 
performed at LUMC using a custom automated liquid handling station (Hamilton, 
Switzerland) [90]. DNA was extracted from 200PL of specimen using a proteinase K heating 
step followed by QIAamp spin columns (QIAGEN Benelux; Venlo, The Netherlands). 
Amplification consists of 15 min at 95qC followed by 50 cycles of 15 seconds at 95qC, 30 
seconds at 60qC, and 30 seconds at 72qC.  
 
The output in Ct was analysed using BioRad CFX software. Negative and positive control 
samples were included in each amplification run. Parasite DNA load is categorized by the 
following pre-specified Ct threshold for all specimens processed by PCR (urine, cervical 
swab, vaginal swab, and CVL): any Ct-value observed was interpreted as positive and no Ct-
value observed was interpreted as negative [111]. 
 
4.3 FGS definitions 
 
For the purposes of this PhD thesis, we defined FGS using a variety of diagnostics to evaluate 
both schistosome infection (CAA and urine microscopy), and FGS (portable colposcopy and 
Schistosoma DNA on CVL and cervical and vaginal self-collected swabs) [25] . Participants 
were grouped by the outcomes of these diagnostic tests into three mutually exclusive 
categories (Figure 4.2). FGS was defined as at least one positive Schistosoma PCR on a 
genital specimen (cervical swab and/or vaginal swab and/or CVL). In participants who 
Schistosoma PCR negative on all genital specimens, probable FGS was defined as the 
presence of urinary schistosomiasis, detected with either urine CAA or urine microscopy, in 
combination with one of four clinical findings suggestive of FGS on any colposcope-obtained 
photograph [27]. Negative FGS was defined as negative results on all diagnostic assays. All 
participants with FGS (n=30) and all participants with probable FGS (n=25) were selected 
for characterization of the cervicovaginal microbiota and STIs by PCR on cervical swabs. 
Three negative FGS participants were selected for every FGS and probable FGS participant 
using a random number generator. The negative FGS participants were frequency matched by 
age to participants with FGS. 
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Figure 4.2  Female genital schistosomiasis categories 
 




Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab Combo 
Assay) was performed for HPTN 071 (PopART) Population Cohort participants at each study 
visit [105]. Additional testing using antigen/antibody screening tests, a discriminatory test, 
and an HIV-1 RNA test was used to confirm incident HIV-1 infection, as previously 
described [112]. 
 
4.5 Cervicovaginal microbiota characterization and STI detection 
 
We quantified key markers vaginal health (L. crispatus), BV (G. vaginalis and A. vaginae), 
as well as L. iners (a highly prevalent lactobacillus with an enigmatic role), C. albicans and 
STIs (Chlamydia (C.) trachomatis, Neisseria (N.) gonorrhoeae, Mycoplasma (M.) 
genitalium, and Trichomonas (T.) vaginalis). STIs were quantified by quantitative PCR using 
the S-DiaCTNGTM (for C. trachomatis and N. gonorrhoeae) and S-DiaMGTVTM kits (for M. 
genitalium and T. vaginalis) (both Diagenode Diagnostics, Seraing, Belgium) on DNA 
obtained from cervical swabs at Ghent University (Ghent, Belgium) according to the 
manufacturer s instructions. Quantification of Atopobium vaginalis, Gardnerella vaginalis, 
Lactobacillus crispatus, L. iners and Candida species was performed in the Laboratory 
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Bacteriology Research, Ghent using the LightCycler480® and the LightCyclerR 480 
Software Version 1.5 (Roche, Basel, Switzerland). The specific species of Candida were 
determined based on melting peaks. Amplification was carried out on the LightCycler480® 
and the LightCyclerR 480 Software Version 1.5 (Roche, Basel, Switzerland). To quantify 
each of the target species, standard curves were constructed from a tenfold dilution series of 
DNA from reference strains. The genomic concentrations were calculated using the described 
genomic sizes of the type strains. The concentration of each species was expressed as genome 
equivalents per mL (ge/mL) [113]. 
 
4.6 The MAGPIX bioanalyzer 
 
Luminex MAGPIX technology uses magnetic color-coded beads and an antibody-capture 
system to quantify the amount of unknown analyte in a clinical specimen [114]. Within a test 
kit, specific antibodies are coupled to magnetic microbeads. When a clinical specimen is 
added, the microbead-bound antibodies bind with the analyte of interest. Similar to a 
sandwich-ELISA, specific biotin-bound antibodies then bind the clinical specimen s epitope 
of interest that has been captured on the magnetic bead [115, 116]. Streptavadin-
phycoerythrin (a fluorochrome) has a high affinity for biotin and is used to detect biotinylated 
antibody binding. Often this reaction occurs in a 96-well plate [114], which is then placed 
directly within a Luminex MAGPIX bioanalyzer. The beads are carried into a chamber 
where a magnet captures the beads in a monolayer and uses light emitting diode (LED) 
technology to identify the beads and the amount of fluorescence present [117]. A red LED 
light excites dyes that allow microbead identification. A green LED excites the streptavadin-
phycoerythrin and fluorescence is captured with a charge-coupled device (CCD) camera, this 








Adapted from [117] 
 
4.6.1 Multiplex bead-based assays 
 
Prior to beginning work in the laboratory, I obtained permission from Occupational Health to 
work with specimens known to contain S. haematobium DNA (Appendix 3) and performed a 
risk assessment, which was certified by my project supervisor and the Faculty Safety 
Supervisor (Appendix 4). Luminex MAGPIX was used to measure concentrations of 
seventeen soluble cytokines and chemokines using MILLIPLEX Human 
Cytokine/Chemokine Magnetic Bead kits (Merck Millipore, Darmstadt, Germany) according 
to the manufacturer s instructions and recommendations for dilute samples, i.e. CVL. The 
concentrations of eotaxin (CCL-11), interferon-gamma (IFN-J), interleukin (IL)-10, IL-13, 
IL-15, IL-17A, IL-1D, IL-1E, IL-4, IL-5, IL-6, IL-8 (CXCL-8), IP-10 (CXCL-10), monocyte 
chemoattractant protein (MCP-1) (CCL-2), macrophage inflammatory protein-1 (MIP-1D) 
(CCL-3), macrophage inflammatory protein-1E (MIP-1E) (CCL-4) and tumour necrosis 
factor-D (TNF-D) were measured in undiluted CVL in duplicate. I set the HCYTOMAG-60K 
kit up on a 96-well plate employing four different types of wells: standards, quality control 
(QC), background, and unknowns. The reagent for the standard is provided in the test kit and 
is prepared in serial dilutions. The standard contains a known concentration of the analytes of 
interest and is used to calculate standard curves and convert specimen and QC MFI into 
concentrations. The quality control wells contain specific concentrations of the analytes of 
interest and aid in minimizing between-plate variations in cytokine and chemokine 
 75 
concentrations. The background wells contain only assay buffer and are used to subtract any 
non-specific fluorescence. The CVL specimens collected in the BILHIV study were the 
unknowns. Additionally, equal proportions of specimens with FGS, probable FGS, and 
negative FGS were distributed across six 96-well plates [118]. 
 
Briefly, we wetted a 96-well microtitre plate by adding wash buffer to each well of the plate 
[116]. The plate was sealed and mixed on a plate shaker for 10 minutes at room temperature. 
The wash buffer was then decanted and each standard and control was added to the 
appropriate wells followed by assay buffer. Neat CVL and assay buffer was added to sample 
and background wells, respectively. Assay buffer was added into the background wells. The 
mixed beads were vortexed and added to each well. The plates were sealed, wrapped in foil, 
and incubated with agitation on a plate shaker overnight at 4ºC [116]. Maintaining the plate 
on a magnet to retain microbeads and bound specimen, the contents of the well were 
removed, and the plates were washed two times with wash buffer. We then added detection 
antibodies into each well and sealed, covered with foil and incubated with agitation on a plate 
shaker for 1 hour at room temperature. We then added streptavidin-phycoerythrin to each 
well containing detection antibodies [116]. We then performed 2 washes and added drive 
fluid to all wells and resuspended the beads on the plate shaker for 5 minutes. We then ran 
the plates on the MAGPIX bioanalyzer with a 100PL acquisition volume [116]. 
 
With xPONENT software (version 4.2), the MFI was measured, background-adjusted, and 
converted into analyte concentrations using a 5-parameter logistic regression (5PL) equation 
to interpolate standard curves. The lower limit of detection was between 0.26 and 5.66 pg/ml 
for the 17 cytokines and chemokines measured. Cytokine or chemokine concentrations below 
the lower limit of quantification (LLOQ) were imputed to be the midpoint of the lowest 
concentration for each analyte and zero, and concentrations above the upper limit of 
quantification were imputed as the highest concentration for each analyte.  
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4.6.2 Quality control 
 
I identified the total bead count in each well and each well had no less than 50 beads. I 
created histograms for each analyte and also inspected standard curves visually for each 
analyte across plates for the presence of outliers. The xPONENT software (version 4.2) used 
a 5PL equation to determine concentrations of analytes from the standard curve. I generated 
my own 5PL and 4 parameter logistic (4PL) regression equations and standard curves. The 
data generated from the 5PL equation best described the data. Additionally, my 5PL 
equation, and the subsequent standard curves I generated were similar to those generated by 
xPONENT (r2>0.9). Thus, ultimately, I used concentrations calculated by xPONENT for the 
remainder of the analysis.  
 
Levey-Jennings plots can be used to show changes in quality-control metrics across plates 
[119]. I used these graphs to display show the mean MFI, plus/minus one and two standard 
deviations, per analyte and each standard at 16 pg/mL, 80pg/mL and 400pg/mL on the 
standard curve. There were no observed outliers. The coefficient of variation (CV) can also 
be used to identify changes across duplicate wells and across plates. A priori I specified a 
mean CV of <15% for plates to indicate an acceptable level of heterogeneity, and no mean 
plate CVs exceeded this threshold. I also evaluated duplicate wells and no duplicate wells 
exceeded a CV of 25%. I also included two control reagents across the six plates, as 
recommended by the manufacturer.  
 
Vaginal cytokines and chemokine levels may be low when using cervicovaginal lavage 
samples. Thus, I validated assay results by confirming an association of the pro-inflammatory 
cytokines IL-1D, IL-1E, and TNF-D with the presence and concentrations of Gardnerella 
vaginalis and Atopobium vaginae, bacteria associated with bacterial vaginosis. I used the 
Wilcoxon rank-sum test to compare the concentrations of the pro-inflammatory cytokines by 
presence and absence in participants with G. vaginalis and by presence and absence with A. 
vaginae. Additionally, the pro-inflammatory cytokine concentrations were also compared by 
G. vaginalis and A. vaginae concentration levels using the Kruskal-Wallis test. Results were 
similar by both analysis strategies. The results of pro-inflammatory cytokine concentrations 
by presence and absence of G. vaginalis and A. vaginae are presented in Chapter 6 
(Supplementary Figures 8 and 9, respectively). 
 
 77 
4.7 The role of the Open Data Kit in data collection 
 
The BILHIV parent study operated in participant homes, the cervical cancer clinic, and the 
clinical laboratory. Data were collected across these three locations using xforms-based 
questionnaires on handheld tablets. Community workers conducted questionnaires at home 
isits and entered the participant s data directly into handheld tablets. The midwives used a 
tablet-based clinical research form to capture information regarding the participant s clinical 
encounter. The laboratory technician also used a handheld tablet device to enter specimen 
and processing-related data. I used the ODK, an open-source software to collect and manage 
data [120]. As there was not reliable internet connectivity in Livingstone, ODK allowed us to 
collect data offline and then sync data to the LSHTM server when internet connectivity was 
available. All data were stored in the LSHTM secure server. 
 
4.8 Statistical analysis plan 
 
Full details of the statistical analyses are included in each individual research paper, and this 
section contains an overview of the statistical methods applied in this PhD thesis. For all 
analyses, participant characteristics were summarized by median and interquartile range 
(IQR) for continuous variables, and by frequency and percentage for categorical variables. 
Differences in characteristics bet een the FGS categories ere e aluated using Fisher s 
exact or chi-squared tests. In each manuscript, the primary comparison was between FGS and 
negative FGS women. In Research Paper 2 (Chapter 5  FGS, the cervicovaginal microbiota, 
and STI) and Research Paper 3 (Chapter 6  FGS and cervicovaginal immune activation) a 
secondary analysis compared FGS and probable FGS groups with the negative FGS 
participants. In Research Paper 4 (Chapter 7  FGS and HIV-1 incidence), to be able to use 
all HIV-1 seroconversion data, e created a probable/possible FGS  categor , defined as 
the presence of either a positive urine diagnostic (CAA or microscopy) or one of four 
cervicovaginal manifestations suggestive of FGS on portable colposcopy, or both with a 
negative genital PCR. With FGS, probable/possible FGS, and negative FGS as the exposure 
variables, I calculated the relative risk of HIV-1 seroconversion per unit of the exposure 
variable as a continuous variable. For each of the Research Papers, I performed two 
exploratory analyses to evaluate the association of schistosome infection intensity with study 
outcomes. The first exploratory analysis compared participants with PCR-defined FGS  and 
a moderate/high Schistosoma DNA concentration (Ct <35) with those in the negative FGS 
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group. The second exploratory analysis compared participants with PCR-defined FGS  with 
2 positi e genital PCR specimens ith those in the negative FGS group.  
 
4.8.1 Research paper 2 (Chapter 5)  FGS, the cervicovaginal microbiota and STIs 
 
Log concentration means, medians, and prevalence were calculated by t-tests, ranksum test, 
chi-squared test, respectively, for each reported species when at least 20% of participants had 
results detectable by PCR (>20% prevalence). For species with <20% prevalence, p-values 
comparing presence/absence bet een FGS groups as calculated ith the Fisher s e act test. 
We evaluated for potential confounding using linear and logistic regression. Species with 
>20% prevalence were log-transformed and evaluated by linear regression in univariate and 
multivariate analysis and were adjusted for age, community of residence and education. We 
calculated the crude and adjusted odds of presence/absence of each species by FGS group 
with logistic regression and adjusted for age. 
 
4.8.2 Research Paper 3 (Chapter 6)  FGS and cervicovaginal immune activation  
 
Characteristics of participants were summarized and compared between PCR-defined FGS  
and negative FGS groups. In the initial analysis, cytokines were considered individually. For 
cytokines or chemokines with at least 70% of sample results above the LLOQ, differences in 
median cytokine or chemokine concentrations were compared between FGS categories with 
the Wilcoxon-Mann-Whitney test. For cytokines with <70% of the samples above the lower 
limit of quantification (IL-5, IL-13, IL-15, and TNF-a), these cytokines were evaluated as 
presence/absence and were compared between FGS categories by the chi-squared test. Next, 
cytokine and chemokine responses were compared between FGS and negative FGS 
participants. Finally, FGS and negative FGS participants were compared using multivariable 
regression, with adjustment for potential confounders. Cytokines with <70% of the samples 
above the LLOQ were evaluated by logistic regression and were adjusted for age [107].  
 
I then investigated combining information from multiple cytokines. Initially, I used 
Spearman s rank correlation coefficient for each analyte pair to understand patterns of 
association between cytokines. I then used dimension reduction techniques to evaluate the 
possibility that groups of cytokines may be correlated and/or associated with FGS in a similar 
way. I used principal components analysis to linearly transform the original set of correlated 
MAGPIX-generated analytes to a new set of variable, components , which are uncorrelated, 
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with the first principal component capturing the largest amount of variation from the original 
variables [121]. The means of the first principal components were taken forward for 




4.8.3 Research paper 4 (Chapter 7)  FGS and HIV-1 incidence  
 
Women who were HIV-1 positive at HPTN 071 (PopART) baseline were excluded from the 
analysis of this objective. HIV-1 incidence was calculated as the number of seroconversions 
per 1,000 person-years of follow up. Participants contributed person-time for the calculation 
of HIV-1 incidence starting with their first HIV-1 test and ending at date of HIV-1 
seroconversion for those who seroconverted, or at the date of last follow-up or the end of 
scheduled follow-up (whichever occurred earliest) for women who did not seroconvert. HIV-
1 seroconversion was assumed to occur at the midpoint between the last negative and the first 
positive HIV-1 test. Associations of risk factors with incident HIV-1 infection were 
calculated as rate ratios and 95% confidence intervals, estimated using exact Poisson 
regression in univariable and multivariable analysis. 
 
4.9 Ethical considerations 
 
The parent study and the sub-studies were approved by the University of Zambia Biomedical 
Research Ethics Committee (reference 011-08-17, Appendix 5 and Appendix 6), the Zambia 
National Health Research Authority and the London School of Hygiene and Tropical 
Medicine Ethics Committee (reference 14506, Appendix 7 and Appendix 8). Permission to 
conduct the study was given by Livingstone District Health Office and the superintendent of 
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The cervicovaginal microbiota, including sexually transmitted infections (STI), have not been 
well-described in female genital schistosomiasis (FGS). 
 
Methods 
Women (aged 18-31, sexually active, non-pregnant) were invited to participate at the final follow-
up of HPTN 071 (PopART) Population Cohort in January-August 2018. We measured key species 
of the cervicovaginal microbiota (Lactobacillus crispatus, L. iners, Gardnerella vaginalis, 
Atopobium vaginae and Candida) and STI (Chlamydia trachomatis, Neisseria gonorrhoeae, 
Trichomonas vaginalis and Mycoplasma genitalium) using quantitative PCR (qPCR). We 
evaluated associations of microbiota and STI presence and concentration with FGS (qPCR-
detected Schistosoma DNA in any of three genital specimens).  
 
Results 
The presence and concentration of key cervicovaginal species did not differ between participants 
with (n=30) or without FGS (n=158). A higher proportion of participants with FGS had T. 
vaginalis compared to FGS negative women (p=0.08), with further analysis showing that T. 
vaginalis was more prevalent among women with 2 Schistosoma qPCR positive genital 




We found weak evidence of an association between T. vaginalis presence and FGS, with a stronger 
association in women with a higher burden FGS infection. Additional research is needed on 





Female genital schistosomiasis (FGS), caused when eggs from the waterborne parasite S. 
haematobium are entrapped in genital tissue, is prevalent in sub-Saharan Africa and is associated 
with adverse reproductive outcomes, including ectopic pregnancy, infertility, and prevalent HIV-
1 [1, 2]. The cervicovaginal environment ha  bee  de c ibed a  i a  he  i  is dominated by 
lactic-acid producing lactobacilli, commensal microorganisms that adhere to an intact vaginal 
squamous epithelium [3, 4], protecting against pathogens by acidifying the vagina and producing 
antimicrobial substances such as bacteriocins [3]. Bacterial vaginosis (BV) and vulvovaginal 
candidiasis are examples of non-optimal  microbiota, characterized by a shift from lactobacilli 
dominance to an increase in anaerobic species or yeast [4]. BV is prevalent in women in sub-
Saharan Africa [5, 6] and has important sexual and reproductive health consequences, including 
increased risk of pelvic inflammatory disease, and adverse pregnancy outcomes such as pre-term 
delivery [5, 7], a leading cause of under-five mortality in sub-Saharan Africa [8]. BV is also 
strongly associated with HIV-1 acquisition and other sexually transmitted pathogens infecting the 
genital tract, [5, 9, 10] yet the relationship between cervicovaginal microbiota and FGS is not well 
characterized. 
 
Studies employing 16S rRNA sequencing to evaluate the cervicovaginal microbiota suggest that 
high-intensity urinary S. haematobium infection, in the absence of investigation for genital 
involvement, may alter cervicovaginal microbiota diversity [11]. In addition, studies reporting 
qPCR-defined FGS have either not investigated or reported STI prevalence [12-14] or STI 
prevalence has been correlated with visual FGS findings [15]. In this cross-sectional study we 
utilized qPCR to detect Schistosoma DNA in the female genital tract and evaluated the association 
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of PCR-defined FGS with the concentration and presence of key markers of the cervicovaginal 
microbiota, including STI. 
 
Methods 
Study setting and participants 
The cross-sectional bilharzia and HIV (BILHIV) study [16] was nested in HPTN 071 (PopART), 
a cluster randomized trial to measure the impact of an HIV-1 combination prevention package 
[17]. In HPTN 071 (PopART), HIV-1 incidence was measured in a Population Cohort at baseline, 
12, 24, and 36 months [17]. Between January and August 2018, after the 36-month HPTN 071 
(PopART) visit, community workers made home visits to women expressing interest in the 
BILHIV study [16]. Eligible women were 18-31 years, not pregnant, sexually active, and resident 
in one of two urban communities that participated in HPTN 071 (PopART) in Livingstone, 
Zambia. 
 
Home and clinic-based sample collection  
The home visit included written informed consent, a questionnaire, genital self-sampling (cervical 
and vaginal), and urine specimen collection, as previously described [16]. Enrolled women not 
currently menstruating were invited to attend Livingstone Central Hospital cervical cancer clinic, 
where midwives performed cervicovaginal lavage (CVL). After speculum insertion, a bulb syringe 
was used to flush normal saline (10 mL) across the cervix and vaginal walls for one minute. CVL 
fluid was collected from the posterior fornices (S1-Text). CVL, vaginal and cervical swab 
specimens were used for quantitative PCR (qPCR) detection of Schistosoma; cervical swabs were 
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used for characterization of the microbiota and STI by qPCR; urine was used for detection of 
circulating anodic antigen (CAA) and S. haematobium eggs by microscopy. 
 
Cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, Israel) 
and were evaluated (EFK) for any of the four recognized FGS cervicovaginal manifestations: 
grainy sandy patches, homogenous yellow sandy patches, rubbery papules, and abnormal blood 
vessels [18]. Women with at least one of these manifestations [18] or with any positive urine or 
genital Schistosoma diagnostic were treated free of charge with 40 mg/kg praziquantel. Testing for 
STI was not performed at the point-of-care and participants with suspected STI were offered 
syndromic management, as per local guidelines [19].  
 
HIV-1 
Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab Combo Assay) 
was performed for HPTN 071 (PopART) Population Cohort participants at each study visit [17].  
 
Urine microscopy and Circulating Anodic Antigen 
Urine was centrifuged and examined by microscopy for S. haematobium eggs. The participant was 
considered positive if a pellet contained at least one S. haematobium egg [16]. A lateral flow assay 
utilizing up-converting reporter particles for the quantification of CAA was performed on urine 
samples, as previously described [16, 20]. Analyzing the equivalent of 417 PL urine (wet reagent, 
UCAAhT417), a test result indicating a CAA value >0.6 pg/mL was considered positive [21]. 
 
qPCR for detection of Schistosoma DNA 
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Detection of the Schistosoma-specific internal-transcribed-spacer-2 (ITS2) target by qPCR was 
performed at LUMC, as previously described (S1-Text) [16, 22]. DNA extraction of 200 µL of 
CVL, cervical or vaginal swab fluid was done with QIAamp spin columns (QIAGEN Benelux; 
Venlo, The Netherlands) acc di g  a fac e  g ide i e . The qPCR output was reported 
in cycle threshold values (Ct-values) and parasite DNA loads were categorized by the following 
pre-specified values: high (Ct<30), de a e (30 Ct <35),  (35 Ct<50) and negative (no 
amplification) [23].  
 
Cervicovaginal microbiota characterization and STI detection 
We quantified Lactobacillus crispatus as a key marker of vaginal health. Additionally, we 
characterized BV (Gardnerella vaginalis and Atopobium vaginae), as well as L. iners (an 
enigmatic and highly prevalent lactobacillus), Candida spp. and STI (Chlamydia trachomatis, 
Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis). STI were quantified 
by qPCR using the S-DiaCTNGTM (for C. trachomatis and N. gonorrhea) and S-DiaMGTVTM kits 
(for M. genitalium and T. vaginalis) (Diagenode Diagnostics, Seraing, Belgium) on DNA from 
ce ica  ab  a  Ghe  U i e i  (Ghe , Be gi ) acc di g  he a fac e  i c i . 
Quantification of A. vaginae, G. vaginalis, L. crispatus, L. iners and Candida species was 
performed in the Laboratory Bacteriology Research, Ghent using the LightCycler480® and 
Software Version 1.5 (Roche, Basel, Switzerland) (S1-Text). The concentration of each species 




In this study we employed various diagnostic tests to evaluate urinary schistosome infection (CAA 
and urine microscopy), and FGS (portable colposcopy and Schistosoma DNA on CVL and genital 
swabs). As previously described [25], participants were grouped by diagnostic test results into 
three mutually exclusive categories: FGS, at least one positive Schistosoma qPCR on a genital 
specimen (cervical swab, vaginal swab and/or CVL); FGS negative, negative results on all 
diagnostic methods; probable FGS, genital Schistosoma qPCRs negative but urinary 
schistosomiasis positive (as defined above), in combination with one of four clinical findings 
suggestive of FGS on any colposcope-obtained photograph [18].  
 
Patient consent statement 
The study was approved by the University of Zambia Biomedical Research Ethics Committee 
(011-08-17), the Zambia National Health Research Authority and the London School of Hygiene 
and Tropical Medicine Ethics Committee (14506). Permission to conduct the study was given by 
Livingstone District Health Office and the Livingstone Central Hospital superintendent. 
Participants provided written informed consent. 
 
Statistical Methods 
All participants with FGS (n=30) and all participants with probable FGS (n=25) were selected for 
characterization of the cervicovaginal microbiota and STI by qPCR on cervical swabs. Three FGS 
negative participants were selected for every FGS and probable FGS participant using a random 
number generator. The FGS negative participants were frequency matched by age to participants 
with FGS (age groups 18-19, 20-21, 22-23, 24-25, 26-27, 28-29, 30-31).  
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Participant characteristics were summarized by median and interquartile range (IQR) for 
continuous variables, and by frequency and percentage for categorical variables. Differences in 
cha ac e i ic  be ee  FGS ca eg ie  e e e a a ed i g Fi he  e act or chi-squared tests. 
For cervicovaginal microbiota and STI species with at least 20% of sample results detectable by 
qPCR (i.e. 20% prevalence), p-values for comparison of presence, median (IQR), and log10 
concentration mean between FGS and FGS negative groups were calculated from chi-squared test, 
ranksum test, and t-test, respectively. For species with <20% prevalence, species presence was 
compared between FGS groups i g Fi he  e ac  e . To enable investigation of potential 
confounding, concentrations of cervicovaginal microbiota with 20% prevalence were log-
transformed to normalize their distribution, and linear regression used to evaluate the association 
between FGS and mean log concentration of each organism (ge/mL) in univariable and 
multivariable analysis. We developed a causal framework (Figure 5.S1) to inform our minimal 
adjustment set, and adjusted for age, education and community of residence. For all species, 
logistic regression was used to calculate crude and adjusted odds ratio (OR) for presence versus 
absence by FGS group; due to the relatively low number of participants with detectable 
concentrations, logistic regression analyses only adjusted for age. Given the exploratory nature of 
this work, we did not correct for multiple comparisons. 
Our primary analysis focused on the detection of Schistosoma DNA in the genital tract (FGS versus 
FGS negative). A secondary analysis compared FGS and probable FGS groups with the FGS 
negative participants. To evaluate the possible association between FGS burden and changes in 
presence and concentration of cervicovaginal key species, two ad-hoc analyses were performed: 
(1) participants with 2 genital samples with detectable Schistosoma DNA were compared with 
the FGS negative group, (2) participants with a moderate/high genital Schistosoma DNA 
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concentration (Ct <35 in at least one of three samples) were compared with the FGS negative 
group. Data were analyzed using STATA 15.1 (Stata Corporation, College Station, TX).  
Results 
A total of 603 eligible women were enrolled and 213 (35.3%) were included in this study (Figure 
5.S2). Of those included, 14.1% (30/213) had FGS, defined by a positive genital Schistosoma 
qPCR from any of the following sites: 9.4% (20/213) cervical swab, 7.0% (15/213) vaginal swab, 
and 6.6% (14/211) CVL. Of participants with FGS, 53.3% (16/30) had Schistosoma qPCR detected 
from multiple sites and 53.3% (16/30) had moderate/high genital Schistosoma DNA loads, these 
groups overlapped by 12 participants. Twenty-five women had probable FGS, and 74.2% 
(158/262) of the women who were negative on all diagnostic tests were randomly selected for 
inclusion in this study.  
 
Baseline characteristics  
The majority of the participants were married/cohabitating, had received some secondary 
education, and were using hormonal contraception (Table 5.1). At the conclusion of HPTN 071 
(PopART), HIV-1 prevalence was 17.4% (37/213) among the women included in this study and 
one-third had at least one STI (Table 5.1). Urinary schistosome infection, defined as either a 
positive urine microscopy (11.7%, 25/213) and/or positive CAA (20.7%, 44/213), was reported in 
21.6% (46/213) of participants. There were differences between the three categories of FGS status 
for age (p=0.002), marital status (p=0.04), education (p=0.06), and employment (p=0.04) with 
participants in the probable FGS group more likely to be older, employed, and married than FGS 
and FGS negative participants. There was strong evidence of a difference in community of 
residence by FGS status (p<0.001) with participants with FGS and probable FGS more likely to 
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live in Community A than participants in the FGS negative group (Table 5.1). Other characteristics 
were similar by FGS status. 
 
Primary comparison: FGS vs FGS negative 
Concentrations of evaluated species are shown in Figure 5.1. Compared to FGS negative women, 
there was no evidence of a difference in the presence or concentration of cervicovaginal L. 
crispatus, L. iners, A. vaginae, G. vaginalis or Candida spp. in participants with FGS (Table 5.2). 
There was weak evidence that a higher proportion of participants with FGS had T. vaginalis present 
(OR 2.11, 95% CI: 0.92  4.86, p=0.08, Table 5.S2). This association remained after adjusting for 
age (Table 5.S1). Otherwise, compared to FGS negative women, the presence and concentration 
of other STI was similar in women with FGS (Table 5.2).  
 
Combining FGS and probable FGS groups, participants with FGS/probable FGS similarly had a 
higher prevalence of T. vaginalis compared to FGS negative participants (Table 5.S2, p=0.05). 
Otherwise, compared to FGS negative women, the presence and concentrations of cervicovaginal 
microbiota and the presence of STI was similar in women with FGS/probable FGS compared to 
FGS negative participants (Table 5.S2). 
 
Ad-hoc Analysis – Schistosoma DNA concentration  
In participants (n=16) with FGS and moderate/high genital Schistosoma DNA concentration 
(Schistosoma qPCR Ct<35) the presence of T. vaginalis was higher than among the FGS negative 
participants (p=0.01, Table 5.3). Women with FGS and a moderate/high Schistosoma DNA 
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concentration (Ct<35) had a higher mean concentration of G. vaginalis compared to FGS negative 
women (p=0.03, Table 5.3).   
 
Ad-hoc analysis – clinical disease burden 
In an ad-hoc analysis, participants (n=16) with a higher FGS burden, defi ed a  2 Schistosoma 
qPCR positive genital specimens, had higher prevalence of T. vaginalis compared to FGS negative 
participants (p=0.01, Table 5.4). There was also evidence of a difference in the median 
concentration and the mean log-concentration of L. iners (both p=0.03) compared to FGS negative 
women, with lower levels among the higher FGS burden group (Table 5.4).  
 
Discussion  
In this study, we describe the association of FGS with the cervicovaginal microbiota, including 
lactobacilli, Candida spp., a e  f a - i a  ce ic agi a  e i e , a d STI. We 
did not find evidence that the presence or concentration of key cervicovaginal species was 
associated with FGS. While FGS was not associated with C. trachomatis, M. genitalium, or N. 
gonorrhoeae, there was weak evidence of an association of T. vaginalis presence with FGS, which 
remained after adjusting for age. This association was also present when participants with FGS 
and probable FGS were combined and is strengthened in the ad-hoc analyses of participants with 
higher burden FGS.  
 
We performed two ad-hoc analyses. High-intensity S. haematobium infection, in the absence of 
evaluation for FGS, has been associated with higher cervicovaginal alpha diversity [11]. Thus, 
first we investigated whether Schistosoma DNA concentrations might be associated with the 
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cervicovaginal microbiota in 16 participants with a higher FGS burden, indicated by moderate/high 
genital Schistosoma DNA concentrations. In this ad-hoc analysis, we found that the G. vaginalis 
log-concentration mean was higher in women with a higher FGS burden. Participants underwent 
CVL when they were not menstruating, and we have previously described that 66.2% (139/210) 
of women in this cohort had detectable CVL hemoglobin. Iron sources, like hemoglobin, are often 
required for bacterial growth [26]. G. vaginalis is well adapted to harvest iron from the 
environment [27] and higher concentrations of G. vaginalis coincide with menses [26]. Cervical 
tissue in women with FGS is more vascularized than non-egg containing tissue and thus, the 
abnormal cervical vessels and contact bleeding seen in clinical FGS provides a plausible link to 
increased concentrations of G. vaginalis in high-burden FGS [28].  
 
In a second ad-hoc analysis, we examined participants with multiple qPCR-positive genital 
specimens as a potential proxy marker of high-burden FGS and found that reduced L. iners 
concentration (median and log mean) was associated with high-burden FGS. The cervicovaginal 
microbiota was characterized with 16S rRNA sequencing in Tanzanian women with S. 
haematobium infection (n=16). Although power was limited, women with high-intensity S. 
haematobium infection had reduced abundance of L. iners compared to women with low-intensity 
infection, albeit without evidence of a difference (p=0.39) [11]. Though a Lactobacillus species, 
L. iners can be present in both i a  a d - i a  ce ic vaginal microbiomes [29]. L. 
iners does not produce D-lactic acid, which may influence cervical mucus thickness and 
permeability [29, 30]. Additionally, L. iners’ small genome size may suggest it has adapted well 
to relying on the host environment [29]. Further research is needed to evaluate the relationship 
between L. iners presence and concentration in FGS.  
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In both ad-hoc analyses, we found that T. vaginalis presence was higher among the participants 
with a higher FGS burden. Our finding supports results from a small South African study (n=45) 
that reported an association between FGS (diagnosed by identification of sandy patches on 
colposcopy) and T. vaginalis presence in young women (ages 15-23) [31]. Acquisition of T. 
vaginalis and S. haematobium may share common risk factors, like age and socioeconomic status 
[16]. We have previously described higher FGS prevalence amongst younger age groups [16]. 
Epidemiologic data from Zambian adolescents, sex-workers and pregnant women (aged 13-45 
years) describes a T. vaginalis prevalence between 24.6-33.2% [32], consistent with the prevalence 
in our population (24.9%). While S. haematobium is geographically restricted to Africa and the 
Middle East, it is associated with poverty [33] and is acquired through contact with cercariae 
infested water [2]. T. vaginalis is primarily sexually transmitted, is prevalent worldwide, with the 
highest prevalence in women from low-income countries [34]. Macrophage polarization can be 
influenced by the local immune environment, schistosomes, and T. vaginalis [35, 36]. We have 
previously shown that, compared to FGS negative women, high-burden FGS is associated with 
higher concentrations of cervicovaginal Th2 cytokines [25]. A mouse model of urogenital S. 
haematobium infection suggested that the Th2 immune environment may be associated with 
delayed pathogen clearance [37]. Thus, further research is needed regarding the interaction 
between the immune environment and macrophage phenotypes in FGS and their role in potentially 
influencing T. vaginalis persistence.  
 
Our study is the first to evaluate cervicovaginal microbiota and STI in FGS defined by qPCR. This 
is particularly relevant in a population of sexually active, non-pregnant women in the context of 
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high HIV-1 prevalence. Many studies evaluating the cervicovaginal microbiota apply either a 
PCR-based or a 16s rRNA sequencing approach. A strength of the qPCR-based approach was the 
ability to determine concentrations of the species of interest. Additionally, since 16s rRNA only 
identifies bacterial pathogens, the use of a PCR-based technique allowed us to identify a protozoan 
(T. vaginalis) and yeast (Candida spp.) that would not be detected by 16s rRNA sequencing. A 
limitation of the PCR-based approach is that we were only able to identify the organisms for which 
we had chosen primers, whereas 16s rRNA sequencing allows a broader analysis of cervicovaginal 
microbial populations [38]. A limitation of the 16s rRNA sequencing approach is that 16s rRNA 
generates relative rather than absolute bacterial abundance [39]. Other experimental limitations of 
a 16s rRNA approach include bias that can potentially be introduced due to primer affinity and 
guanine/cytosine composition, with the outcome that not all 16s genes amplify similarly [39]. 
Additionally, computational limitations of 16s rRNA sequencing include challenges with quality 
control, genome assembly, and taxonomic classification [38].  
 
The study was conducted in an urban location with relatively low S. haematobium prevalence, thus 
the numbers of FGS cases in the primary and ad-hoc analyses were small, limiting precision in the 
effect sizes. This analysis also included multiple statistical comparisons; thus, we focused on the 
species that showed a consistent pattern of association across primary and ad-hoc analyses, rather 
than over-interpreting significance testing for any one species in insolation. Evidence for these 
associations in the ad-hoc analyses should be viewed as hypothesis generating. Additionally, the 
cross-sectional study design limited our ability to assess FGS duration or the long-term impact on 
the prevalence and concentrations of key species or STI. There were a number of behavioral and 
biological factors that were not measured in our study including tobacco use [40], viral STI (human 
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papillomavirus and herpes simplex virus-2) [40], intravaginal cleansing practices [41], and 
menstrual hygiene [42]. As these factors may be associated with the cervicovaginal microbiota, 
we cannot exclude residual or unmeasured confounding. Genital swabs were self-collected by 
participants, raising the potential for false negative genital swabs. In future work, -globin PCR 
could be implemented as a positive control to confirm the presence of human DNA [16]. Lastly, 
we defined FGS by Schistosoma DNA detection on qPCR, however we cannot exclude that 
cervicovaginal qPCR detected S. haematobium eggs from a sexual partner  e e  [16]. 
 
In conclusion, we report weak evidence of an association between T. vaginalis presence and FGS, 
with a consistently stronger association in women with a higher burden FGS infection. Additional 
research is needed to understand the interactions between S. haematobium and T. vaginalis, 
especially regarding HIV-1 vulnerability.  
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 FGS Negative 
(n)%  
(n=158) 







Age in years  Median(IQR)  23 (22  24) 27 (23  31) 22 (21  24) 0.002   
Marital status Single 72 (45.6) 4 (16.0) 13 (43.) 0.04 
 Married or Cohabitating 81 (51.3) 20 (80.0) 17 (56.7)  
 Divorced, or Separated 5 (3.2) 1 (4.0) 0 (0.0)  
Education (highest level) None or Any Primary School 35 (22.2) 12 (48.0) 10 (33.3 (10) 0.06 
 Any Secondary School 1111 (70.3) 13 (52.0) 19 (63.3)  
 Trade, Degree or higher 12 (7.6) 0 (0.0) 1 (3.3)  
District Community A 66 (41.8) 20 (80.0) 22 (73.3) <0.01 
 Community B 92 (58.2) 5 (20.0) 8 (26.7)  
Household members 1-3 51 (32.3) 4 (16.0) 12 (40.0) 0.3 
 4-5 61 (38.6) 13 (52.0) 8 (26.7)  
 6+ 46 (29.1) 8 (32.0) 10 (33.3)  
Employment status Not Working 117 (74.1)  14 (56.0) 26 (86.7) 0.04 
 Working 41 (25.9)  11 (44.0) 4 (13.3)  
Sexual behaviour characteristics       
Age at sexual debut (years) 8-16 64 (40.5) 11 (44.0) 17 (56.7) 0.4 
 17-19 74 (46.8) 13 (52.0) 10 (33.3)  
 20-24 20 (12.7) 1 (4.0) 3 (10.0)  
Lifetime sexual partners 1 57 (36.1) 8 (32.0) 5 (16.7) 0.3 
 2 36 (22.8) 6 (24.0) 9 (30.0)  
 3 23 (14.6) 6 (24.0) 8 (26.7)  
 4+ 42 (26.6) 5 (20.0) 8 (26.7)  
Currently sexually active**,  No 26 (16.6) 2 (8.0) 3 (10.0) 0.5 
 Yes 131 (83.4) 23 (92.0) 27 (90.0)  
Condom use with last sex  No 120 (76.9) 16 (66.7) 22 (73.3) 0.6  
 Yes 36 (23.1) 8 (33.3) 8 (26.7)  
HIV-1 Status Not Detected 132 (83.5) 20 (80.0) 24 (80.0) 0.8 
 Detected 26 (16.5) 5 (20.0) 6 (20.0)  
Any STI*** Not Detected 106 (67.1) 14 (56.0) 18 (60.0) 0.5 
 Detected 52 (32.9) 11 (44.0) 12 (40.0)  
Contraceptive Use      
Condoms No 132 (83.5) 20 (80.0) 26 (86.7) 0.8 
 Yes 26 (16.5) 5 (20.0) 4 (13.3)  
OCP No 148 (93.7) 22 (88.0) 29 (96.7) 0.5 
 Yes 10 (6.3) 3 (12.0) 1 (3.3)  
Injectable No 82 (51.9) 13 (52.0) 15 (50.0) 1.0  
 Yes 76 (48.1) 12 (48.0) 15 (50.0)  
Implant No 144 (91.1) 23 (92.0) 28 (93.3) 1.0 
 Yes 14 (8.9) 2 (8.0) 2 (6.7)  
An  Hormonal Contraception  No 58 (36.7) 8 (32.0) 10 (35.7) 0.9  
 Yes 100 (63.3) 17 (68.0) 18 (64.3)  
Schistosomiasis-related Factors     
Urine microscopy Not Detected 158 (100.0) 19 (76.0) 11 (36.7) <0.001II 
 Detected 0 (0.0) 6 (24.0) 19 (63.3)  
Urine CAA Negative 158 (100.0) 0 (0.0) 11 (36.7) <0.001II 
 Positive 0 (0.0) 25 (100.0) 19 (63.3)  
Active Infection~~ Not Present 158 (100.0) 0 (0.0) 9 (30.0) <0.001II 
 Present 0 (0.0) 25 (100.0) 21 (70.0)  
      
*Fisher s e act p-value unless otherwise indicated 
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 Kruskal Wallis p-value 
 Chi squared p-value 
**Any sexual activity in the last 6 months 
Participants ho responded ith no ans er  (n=1) are not sho n in the table  
 Participants ho responded ith no ans er  (n=3) are not sho n in the table  
*** Any STI defined as the presence of at least one of N. gonorrhoeae, C. trachomatis, M. 
genitalium or T. vaginalis 
An  hormonal contraception is defined as use of injectable agents, implants, or oral 
contraceptive pills 
~~ Active infection defined as the presence of either a positive CAA or urine microscopy for 
S. haematobium eggs, or both 
IIPart of the definition for FGS categories 
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Table 5.2  Presence and concentration of vaginal Lactobacilli, other key microbiota, and sexually transmitted infection, overall and by female 
genital schistosomiasis status  
 
Organism n(%) and 
Concentration* 






      
L. crispatus Presence 69 (32.4) 49 (31.0) 13 (43.3) 0.19 
 Median (IQR) 8.7x106 (2.6x105  4.2x108) 1.1x107 (2.6x105  7.0x108) 7.5x105 (1.9x105  2.7x107) 0.20 
 Log concentration mean 16.01 16.38 14.82 0.19 
L. iners Presence 156 (73.2) 113 (71.5) 24 (80.0) 0.34 
 Median (IQR) 2.7x108 (3.8x107  1.5x109) 2.8x108 (3.9x107  1.6x109) 1.7x108 (1.6x107  1.0x109) 0.39 
 Log concentration mean 18.93 18.98 18.36 0.33 
G. vaginalis Presence 156 (73.2) 115 (72.8) 23 (76.7) 0.66 
 Median (IQR) 7.7x106 (8.3x105  5.2x107) 8.1x106 (7.7x105  4.8x107) 3.8x106 (6.8x105  6.4x107) 0.93 
 Log concentration mean 15.85 15.74 15.91 0.79 
A. vaginae Presence 152 (71.4) 112 (70.9) 19 (63.3) 0.41 
 Median (IQR) 5.8x107 (8.2x106  2.1x108) 5.8x107 (8.7x106  2.0x108) 3.0x107 (1.06x106  2.8x108) 0.83 
 Log concentration mean 17.31 17.33 17.06 0.66 
T. vaginalis Presence 53 (24.9) 34 (21.5) 11 (36.7) 0.08 
 Median (IQR) 4.2x104 (173.0  2.3x106) 1.7x105 (56.9  6.3x106) 1.0x104 (5030.0  4.5x105) 0.53 
 Log concentration mean 10.39 10.88 10.19 0.69 
Vaginal Microbiota with prevalence <20%    
N. gonorrhoeae Presence 13 (6.1) 12 (7.6) 0.0 (0) 0.22 
C. trachomatis Presence 17 (8.0) 13 (8.2) 3 (10.0) 0.72 
M. genitalium Presence 8 (3.8) 7 (4.4) 0 (0.0) 0.60 
Candida spp. Presence 12 (5.63) 8 (5.1) 2 (6.7) 0.66 
 
*concentrations are expressed in genome equivalents/mL; 
** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-
test, respectively. For species with <20% prevalence, p- alues for presence are from Fisher s e act test. 
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Table 5.3  Ad-hoc analysis of the presence and concentration of vaginal Lactobacilli, other cervicovaginal microbiota, and sexually transmitted 
infection in participants with moderate to high concentration of Schistosoma DNA (Ct <35) compared to female genital schistosomiasis negative 
participants 
 




FGS with Ct<35 
(n=16) 
p-value** 
     
L. crispatus Presence 49 (31.0) 6 (37.5) 0.60 
 Median (IQR) 1.1x107 (2.6x105  7.0x108) 1.2x106 (3.0x105  2.0x107) 0.28 
 Log concentration mean 16.38 14.27 0.19 
L. iners Presence 113 (71.5) 11 (68.75) 0.82 
 Median (IQR) 2.8x108 (3.9x107  1.6x109) 7.5x107 (3.6x106  7.5x108) 0.30 
 Log concentration mean 18.98 17.86 0.21 
G. vaginalis Presence 115 (72.8) 13 (81.3) 0.46 
 Median (IQR) 8.1x106 (7.7x105  4.8x107) 1.5x107 (3.8x106  3.1x108) 0.11 
 Log concentration mean 15.74 17.45 0.03 
A. vaginae Presence 112 (70.9) 13 (81.3) 0.38 
 Median (IQR) 5.8x107 (8.7x106  2.0x108) 1.6x108 (1.6x107  2.8x108) 0.70 
 Log concentration mean 17.33 17.38 0.95 
T. vaginalis Presence 34 (21.5) 8 (50.0) 0.01 
 Median (IQR) 1.7x105 (56.9  6.3x106) 8085.0 (5210.0  1.0x106) 0.56 
 Log concentration mean 10.88 10.09 0.70 
Vaginal Microbiota with Prevalence <20%   
N. gonorrhoeae Presence 12 (7.6) 0 (0.0) 0.61 
C. trachomatis Presence 13 (8.2) 2 (12.5) 0.63 
M. genitalium Presence 7 (4.4) 0 (0.0) 1.0 
Candida spp. Presence 8 (5.1) 2 (12.5) 0.23 
 
*concentrations are expressed in genome equivalents/mL 
** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-test, 
respectively. For species with <20% prevalence, p-values for presence are from Fisher s e act test. 
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Table 5.4  Ad-hoc analysis of the presence and concentration of vaginal Lactobacilli, cervicovaginal microbiota, and sexually transmitted 
infection in participants with Schistosoma DNA detected in  2 genital specimens compared to female genital schistosomiasis negative 
participants 
 




 2 PCR FGS 
(n=16) 
p-value** 
     
L. crispatus Presence 49 (31.0) 7 (43.8) 0.30 
 Median (IQR) 1.1x107 (2.6x105  7.0x108) 1.9x106 (7.7x104  2.7x107) 0.32 
 Log concentration mean 16.38 14.90 0.34 
L. iners Presence 113 (71.5) 10 (62.5) 0.45 
 Median (IQR) 2.8x108 (3.9x107  1.6x109) 5.1x107 (9.0x105  1.1x108) 0.03 
 Log concentration mean 18.98 17.00 0.03 
G. vaginalis Presence 115 (72.8) 14 (87.5) 0.20 
 Median (IQR) 8.1x106 (7.7x105  4.8x107) 1.6x107 (1.1x106  3.6x108) 0.29 
 Log concentration mean 15.74 16.85 0.16 
A. vaginae Presence 112 (70.9) 11 (68.8) 0.86 
 Median (IQR) 5.8x107 (8.7x106  2.0x108) 1.6x108 (2.7x107  3.2x108) 0.33 
 Log concentration mean 17.33 18.04 0.36 
T. vaginalis Presence 34 (21.5) 8 (50.0) 0.01 
 Median (IQR) 1.7x105 (56.9  6.3x106) 5680.0 (2967.5  1.0x106) 0.50 
 Log concentration mean 10.88 9.71 0.56 
Vaginal Microbiota with Prevalence <20%  
N. gonorrhoeae Presence 12 (7.6) 0 (0.0) 0.61 
C. trachomatis Presence 13 (8.2) 2 (12.5) 0.63 
M. genitalium Presence 7 (4.4) 0 (0.0) 1.0 
Candida spp. Presence 8 (5.1) 1 (6.3) 0.59 
     
*concentrations are expressed in genome equivalents/mL 
** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-








Table 5.S1  Crude and adjusted associations of presence and mean log-transformed concentrations of vaginal Lactobacilli, other cervicovaginal 
microbiota, and sexually transmitted infection with female genital schistosomiasis status 
 

















Estimate  (OR, 




         
L. crispatus Presence** 69 (32.4) 49 (31.0) 13 (43.3) 1.70 (0.77  3.77) 0.19 1.68 (0.74  3.79) 0.22 
 Log conc mean  16.01 16.38 14.82 -1.56 (-3.90  0.78) 0.19 -1.93 (-4.57  0.71) 0.13 
L. iners Presence** 156 (73.2) 113 (71.5) 24 (80.0) 1.60 (0.61  4.16) 0.34 1.68 (0.74  3.79) 0.22 
 Log conc mean  18.93 18.98 18.36 -0.62 (-1.88  0.64) 0.33 -0.53 (-1.83  0.77) 0.41 
G. vaginalis Presence** 156 (73.2) 115 (72.8) 23 (76.7) 1.23 (0.49  3.07) 0.66 1.22 (0.49  3.05) 0.67 
 Log conc mean  15.85 15.74 15.91 -0.17 (-1.08  1.41) 0.79 0.24 (-1.05  1.53) 0.71 
A. vaginae Presence** 152 (71.4) 112 (70.9) 19 (63.3) 0.71 (0.31  1.61) 0.41 0.71 (0.31  1.61) 0.42 
 Log conc mean  17.31 17.33 17.06 -0.27 (-1.51  0.96) 0.66 -0.18 (-1.44  1.07) 0.77 
T. vaginalis Presence** 53 (24.9) 34 (21.5) 11 (36.7) 2.11 (0.92  4.86) 0.08 2.09 (0.90  4.83) 0.09 
 Log conc mean  10.39 10.88 10.19 -0.69 (-4.16  2.77) 0.69 -0.65 (-4.47  3.17) 0.71 
Vaginal microbiota with prevalence <20%       
N. gonorrhoeae Presence 13 (6.1) 12 (7.6) 0.0 (0) Not applicable 0.22 Not applicable NA 
C. trachomatis Presence** 17 (8.0) 13 (8.2) 3 (10.0) 1.24 (0.33  4.64) 0.72 1.20 (0.32  4.54) 0.79 
M. genitalium Presence 8 (3.8) 7 (4.4) 0 (0.0) Not applicable 0.60 Not applicable NA 
Candida spp. Presence** 12 (5.63) 8 (5.1) 2 (6.7) 1.34 (0.27  6.64) 0.66 1.33 (0.27  6.61) 0.73 
 
*concentrations are expressed in genome equivalents/mL 
** for presence/absence, regression estimates are odds ratios (OR) generated by logistic regression, for log concentration mean, regression estimates are differences in means 
generated by linear regression 
 For species with >20% prevalence, p-values for presence and log concentration mean are from chi-squared test and t-test, respectively. For species with <20% prevalence, 
p- alues for presence are from Fisher s e act test. 
presence/absence logistic regression adjusted for age, log concentration mean linear regression adjusted for age, community of residence and education 
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Table 5.S2  Presence and mean log-transformed concentrations of vaginal Lactobacilli, other cervicovaginal microbiota, and sexually 
transmitted infection with crude and adjusted associations comparing participants with FGS or probable FGS (combined) with those who were 
FGS negative 
 
Organism n(%) and 
Concentration* 




FGS & Probable FGS 
(n=55) 
p-value** 
      
L. crispatus Presence 69 (32.4) 49 (31.0) 20 (36.4) 0.47 
 Median (IQR) 8.7x106 (2.6x105  4.2x108) 1.1x107 (2.6x105  7.0x108) 1.3x106 (2.3x105  2.3x107) 0.24 
 Log concentration mean 16.01 16.38 15.11 0.21 
L. iners Presence 156 (73.2) 113 (71.5) 43 (78.2) 0.34 
 Median (IQR) 2.7x108 (3.8x107  1.5x109) 2.8x108 (3.9x107  1.6x109) 2.7x108 (3.3x107  1.4x109) 0.73 
 Log concentration mean 18.93 18.98 18.81 0.74 
G. vaginalis Presence 156 (73.2) 115 (72.8) 41 (74.6) 0.80 
 Median (IQR) 7.7x106 (8.3x105  5.2x107) 8.1x106 (7.7x105  4.8x107) 5.9x106 (1.1x106  1.0x108) 0.52 
 Log concentration mean 15.85 15.74 16.14 0.42 
A. vaginae Presence 152 (71.4) 112 (70.9) 40 (72.7) 0.79 
 Median (IQR) 5.8x107 (8.2x106  2.1x108) 5.8x107 (8.7x106  2.0x108) 6.1x107 (4.7x106  2.7x108) 0.97 
 Log concentration mean 17.31 17.33 17.25 0.87 
T. vaginalis Presence 53 (24.9) 34 (21.5) 19 (34.6) 0.05 
 Median (IQR) 4.2x104 (173.0  2.3x106) 1.7x105 (56.9  6.3x106) 6.0x103 (361.0  4.5x105) 0.35 
 Log concentration mean 10.39 10.88 9.52 0.35 
Vaginal microbiota with prevalence <20%    
N. gonorrhoeae Presence 13 (6.1) 12 (7.6) 1 (1.8) 0.19 
C. trachomatis Presence 17 (8.0) 13 (8.2) 4 (7.3) 1.0 
M. genitalium Presence 8 (3.8) 7 (4.4) 1 (1.8) 0.68 
Candida spp. Presence 12 (5.63) 8 (5.1) 4 (7.3) 0.51 
 
*concentrations are expressed in genome equivalents/mL 
** For species with >20% prevalence, p-values for presence, median (IQR) and log concentration mean from chi-squared test, ranksum test and t-test, 
respectively. For species with <20% prevalence, p- alues for presence are from Fisher s e act test. 
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Figure 5.S2  Study flow diagram 
 
 
Further details of home and clinic-based sample collection  
This section provides additional detail to the details of home and clinic-based sample collection 
provided in the main manuscript.  
The BILHIV study home visit included written informed consent, a questionnaire, genital self-
sampling (cervical and vaginal), and collection of a urine specimen, as previously described [1]. 
Specimens were placed in cool boxes for transportation and were stored in the laboratory at -80qC. 
Vaginal and cervical swab specimens were used for PCR detection of Schistosoma species; 
cervical swabs were used for characterization of the microbiota and STI by quantitative PCR 
(qPCR); urine was used for detection of circulating anodic antigen (CAA) and microscopic 
evaluation of the urine for S. haematobium eggs. 
 
Enrolled women who were not currently menstruating were invited to attend Livingstone Central 
Hospital cervical cancer screening clinic, where one of two trained midwives performed 
cervicovaginal lavage (CVL), which was used for Schistosoma PCR. After speculum insertion, a 
bulb syringe was used to flush normal saline (10 mL) continuously across the cervix and vaginal 
walls for one minute. CVL fluid was collected from the posterior fornices and stored temporarily 
in a refrigerator (4 qC) on ice until transfer to the laboratory, where specimens were stored at -
80°C. All specimens were shipped on dry ice to Leiden University Medical Center (LUMC). 
 
Cervicovaginal images were captured with a portable colposcope (MobileODT, Tel Aviv, Israel) 
and were evaluated by one author (EFK) for the presence of any of the four recognized FGS 
cervicovaginal manifestations: grainy sandy patches, homogenous yellow sandy patches, rubbery 
papules, and abnormal blood vessels [2]. Women with at least one of these manifestations [2] and 
women with any positive urine or genital Schistosoma diagnostic were treated free of charge with 
40 mg/kg praziquantel. Testing for STI was not performed at the point-of-care and participants 
with suspected STI were offered syndromic management, as per local guidelines [3].  
 
Urine microscopy and Circulating Anodic Antigen 
After aliquoting for CAA quantification, urine was centrifuged in 15 mL aliquots and examined 
by microscopy for S. haematobium eggs within 24 hours. The participant was considered positive 
if a pellet contained at least one S. haematobium egg, as previously described [1]. A lateral flow 
assay utilizing up-converting reporter particles for the quantification of CAA was performed on 
urine samples, as previously described [1, 4]. CAA levels reflect the burden of live schistosomes 
and decline after successful treatment with praziquantel [5, 6]. Analyzing the equivalent of 417 
PL urine (wet reagent, UCAAhT417), a test result indicating a CAA value of >0.6 pg/mL was 
considered positive [6]. 
 
PCR for detection of Schistosoma DNA 
DNA extraction and detection of the Schistosoma-specific internal-transcribed-spacer-2 (ITS2) 
target by real-time PCR were performed at LUMC, using a custom automated liquid handling 
station (Hamilton, Switzerland), as previously described [1, 7]. DNA extraction of 200 PL of  
CVL, cervical or vaginal swab fluid was done with QIAamp spin columns (QIAGEN, Benelux; 
V , T  N a d ) acc d    a ac  d . Schistosome DNA 
amplification and detection were performed with the CFX96 Real Time PCR Detection System 
and BioRad CFX software (BioRad, California, USA). DNA extracted from cervical swabs was 
transported to Ghent University for further analysis. 
 
Cervicovaginal microbiota characterization and STI detection 
DNA from cervical swabs were used to quantified key markers of vaginal health (Lactobacillus 
crispatus), BV (Gardnerella vaginalis and Atopobium vaginae), Lactobacillus iners (a highly 
prevalent lactobacillus with an enigmatic role), Candida spp. and STI (Chlamydia trachomatis, 
Neisseria gonorrhoeae, Mycoplasma genitalium, and Trichomonas vaginalis) by means of qPCR 
at the Laboratory Bacteriology Research (Ghent University, Ghent, Belgium). 
 
For the L. crispatus, L. iners, G. vaginalis, A. vaginae and Candida spp qPCR, a total reaction 
volume of 10 µL was prepared by the addition of 2 µL of DNA extract of the CVL, positive control 
(i.e., DNA of the corresponding type strain (listed for each species in Table 1)) or negative control 
(HPLC water) to 8 µL of reaction mixture. The final reaction mixture of each qPCR consisted of 
primers (listed in Table 2) in 1X LightCycler 480 SYBR Green I master mix in HPLC water. 
Reaction conditions for A. vaginae were pre-incubation for 10 min at 95 °C, followed by 40 cycles 
of 15 s at 95 °C, 20 s at 62 °C and 40 s at 72 °C, for G. vaginalis pre-incubation 5 min at 95 °C, 
followed by 40 cycles of 15 s at 95 °C, 30 s at 56 °C and 30 s at 72 °C, for L. crispatus pre-
incubation for 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C, 30 s at 60 °C and 30 s at 
72 °C, for L. iners pre-incubation for 10 min at 95 °C, followed by 40 cycles of 10 s at 95 °C, 20 
s at 50 °C and 4 s at 72 °C and Candida spp. by pre-incubation for 10 min at 95 °C, followed by 
45 cycles of 20 s at 95 °C, 30 s at 55 °C and 30 s at 72 °C. High resolution melting curves were 
generated for each species by melting all amplified double stranded DNA at 95 °C for 5 s, followed 
by renaturating DNA for 30 s at 50 °C (A. vaginae), 60 s at 55 °C (G. vaginalis), 60 s at 60 °C (L. 
crispatus, L. iners and Candida spp.), whereafter the temperature was increased to 97 °C at a ramp 
rate of 0.02 °C per s. Candida speciation was determined based on the melting peak temperatures 
as previously described [8].  
 
We quantified C. trachomatis, N. gonorrhoeae, M. genitalium, and T. vaginalis using the S-
DiaCTNGTM (for C. trachomatis and N. gonorrhea) and S-DiaMGTVTM (for M. genitalium and T. 
vaginalis) (b  D a d  D a c , S a , B ) acc d    a ac  
instructions.  
 
To quantify each of the target species, standard curves were constructed from a tenfold dilution 
series of DNA from C. trachomatis (ATCC VR-571B), N. gonorrhoeae, M. genitalium (ATCC 
G37), and T. vaginalis (ATCC 50148) (all commercially purchased). Genomic DNA from N. 
gonorrhoeae (ATCC 43069), A. vaginae, G. vaginalis, L. crispatus, L. iners and C. albicans was 
obtained after culturing the strains according to conditions from Table 1 and extracting DNA from 
colonies using Roche High Pure DNA Purification kit (Roche). All DNA concentrations were 
determined using NanoDrop (Thermo Fisher scientific, Erembodegem, Belgium). The genomic 
concentrations were calculated using the described genomic sizes of the type strains. Both the 
standard curves and samples were run in duplicate. The bacterial, fungal and protozoan 
concentrations were expressed as genome equivalents per mL (ge/mL) [9]. 
 
All non-schistosome qPCR assays were performed using the LightCycler480® and the 
LightCyclerR 480 Software Version 1.5 (Roche, Basel, Switzerland). 
Table 1: Strains used in this study 
Species Strain Culture conditions 
Atopobium vaginae CCUG 38953T Anaerobe, 37 °C, TSA plates 
Gardnerella vaginalis LMG 7832T Anaerobe, 37 °C, chocolate agar plates 
Lactobacillus crispatus LMG 9479T Anaerobe, 37 °C, NYC+ HS agar plates 
Lactobacillus iners ACS-049-V-Sch2 Anaerobe, 37 °C, NYC+ HS agar plates 
Candida albicans ATCC 90028 Aerobe, 30 °C, CHROMID® Candida agar 
Chlamydia trachomatis ATCC VR-571B N/A 
Neisseria gonorrhoeae ATCC 43069 35°C ±1°C for 5 days on chocolate agar (Becton Dickinson) 
Mycoplasma genitalium ATCC G37 N/A 
Trichomonas vaginalis ATCC 50148 N/A 
 
Table 2: Primers used in this study 
Species Forward primer (5 -3 ) Final concentration (µM) Reverse Primer (5 -3 ) Final concentration (µM) 
Atopobium 
vaginae 
CCCTATCCGCTCCTGATACC 0.7  CCAAATATCTGCGCATTTCA 0.7 
Gardnerella 
vaginalis 
TATTATAACTAAAGCTGCTG 0.5 CGCCACTATAGTCG 0.5 
Lactobacillus 
crispatus 
AGCGAGCGGAACTAACAGATTTAC 0.1 AGCTGATCATGCGATCTGCTT 0.1 
Lactobacillus 
iners 
GTCTGCCTTGAAGATCGG 0.2 ACAGTTGATAGGCATCATC 0.2 
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Cervicovaginal Immune Activation in
Zambian Women With Female
Genital Schistosomiasis
Amy S. Sturt1*, Emily L. Webb2, Catriona Patterson3, Comfort R. Phiri 4, Tobias Mweene4,
Eyrun F. Kjetland5,6, Maina Mudenda7, Joyce Mapani7, Mable M. Mutengo8,
James Chipeta9†, Govert J. van Dam10, Paul L. A. M. Corstjens11, Helen Ayles1,4,
Richard J. Hayes2, Isaiah Hansingo7, Piet Cools12, Lisette van Lieshout10,
Helena Helmby3, Grace A. McComsey13, Suzanna C. Francis2 and Amaya L. Bustinduy1
1 Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2 MRC
International Statistics and Epidemiology Group, London School of Hygiene and Tropical Medicine, London, United Kingdom,
3 Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, United Kingdom, 4 Zambart,
Lusaka, Zambia, 5 Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, 6 University of KwaZulu-Natal,
Discipline of Public Health, Durban, South Africa, 7 Department of Obstetrics and Gynecology, Livingstone Central Hospital,
Livingstone, Zambia, 8 Institute of Basic and Biomedical Sciences, Levy Mwanawasa Medical University, Lusaka, Zambia,
9 Department of Pediatrics, University of Zambia, Lusaka, Zambia, 10 Department of Parasitology, Leiden University Medical
Center, Leiden, Netherlands, 11 Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden,
Netherlands, 12 Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium, 13 University Hospitals Cleveland
Medical Center and Case Western Reserve University, Department of Pediatrics and Medicine, Cleveland, OH, United States
HIV-1 infection disproportionately affects women in sub-Saharan Africa, where areas of
high HIV-1 prevalence and Schistosoma haematobium endemicity largely overlap. Female
genital schistosomiasis (FGS), an in!ammatory disease caused by S. haematobium egg
deposition in the genital tract, has been associated with prevalent HIV-1 infection.
Elevated levels of the chemokines MIP-1a (CCL-3), MIP-1b (CCL-4), IP-10 (CXCL-10),
and IL-8 (CXCL-8) in cervicovaginal lavage (CVL) have been associated with HIV-1
acquisition. We hypothesize that levels of cervicovaginal cytokines may be raised in
FGS and could provide a causal mechanism for the association between FGS and HIV-1.
In the cross-sectional BILHIV study, specimens were collected from 603 female
participants who were aged 18–31 years, sexually active, not pregnant and participated
in the HPTN 071 (PopART) HIV-1 prevention trial in Zambia. Participants self-collected
urine, and vaginal and cervical swabs, while CVLs were clinically obtained. Microscopy
and Schistosoma circulating anodic antigen (CAA) were performed on urine. Genital
samples were examined for parasite-speci"c DNA by PCR. Women with FGS (n=28),
de"ned as a positive Schistosoma PCR from any genital sample were frequency age-
matched with 159 FGS negative (de"ned as negative Schistosoma PCR, urine CAA, urine
microscopy, and colposcopy imaging) women. Participants with probable FGS (n=25)
(de"ned as the presence of either urine CAA or microscopy in combination with one of four
clinical "ndings suggestive of FGS on colposcope-obtained photographs) were also
included, for a total sample size of 212. The concentrations of 17 soluble cytokines and
chemokines were quanti"ed by a multiplex bead-based immunoassay. There was no
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difference in the concentrations of cytokines or chemokines between participants with and
without FGS. An exploratory analysis of those women with a higher FGS burden, de"ned
by !2 genital specimens with detectable Schistosoma DNA (n=15) showed, after
adjusting for potential confounders, a higher Th2 (IL-4, IL-5, and IL-13) and pro-
in!ammatory (IL-15) expression pattern in comparison to FGS negative women, with
differences unlikely to be due to chance (p=0.037 for IL-4 and p<0.001 for IL-5 after
adjusting for multiple testing). FGS may alter the female genital tract immune environment,
but larger studies in areas of varying endemicity are needed to evaluate the association
with HIV-1 vulnerability.
Keywords: HIV-1, female genital schistosomiasis, S. haematobium, in!ammation, sub-Saharan Africa, genital tract,
cervicovaginal lavage (CVL), polymerase chain reaction (PCR)
INTRODUCTION
HIV-1 infection disproportionately affects women in sub-
Saharan Africa (1), where areas of high HIV-1 prevalence and
Schistosoma haematobium endemicity largely overlap (2).
Female genital schistosomiasis (FGS), caused most frequently
by S. haematobium egg deposition in the genital tract, has been
associated with prevalent HIV-1 infection in cross-sectional
studies (3). The presence of S. haematobium eggs in genital
tissue is also associated with vascularization (4) and the
accumulation of CD4+ lymphocytes and macrophages (5),
making the granuloma-associated environment a potential
contributor to HIV-1 vulnerability. In addition to modulation
of the local cervicovaginal environment, FGS has also been
associated with a higher frequency of systemic CD4 T-cells
expressing the chemokine receptor CCR5 (6). Tissue-entrapped
eggs are also associated with clinically visible FGS-associated
manifestations in the cervicovaginal mucosa (7). FGS lesions
may breach the intact cervicovaginal immune barrier and are
hypothesized to provide an entry point for HIV-1 infection (2,
3). However, the underlying mechanism for potential HIV-1
vulnerability in FGS has not been fully characterized and
requires further investigation.
The presence of S. haematobium eggs in human tissue
commonly provokes an in!ammatory response (5).
Cervicovaginal in!ammation has emerged as an important risk
factor for HIV-1 acquisition, with the presence of increased
chemotactic cytokine concentrations, speci"cally macrophage
in!ammatory protein-1a (MIP-1a [CCL-3]), MIP-1ß [CCL-4],
interleukin (IL)-8 [CXCL-8], and interferon-g inducible protein-
10 (IP-10 [CXCL-10]), conferring increased risk (8). Broadly,
while pro-in!ammatory cytokines are central in recruiting and
activating HIV-1 target cells, they also propagate a cascade of
downstream cellular processes that enact functions central to
HIV-1 pathogenesis (9). The presence of pro-in!ammatory
cytokines in the female genital tract may also be associated
with HIV-1 replication (via stimulation of transcription
factors) (10), an increased frequency and activation of HIV-1
target cells (9, 11, 12) and proteomic signatures suggestive of
tissue remodeling that may compromise cervicovaginal barrier
function (12).
Sexually transmitted infection (STI) and a “non-optimal”
cervicovaginal microbiota contribute to a vaginal pro-
in!ammatory environment (11, 13), and are thus important risk
factors for HIV-1 acquisition (14, 15), but elevated cervicovaginal
cytokine and chemokine levels have also been detected in their
absence (8). In addition to STI and cervicovaginal microbiota, a
number of additional biological and behavioral factors in!uence
the levels of detectable soluble immune proteins in the female
genital tract, including the presence of semen (16), cervical ectopy
(16), use of hormonal contraception (17), menstrual cycle (18),
and intravaginal cleansing practices (13, 17).
FGS may be an unmeasured co-factor contributing to
cervicovaginal in!ammatory signatures in endemic sub-Saharan
African populations (8, 11). S. haematobium infection, in the
absence of evaluation for genital involvement, has been associated
with altered levels of systemic (19) and cervicovaginal cytokines
(20). While male genital schistosomiasis has been associated with
elevated seminal !uid cytokine concentrations (21), little is known
regarding the human cervicovaginal environment in FGS or the
role of the immune response. We hypothesize that FGS modulates
the cervicovaginal immune environment and that evidence of
FGS-associated cervicovaginal in!ammation may provide insight
into a causal mechanism for the association between FGS and
HIV-1. In this cross-sectional study, we evaluate cervicovaginal
cytokines and chemokines in women with and without FGS.
METHODS
Study Setting and Participants
The cross-sectional bilharzia and HIV (BILHIV) study was
nested in HPTN 071 (PopART), a cluster randomized trial to
measure the impact of an HIV-1 combination prevention
package (22). HIV-1 incidence was measured in an HPTN 071
(Pop-ART) Population Cohort comprised of one randomly
selected adult (18 to 44 years of age) from a random sample of
households in each community who provided data and blood
samples at baseline, 12, 24, and 36 months (22). After the 36-
month HPTN 071 (PopART) visit, trained community workers
made home visits between January and August 2018 to women
who had expressed interest in the BILHIV study (23). Women
Sturt et al. FGS and Cervicovaginal Immune Activation
Frontiers in Immunology | www.frontiersin.org March 2021 | Volume 12 | Article 6206572
were eligible if they were 18–31 years old, not pregnant, sexually
active, and resident in one of the two urban communities that
participated in HPTN 071 (PopART) in Livingstone, Zambia.
Following written informed consent, the BILHIV study home
visit included a questionnaire, genital self-sampling (cervical and
vaginal), and a urine specimen, as previously described (23).
Clinic-Based Sample Collection
Within days of self-sampling, enrolled women who were not
currently menstruating were invited to attend Livingstone
Central Hospital cervical cancer screening clinic, where one of
two trained midwives performed a cervicovaginal lavage (CVL).
Cervicovaginal images were captured with a portable colposcope
(MobileODT, Tel Aviv, Israel) and were evaluated by one author
(EFK) for the presence of any of the four recognized FGS
cervicovaginal manifestations: homogenous yellow sandy
patches, grainy sandy patches, rubbery papules, and abnormal
blood vessels (24). Women having these manifestations (24) and
women with any positive urine or genital Schistosoma diagnostic
were treated free of charge with 40 mg/kg praziquantel. Testing
for STI was not performed at the point-of-care and participants
with suspected STI were offered syndromic management, as per
local guidelines (25).
CVL Specimen Processing
After speculum insertion, normal saline (10 ml) was !ushed
continuously with a bulb syringe across the cervix and vaginal
walls for 1 min and collected from the posterior fornices. CVL
!uid was transferred to a 15 ml conical polypropylene tube and
stored temporarily in a refrigerator (4°C) on ice until transfer to
the laboratory. Protease inhibitor (Cocktail Set I, Calbiochem,
Merck Millipore, Darmstadt, Germany) was added to one 1.5 ml
aliquot for cytokine and chemokine testing and stored at !80°C, as
previously described (17). Specimens were stored for a maximum
of 20months (range 12–20) and were not previously thawed. After
thawing, specimens were centrifuged at 320g for 10 min and the
supernatant removed. CVL color was visually assessed and a 10 ml
aliquot was placed on a Hemastix test strip (Siemens, Erlangen,
Germany). As per the manufacturer’s instructions, CVL
hemoglobin concentrations were recorded after comparing the
test strip with color categories representing approximate quantities
of erythrocytes (ery) per µL: none, trace, low (25 ery/mL),
moderate (80 ery/mL), high (200 ery/mL) (17).
Multiplex Bead Based Assays
Luminex MAGPIX© was used to measure concentrations of
seventeen soluble cytokines and chemokines using MILLIPLEX
HumanCytokine/ChemokineMagnetic Bead kits (MerckMillipore,
Darmstadt, Germany) according to the manufacturer’s instructions
and recommendations for dilute samples, i.e. CVL. The
concentrations of eotaxin (CCL-11), interferon-gamma (IFN-g),
IL-10, IL-13, IL-15, IL-17A, IL-1a, IL-1b, IL-4, IL-5, IL-6, IL-8
(CXCL-8), IP-10 (CXCL-10), monocyte chemoattractant protein
(MCP-1) (CCL-2), MIP-1a, (CCL-3), MIP-1b (CCL-4) and tumor
necrosis factor-a (TNF-a) were measured in undiluted CVL in
duplicate. The lower limit of detection was between 0.26 and 5.66
pg/ml for the 17 cytokines and chemokines measured (S1 Table).
Using a Luminex MAGPIX© bioanalyzer and xPONENT software
(version 4.2), the median !uorescent intensity was measured,
background-adjusted, and converted into analyte concentrations
using a 5 parameter logistic regression equation to interpolate
standard curves. To minimize between-plate variations in
cytokine and chemokine concentrations, two specimen controls
were included in duplicate across plates and equal proportions of
specimens with FGS, probable FGS, and FGS negative were
distributed across six 96-well plates (8). Cytokine or chemokine
concentrations below the lower limit of quanti"cation (LLOQ) were
imputed to be the midpoint of the lowest concentration for each
analyte and zero and concentrations above the upper limit of
quanti"cation were imputed as the highest concentration for
each analyte.
HIV-1
Laboratory-based fourth-generation HIV-1 testing (Abbott
Architect HIV Ag/Ab Combo Assay). was performed for
HPTN 071 (PopART) Population Cohort participants at each
study visit (22).
Circulating Anodic Antigen
A lateral !ow assay utilizing up-converting reporter particles for
the quanti"cation of CAA was performed on urine samples at the
Leiden University Medical Center (LUMC), as previously
described (23, 26). CAA levels re!ect the burden of live
schistosomes and decline after successful treatment with
praziquantel (27, 28). Analyzing the equivalent of 417 µl urine
(wet reagent, UCAAhT417), a CAA value of >0.6 pg/ml was
considered positive (28).
PCR for Detection of Schistosoma DNA
DNA extraction and PCR set up was performed at LUMC, using a
custom automated liquid handling station (Hamilton,
Switzerland), as previously described (23). DNA was extracted
from 200 µl of specimen (cervical swab, vaginal swab, CVL): with
QIAamp spin columns (QIAGEN Benelux; Venlo, The
Netherlands). Detection of the schistosome-speci"c internal-
transcribed-spacer-2 (ITS2) target was performed by real-time
PCR as previously described (23, 29). This PCR does not
differentiate between Schistosoma species. DNA ampli"cation
and detection were performed with the CFX96 Real Time PCR
Detection System (BioRad, California, USA). The output in cycle
quanti"cation value (Cq), re!ecting the parasite-speci"c DNA load
in the tested sample, was analyzed using BioRad CFX software.
Parasite DNA loads were categorized by the following pre-speci"ed
Cq thresholds: high (Cq<30), moderate (30" Cq <35), low (35" Cq
<50) and negative (no Cq detected), as previously described (30).
STI Detection
We quanti"ed Chlamydia trachomatis, Neisseria gonorrhoeae,
Mycoplasma genitalium, and Trichomonas vaginalis using the S-
DiaCTNG™ (for C. trachomatis and N. gonorrhea) and S-
DiaMGTV™ (for M. genitalium and T. vaginalis) (both
Diagenode Diagnostics, Seraing, Belgium) on DNA obtained
from cervical swabs at Ghent University (Ghent, Belgium)
according to the manufacturer’s instructions. Ampli"cation was
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carried out on the LightCycler480® and the LightCyclerR 480
Software Version 1.5 (Roche, Basel, Switzerland). To quantify each
of the target species, standard curves were constructed from a
tenfold dilution series of DNA from C. trachomatis, N.
gonorrhoeae, M. genitalium, and T. vaginalis. Genomic DNA of
C. trachomatis ATCC VR-571B, T. vaginalis ATCC 50148 and M.
genitalium G37 was obtained from the American Type Culture
Collection (ATCC). Genomic DNA from N. gonorrhoeae was
obtained after culturing strain ATCC 43069 at 35°C ±1°C for 5
days on chocolate agar (Becton Dickinson) and extracting DNA
from colonies using Roche High Pure DNA Puri"cation kit
(Roche). All DNA concentrations were determined using
NanoDrop (Thermo Fisher scienti"c, Erembodegem, Belgium).
The genomic concentrations were calculated using the described
genomic sizes of the type strains. Both the standard curves and
samples were run in duplicate. The number of bacteria and
protozoan concentration was expressed as genome equivalents
per ml (geq/ml) (31).
Ethical Considerations
The study was approved by the University of Zambia Biomedical
Research Ethics Committee (reference 011-08-17), the Zambia
National Health Research Authority and the London School of
Hygiene and Tropical Medicine Ethics Committee (reference
14506). Permission to conduct the study was given by
Livingstone District Health Of"ce and the superintendent of
Livingstone Central Hospital.
FGS De"nitions
The FGS categories were de"ned by the results of four
investigations: Schistosoma PCR (on DNA extracted from
cervical swabs, vaginal swabs, or CVL), colposcopy image
review, urine CAA, and urine microscopy. Participants were
grouped by the outcomes of their diagnostic tests into three
mutually exclusive categories. FGS was de"ned as at least one
positive Schistosoma PCR on a genital specimen (cervical swab,
vaginal swab and/or CVL). In participants with a negative
Schistosoma PCR, probable FGS was de"ned as the presence of
urinary schistosomiasis, detected with either urine CAA or urine
microscopy, in combination with one of four clinical "ndings
suggestive of FGS on any colposcope-obtained photograph (24).
FGS negative was de"ned as negative results on all diagnostic
assays. Participants with results for all available diagnostic tests
who were Schistosoma genital PCR negative and did not qualify
for the FGS, probable FGS, or FGS negative groups (n=190) were
not eligible for study inclusion (Figure 1). All participants with
FGS (n=28) who attended clinic follow up and provided a CVL
specimen and all participants with probable FGS (n=25) were
selected for measurement of cytokines and chemokines in CVL
samples. Three FGS negative participants were selected for every
FGS and probable FGS participant, using a random number
generator. The FGS negative participants were frequency
matched by age to the participants with FGS.
STATISTICAL METHODS
Participant characteristics were summarized by median and
interquartile range (IQR) for continuous variables, and by
frequency and percentage for categorical variables.
Differences in characteristics between the FGS categories
were evaluated using Fisher’s exact and chi-squared tests. For
cytokines or chemokines with at least 70% of sample results
above the LLOQ, differences in median cytokine or chemokine
FIGURE 1 | Study Flow Diagram. Not visited (n=189)– the participant was not visited before the study closed for enrollment; Visited but not contacted (n=110)– a
visit was made to the study household, but the participant could not be located (70), had relocated (39), or died (1); Contacted & not immediately enrolled (n=120)–
visited but not recruited (42), out of town (18), declined to participate (60); Contacted & ineligible (n=41)– virgin (16), pregnant (17), over 31 (8).
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concentrations between FGS categories were evaluated using
the Wilcoxon-Mann-Whitney test. Cytokines or chemokines
with <70% of the sample results above the LLOQ were
analyzed as binary variables (presence/absence) and
compared between FGS categories using Fisher’s exact and
chi-squared tests. To correct for multiple comparisons we used
a Monte Carlo simulation approach with 1000 replicates (32):
for each replicate the labels of the groups being compared were
randomly permuted and statistical tests were repeated, to
generate empirical p-values. For further analysis, cytokine or
chemokine concentrations with at least 70% of sample results
above the LLOQ were log-transformed to normalize their
distribution, and linear regression was performed to evaluate
the association between FGS and mean cytokines or
chemokine in univariable and multivariable analysis and
expressed with 95% con"dence intervals. For the cytokines
with <70% of the sample results above the LLOQ (IL-5, IL-13,
IL-15, and TNF-a), logistic regression was used to evaluate the
assoc ia t ion between FGS and detec tab le cytok ine
concentrations and expressed with 95% con"dence intervals.
To adjust for potential confounders, we developed a causal
conceptual framework (S1 Figure) to inform our minimal
adjustment set. For the cytokines and chemokines analyzed
by linear regression, we adjusted for age, education,
community of residence, and the presence of any STI. Since
hormonal contraception is associated with the outcome, but
not the exposure (FGS), it was also included in the
multivariable model to improve precision. For the cytokines
analyzed by logistic regression (IL-5, IL-13, IL-15, and TNF-
a), due to the relatively low number of participants with
concentrations above the LLOQ, these cytokines were
adjusted for age and STI. Because HIV-1 status and the
presence of hemoglobin in CVL are both potentially
in!uenced by FGS (2), and may also affect CVL cytokine or
chemokine concentrations, these variables were considered to
be on the causal pathway and were not included in the "nal
multivariable model (S1 Figure).
Our primary hypothesis was that FGS modulates the
cervicovaginal microenvironment with a secondary hypothesis
that FGS may increase the concentration of selected HIV-1
acquisition associated chemokines (8). Thus, our primary
analysis focused on the detection of Schistosoma DNA in the
genital tract, comparing FGS vs FGS negative participants. As a
secondary aim, participants with FGS and probable FGS were
combined and compared with the FGS negative group.
Spearman’s rank correlation was used to evaluate the strength
of the relationship between individual analytes (S2 Figure). Since
many cytokines and chemokines were correlated, we performed
Principal Components Analysis (PCA) on the log-transformed
analyte concentrations to generate new uncorrelated
“components” that were linear combinations of the initial
variables. The "rst two principal components captured the
majority of the variability in the data and were taken forward
for additional comparisons between FGS groups (S2 Table).
To evaluate the possible association between intensity of FGS
presentation and changes in cytokine or chemokine concentrations,
two ad hoc exploratory analyses were performed: (1) participants
with #2 genital samples with detectable Schistosoma DNA levels
were compared with those in the FGS negative group, (2)
participants with a moderate/high genital Schistosoma DNA
concentration (de"ned by a Cq <35 in at least one of the three
examined samples) were compared with those in the FGS
negative group.
In this study we measured the concentration of cytokines and
chemokines in CVL. However, the presence of hemoglobin in
CVL may serve as a surrogate marker for the presence of
systemic and/or menstrual blood in the cervicovaginal
environment. HIV-1 status and the presence of hemoglobin in
CVL are potentially in!uenced by FGS (2), but may also
independently affect cytokines and chemokine concentrations.
Thus, we performed two sensitivity analyses, one compared
participants with FGS with those in the FGS negative group
after excluding the participants who were HIV-1 positive from
both groups. A second sensitivity analysis compared participants
with FGS with those in the FGS negative group after excluding
the participants whose CVL sample displayed the presence of
hemoglobin. Data were analyzed using STATA 15.1 (Stata
Corporation, College Station, TX). P-values less than 0.05 were
classi"ed as demonstrating “evidence” of an association and p-
values between 0.05 and 0.10 were classi"ed as demonstrating
“some evidence” of an association.
RESULTS
A total of 603 eligible women were enrolled and 212 (35.2%)
were included in this study (Figure 1). Overall, 13.2% (28/212) of
women had FGS, de"ned by a positive genital Schistosoma PCR
from any of the following sites: 8.5% (18/212) cervical swab, 6.6%
(14/212) vaginal swab, and 6.6% (14/212) CVL. Probable FGS
was detected in 25 women, and 61.1% (159/262) of the women
who were negative on all diagnostic tests were randomly selected
for inclusion in this study.
Baseline Characteristics
The majority of the participants had received at least secondary
education, were using hormonal contraception, and had
detectable hemoglobin in their CVL. At the conclusion of
HPTN 071 (PopART), HIV-1 prevalence was 17.0% (36/212)
among the women included in this study and one-third of the
women had at least one STI (Table 1). Active schistosome
infection, de"ned as either a positive urine microscopy (11.8%,
25/212) or detectable CAA (20.2%, 43/212), was reported in
21.2% (45/212). A small proportion of women reported current
water contact, but more than half reported childhood
water contact.
There was strong evidence of a difference in community of
residence between FGS, probable FGS, and FGS negative
participants (p=0.001) with participants with FGS and probable
FGS more likely to live in Community A than participants in the
FGS negative group (Table 1). There were differences between
the three categories of FGS status for age (p<0.001), educational
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attainment (p=0.04), employment (p=0.05), and marital status
(p=0.04) with participants in the probable FGS group more likely
to be older, have a primary school education, be employed, and
be married than FGS and FGS negative participants. Other
characteristics were similar by FGS status.
Expression Pro"les of Cytokines and
Chemokines in CVL
The mean, median and range of concentrations (pg/ml) of the 17
cytokines and chemokines measured are displayed in S1 Table.
The distributions of log-transformed concentrations (median
TABLE 1 | Baseline characteristics of the 212 study participants by female genital schistosomiasis (FGS) status.
Socio-behavioral Characteristics FGS* % (n = 28) FGS Probable* % (n = 25) FGS Negative* % (n = 159) p-value
Age in years Median (IQR) 22 (20–24) 27 (23–31) 23 (22–24) 0.001
Marital Status Single 42.9 (12) 16.0 (4) 45.9 (73) 0.04"
Married or Cohabitating 57.1 (16) 80.0 (20) 50.9 (81)
Divorced or Separated 0.0 (0) 4.0 (1) 3.1 (5)
Education (highest level) None/Any Primary School 32.1 (9) 48.0 (12) 22.0 (35) 0.04"
Any Secondary School 67.9 (19) 52.0 (13) 70.4 (112)
Training in a Trade 0.0 (0) 0.0 (0) 7.6 (12)
Employment Status Working 14.3 (4) 44.0 (11) 25.8 (41) 0.05
Not Working 85.7 (24) 56.0 (14) 74.2 (118)
Current Water Contact None 100.0 (28) 84.0 (21) 86.8 (138) 0.1"
Any 0.0 (0) 16.0 (4) 13.2 (21)
Childhood Water Contact None 14.3 (4) 24.0 (6) 32.1 (51) 0.1
Any 85.7 (24) 76.0 (19) 67.9 (108)
Community of Residence Community A 75.0 (21) 80.0 (20) 41.5 (66) <0.001
Community B 25.0 (7) 20.0 (5) 58.5 (93)
Sexual behavior characteristics and STI
Ever pregnant No# 7.1 (2) 4.0 (1) 17.0 (27) 0.3"
Yes 92.9 (26) 96.0 (24) 82.4 (131)
Age at sexual debut Median (IQR) 16 (15–18) 17 (15–18) 17 (16–18) 0.09
Lifetime sexual partners Median (IQR) 3 (2–4.5) 2 (1–3) 2 (1–4) 0.3
Currently Sexually Active No## 10.7 (3) 8.0 (2) 16.5 (26) 0.6"
Yes 89.3 (25) 92.0 (23) 83.5 (132)
Contraceptive Method Implant 7.1 (2) 8.0 (2) 8.8 (14) 1.0"
Injectable 53.6 (15) 48.0 (12) 47.8 (76) 0.9
Oral Contraceptive Pill 3.6 (1) 12.0 (3) 6.3 (10) 0.5"
Condoms 10.7 (3) 20.0 (5) 16.4 (26) 0.7"
HIV-1 Not Detected 82.1 (23) 80.0 (20) 83.7 (133) 0.9
Detected 17.9 (5) 20.0 (5) 16.4 (26)
Chlamydia trachomatis Not Detected 89.3 (25) 96.0 (24) 91.8 (146) 0.7"
Detected 10.7 (3) 4.0 (1) 8.2 (13)
Neisseria gonorrhea Not Detected 100.0 (28) 96.0 (24) 92.4 (147) 0.4"
Detected 0.0 (0) 4.0 (1) 7.6 (12)
Mycoplasma genitalium Not Detected 100.0 (28) 96.0 (24) 95.6 (152) 0.5"
Detected 0.0 (0) 4.0 (1) 4.4 (7)
Trichomonas vaginalis Not Detected 67.9 (19) 68.0 (17) 78.6 (125) 0.3
Detected 32.1 (9) 32.0 (8) 21.4 (34)
Any STI Not Detected 64.3 (18) 56.0 (14) 67.3 (107) 0.5
Detected 35.7 (10) 44.0 (11) 32.7 (52)
Clinical Findings
Hemoglobin in CVL (ery/µL)! None 28.6 (8) 25.0 (6) 36.1 (57) 0.3"
Trace 17.9 (5) 12.5 (3) 15.2 (24)
25 32.1 (9) 16.7 (4) 17.7 (28)
80 3.6 (1) 16.7 (4) 17.1 (27)
200 17.9 (5) 29.2 (7) 13.9 (22)
Colposcopy Findings!! Sandy Patches 22.2 (6) 76.0 (19) 0.0 (0) N/A
Rubbery Papule 0.0 (0) 0.0 (0) 0.0 (0)
Abnormal Blood Vessels 22.2 (6) 24.0 (6) 0.0 (0)
No FGS "ndings 56.0 (15) 0.0 (0) 100.0 (159)
*FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; probable FGS– Schistosoma PCR negative and either positive circulating anodic
antigen (CAA) or urine microscopy and suggestive expert-reviewed colposcopy imaging; FGS negative – negative Schistosoma PCR and negative CAA and negative urine microscopy and
negative expert-reviewed colposcopy imaging.
!Fisher’s exact test.
#Self-reported history of ever having a pregnancy, participants reporting “no answer” (n=1, FGS negative group) are not shown.
##Participants reporting “no answer” (n=1, FGS negative group) are not shown.
!Hemoglobin was measured with Hemastix® test strips using a color chart measured in erythrocytes (ery) per µl.
!!Colposcopy !ndings were included in the study inclusion criteria, so no p-value is shown; one participant with FGS did not have interpretable colposcopy results. Images were
interpreted based on the presence of sandy patches or rubbery papules, if these !ndings were present, the additional !nding of abnormal blood vessels was not noted.
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and interquartile range) of the 17 cytokines and chemokines are
displayed by FGS status in Figure 2.
FGS Signature - Crude and Adjusted
Expression Pro"les
Compared to FGS negative women, IL-5 was elevated in
participants with FGS (Table 2, Figure 2, crude p-value 0.02, p-
value after adjustment for multiple testing 0.14). Compared to FGS
negative women, women with FGS had similar expression pro"les
of chemokines that predicted HIV-1 acquisition risk in a South
African study (MIP-1a [CCL-3], MIP-1b [CCL-4], IL-8 [CXCL-
8], and IP-10 [CXCL-10]) (8). This was con"rmed after adjusting
for age, STI, community of residence, education, and use of
hormonal contraception (Figure 3). Principal Components
Analysis identi"ed that two Principal Components accounted
for 60.0% of the variability in the data (S2 Table). Taken
forward, there was no difference in mean scores for these two
Principal Components by FGS status (S3 Figure).
When the FGS and probable FGS groups were combined, in
the crude analysis (S4 Figure) and after adjustment for possible
confounders, participants with FGS/probable FGS had higher
concentrations of TNF-a than FGS negative participants (S5
Figure, p=0.03, p-value adjusted for multiple testing 0.09).
Exploratory Analyses – Clinical
Disease Burden
In an exploratory analysis of participants (n=15) with a higher
FGS burden de"ned as #2 Schistosoma PCR positive genital
specimens, there was evidence of an elevated concentration of
cytokines IL-4, IL-5, IL-13, IL-15 compared to FGS negative
women (Figure 4). This association remained after adjusting for
potential confounders (Figure 5). After adjustment for multiple
comparisons strong evidence remained that IL-4 (multiple
testing adjusted p=0.037) and IL-5 (multiple testing adjusted
p<0.001) were associated with FGS.
Exploratory Analyses – Schistosoma
DNA Concentration
In a further exploratory analysis of women (n=15) with FGS and
moderate or high genital Schistosoma DNA concentration
(Schistosoma PCR Cq<35) there was evidence that the
concentrations of cytokines IL-1a, IL-4, IL-5, IL-13, IL-15, and
TNF-a were elevated in participants with Schistosoma PCR
Cq<35 compared to FGS negative women (Figure 6). After
adjustment for potential confounders, evidence remained that
IL-4, IL-5, IL-15, and TNF-a were elevated in participants with
moderate/high Schistosoma DNA concentration compared to
FGS negative women (Figure 7). After adjustment for multiple
comparisons, strong evidence remained that the associations for
IL-5 (multiple testing adjusted p=0.001) and TNF-a (multiple
testing adjusted p=0.045) were unlikely to have occurred by
chance. When comparing the participants with moderate/high
Schistosoma DNA concentration and the participants with #2
PCR positive genital specimens, 11 women overlapped
between groups.
Sensitivity Analyses – HIV-1 and
CVL Hemoglobin
We performed sensitivity analyses removing participants with
HIV-1 infection or the presence of hemoglobin in CVL from
the comparison between FGS and negative FGS groups. When
n=31 participants with HIV-1 from the FGS and FGS negative
groups were excluded from the analysis, there was no difference in
the expression pro"les of cytokines or chemokines in women with
FGS compared to FGS negative women (S6 Figure). When n=139
participants with any detectable hemoglobin in CVL were
removed from the analysis (S7 Figure), there was some evidence
that concentrations of IL-17A and IL-8 (CXCL-8) were higher in
participants with FGS (n=8) compared to the FGS negative group
(n=57) (p=0.13 after allowing for multiple testing).
DISCUSSION
This study is the "rst to describe expression patterns of cytokines
and chemokines in human FGS, diagnosed by Schistosoma PCR
from vaginal swabs, cervical swabs, and CVL. The immune
environment in helminth infection is often characterized as T
helper 2 (Th2) biased and involves the orchestration of cytokines
(IL-4, IL-5, IL-13), antibodies, and regulatory cells (33). We did
not detect an association between FGS, de"ned as Schistosoma
DNA detected in genital PCR specimens, and a change in
FIGURE 2 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage of participants
with (FGS: n=28) and without female genital schistosomiasis (FGS negative: n=159) c. FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal
swab or cervical swab; FGS negative – negative genital PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed
colposcopy imaging. cp-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.14 p-value symbol legend: **p < 0.05.
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expression pattern of cytokines or chemokines in CVL including
those associated with HIV-1 acquisition in a South African study
(8). Compared to the FGS negative participants, the Th2 cytokine
IL-5 was elevated in the participants with FGS, however after
adjustment for multiple comparisons we cannot exclude that this
"nding may be due to chance.
Previous work on male genital schistosomiasis has shown that
infection intensity, de"ned by seminal egg count, is strongly
associated with elevated seminal cytokine concentrations
including Th2 (IL-4), regulatory (IL-10), Th1 (IFN-g) and pro-
in!ammatory (TNF-a) cytokines (21). Thus, we evaluated FGS
burden by performing two exploratory analyses, the results of
which show a Th2 expression pattern. First, we investigated the
association between multiple PCR-positive genital specimens as a
potential proxy marker of higher FGS burden in 15 women with #
two positive genital specimens for Schistosoma DNA. We also
investigated whether Schistosoma DNA concentrations in genital
samples might be associated with a change in cytokine
concentrations in 15 participants with FGS and moderate/high
genital Schistosoma DNA concentrations (de"ned as Schistosoma
PCR Cq<35). After adjusting for potential confounders, the
exploratory analyses found a higher cervicovaginal Th2 cytokine
response (IL-4, IL5-, IL-13) in participants with # two positive
specimens and participants with higher genital Schistosoma DNA
concentrations. This is not unexpected considering that a Th2
biased immune response is associated with helminth infection (33)
and S. haematobium exposure in both human and murine hosts
(34, 35). There was evidence for higher concentrations of IL-5 after
adjustment for multiple comparisons across both exploratory
analyses. IL-5 induces eosinophil maturation and an IL-5
response to Schistosoma antigens has been associated with
microhematuria in children with S. haematobium infection (36).
There was evidence for higher concentrations of IL-4 after
adjustment for multiple comparisons in the exploratory analyses
of multiple PCR-positive genital specimens for Schistosoma DNA.
In the Th2 response, IL-4 directly regulates T-cell differentiation
and proliferation (37). The "nding of elevated levels of pro-
in!ammatory TNF-a in the exploratory analyses of participants
with moderate/high Schistosoma DNA concentrations after
adjustment for potential confounders and multiple comparisons,
suggests that FGS may promote a mixed Th2 and pro-
in!ammatory response. TNF-a may be associated with
Schistosoma granuloma formation (38) and in children with S.
haematobium infection, TNF-a production has been associated
with ultrasound-determined urinary bladder morbidity (39).
We found IL-13 and IL-15 to be associated with a higher clinical
FGS burden and higher genital Schistosoma DNA concentrations
after adjusting for potential confounders, although these
associations no longer remained after adjustment for multiple
comparisons. Predominantly produced by macrophages, IL-15 is
TABLE 2 | Crude and adjusted associations (with 95% con"dence intervals) of FGS* status with concentrations of cytokines and chemokines in cervicovaginal
lavage**.
Analyte %(n) above LLOQ FGS Negative ‡n=159 FGS n=28 p-value‡‡ GMR FGS vs FGS Negative (n=28) † p-value † †
Linear Regression - Analytes with >70% above LLOQ
Eotaxin 73.6 (156) 3.85 3.92 0.22 1.48 (0.95–2.32) 0.08
Interferon–g 84.0 (178) 0.91 0.80 0.71 0.98 (0.64–1.51) 0.94
IL–10 90.1 (191) 0.98 1.33 0.75 1.02 (0.65–1.61) 0.93
IL–17A 93.4 (198) 1.38 1.86 0.14 1.37 (0.85–2.23) 0.64
IL1–a 99.5 (211) 44.00 73.08 0.17 1.24 (0.63–2.44) 0.19
IL1–b 93.4 (198) 9.79 9.05 0.38 1.59 (0.56–4.51) 0.52
IL–4 96.2 (204) 2.79 3.42 0.20 1.41 (0.94–2.12) 0.09
IL–6 87.7 (186) 2.85 3.81 0.67 1.14 (0.56–2.35) 0.71
IL–8 100.0 (212) 526.03 566.68 0.33 1.29 (0.75–2.19) 0.34
IP–10 100.0 (212) 101.86 128.38 0.42 1.34 (0.68–2.66) 0.39
MCP–1 100.0 (212) 29.04 24.68 0.79 0.98 (0.53–1.83) 0.95
MIP1–a 98.1 (208) 4.23 3.61 0.15 0.62 (0.36–1.08) 0.09
MIP1–b 84.0 (177) 1.32 1.64 0.67 1.05 (0.54–2.05) 0.89
Logistic Regression - Analytes with <70% above LLOQ




p-valuec OR FGS vs FGS Negativecc p-value#
IL–5 17.0 (36) 13.84 (22) 32.1 (9) 0.02 3.44 (1.30–9.05) 0.02
IL–13 32.6 (69) 32.7 (52) 35.7 (10) 0.76 1.17 (0.50–2.75) 0.72
IL–15 47.2 (100) 44.7 (71) 60.7 (17) 0.12 1.91 (0.84–4.36) 0.12
TNF–a 41.0 (87) 35.9 (57) 50.0 (14) 0.15 1.85 (0.81–4.22) 0.14
FGS, female genital schistosomiasis; GMR, geometric mean ratio; LLOQ, lower limit of quanti!cation.
*FGS – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen
and negative urine microscopy and negative expert-reviewed colposcopy imaging.
**Concentrations are reported in pg/ml.
‡n=25 Participants with probable FGS are not shown.
‡‡Rank sum p-value.
†Adjusted for age, STI, educational level attained, community of residence, and hormonal contraception.
††F-test p-value.
cChi-squared p-value.
ccAdjusted for age and STI.
#Likelihood ratio test p-value.
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FIGURE 3 | Comparison of the concentration or presence of eleven cytokines and six chemokines in cervicovaginal lavage of participants with (FGS, n=28) and
without (FGS negative, n=159) female genital schistosomiasisc. (A) Concentrations of eotaxin, IFN-g, IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b
were compared between FGS and FGS negative participants by linear regression and adjusted for age, community of residence, education, presence of sexually
transmitted infection and hormonal contraceptive use, with results shown as geometric mean ratios with 95% CI. (B) Presence/absence of IL-5, IL-13, IL-15 and
TNF-a were compared by logistic regression and adjusted for age and sexually transmitted infection, with results shown as odds ratio with 95% CI. The line at 1
indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol legend: *p < 0.1 **p < 0.05. cfemale genital
schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative genital PCR and negative
urine circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.
FIGURE 4 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage by FGSc
burden (Schistosoma PCR in ! two genital specimens: n=15, FGS negative: n=159) cc. cFGS – Schistosoma PCR positive specimen from cervicovaginal lavage,
vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative
expert-reviewed colposcopy imaging. ccp-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p < 0.001. p-value legend *p < 0.1
**p < 0.05.
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FIGURE 5 | Comparison of the concentrations or presence of eleven cytokines and six chemokines in cervicovaginal lavage in participants with greater FGS burden
(Schistosoma PCR positive in ! two genital specimens, n=15) and participants without female genital schistosomiasis (n=159) c. (A) Concentrations of eotaxin, IFN-g,
IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b were compared between FGS and FGS negative participants by linear regression adjusted for age,
community of residence, education, presence of sexually transmitted infection and hormonal contraceptive use, with results shown as geometric mean ratios with
95% CI. (B) Presence/absence of IL-5, IL-13, IL-15 and TNF-a were compared by logistic regression and adjusted for age and sexually transmitted infection, with
results shown as odds ratio with 95% CI. The line at 1 indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol
legend: *p <0.1 **p <0.05. cfemale genital schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS
negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.
FIGURE 6 | Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six chemokines in cervicovaginal lavage by FGS
burden (Schistosoma DNA concentration Cq <35 in any genital specimen, n=15, FGS negative:n=159) c. FGS – Schistosoma PCR positive specimen from
cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative Schistosoma PCR and negative circulating anodic antigen and negative urine
microscopy and negative expert-reviewed colposcopy imaging. cp-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.001
p-value symbol legend: *p < 0.1 **p < 0.05.
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a pro-in!ammatory, immunomodulatory cytokine that stimulates
T, B, and Natural Killer cells (40). Lower levels of IL-15 have been
reported in the cervicovaginal environment of women with S.
haematobium infection, with between-study differences potentially
related to genital Schistosoma DNA detection (20). The Th2
cytokine IL-13 is thought to be an important driver of collagen
deposition in the Schistosoma egg granuloma (41), ultimately
leading to "brosis. Indeed, IL-13 expression levels have been
associated with the severity of hepatic "brosis in S. mansoni
infection (42). The exploratory sub-group analyses thus support
previous work describing that S. haematobium may modulate the
genital immune environment (20, 21). As a protracted Th2 response
is often associated with schistosomiasis-related morbidity (43), our
study "ndings warrant further investigation. The current study
included many statistical tests, and these were allowed for using a
permutation testing approach. However, we cannot exclude the
possibility that some of the associations are due to chance. Thus, it
may be more instructive to consider patterns in cytokine signatures
(Th2, pro-in!ammatory) across analyses, rather than interpreting
signi"cance testing for any one cytokine in isolation. Although
strong evidence remained for some of the associations found in the
exploratory analyses of FGS burden after adjusting for potential
confounders and multiple comparisons, as exploratory analyses,
these "ndings should be viewed as hypothesis generating.
Many hypotheses have been put forward regarding the
mechanism of HIV-1 vulnerability in women with FGS, with
evidence of both local mucosal factors and systemic immuno-
modulation (2, 4–6). In a South African study, women who
acquired HIV-1 in the CAPRISA tenofovir gel trial had higher
concentrations of the chemotactic cytokines MIP1-a (CCL-3),
MIP1-b (CCL-4), IL-8 (CXCL-8), and IP-10 (CXCL-10) prior to
seroconversion than women who did not seroconvert (8). In the
current study, the concentrations of the aforementioned
chemotactic chemokines were not higher in women with FGS
compared to the FGS negative group. While not yet studied in S.
haematobium, herpes simplex virus type 2 infection stimulates
A
B
FIGURE 7 | Comparison of the concentration or presence of eleven cytokines and six chemokines in cervicovaginal lavage in participants with moderate to high
Schistosoma DNA concentrations (Cq <35 in any genital specimen, n=15) and participants without female genital schistosomiasis (n=159) c. (A) Concentrations of
eotaxin, IFN-g, IL-1a, IL-1b, IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1a, and MIP-1b were compared by linear regression adjusted for age, community of residence,
education, presence of sexually transmitted infection and hormonal contraceptive use. Results are represented by geometric mean ratios with 95% CI. (B) Presence/
absence of IL-5, IL-13, IL-15 and TNF-a were compared by logistic regression and adjusted for age and sexually transmitted infection. Results are indicated by odds
ratio with 95% CI. The line at 1 indicates the value at which there is no difference between the FGS and FGS negative groups. p-value symbol legend: * <0.1,
** <0.05. cFemale genital schistosomiasis – Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative – negative
Schistosoma PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging.
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TNF-a production in dendritic cells, enhancing the expression of
the chemokine co-receptor CCR5 and stimulating HIV-1
replication (44). Further research is needed to elucidate
mechanisms for the association of FGS with HIV-1 vulnerability,
and these may include schistosome-related impact on mucosal and
systemic immunity, including the activation of CD4 traf"cking to
the genital mucosa (45), or modi"cation in systemic (46) or cervical
(20) gene expression, speci"cally related to the regulation of
transcription, the in!ammatory response or tissue "brosis.
Cervical tissue containing S. haematobium eggs is more
vascular (4) compared to non-egg containing tissue. Clinically,
these abnormal blood vessels can be found encircling sandy
patches and contact bleeding has been associated with FGS (47).
Thus, FGS studies using cervicovaginal lavage are likely to be
burdened by the presence of hemoglobin (48). Since HIV-1 and
the presence of hemoglobin in CVL are potentially on the causal
pathway between FGS and a change in cytokine or chemokine
concentrations, we were unable to adjust for these possible
confounding variables in a multivariable model. A sensitivity
analysis removing participants with HIV-1 showed no change in
the association between FGS and cytokine or chemokine
concentrations. HIV-1 infection modulates the cervicovaginal
immune environment in women with detectable cervicovaginal
HIV-1 RNA (49) and we did not have complete data on plasma
viral load in this cohort. Additionally, the analysis to remove
participants with any CVL hemoglobin detection was limited by
loss of power. Once participants who had any CVL hemoglobin
were removed from the analysis, there was evidence of higher
concentrations of IL-17A and IL-8 (CXCL-8) in participants
with FGS (n=8) compared with FGS negative participants
(n=57). This "nding, however, was less robust after adjusting
for multiple comparisons. Considering the potential loss of the
FGS phenotype when excluding women with CVL hemoglobin
and the small and likely non-representative sample size, these
"ndings should be interpreted with caution.
Our study has a number of strengths. We are the "rst to
describe the cervicovaginal immune environment in women with
Schistosoma PCR-de"ned FGS and this study illustrates the
importance of evaluating FGS burden. De"ning FGS based on
the detection of Schistosoma DNA in the female genital tract by
PCR results provides a higher certainty of genital involvement and
a quantitative reference standard compared to visually-diagnosed
FGS or the use of urine diagnostics alone. Due to the small
numbers of FGS cases, we employed a matching strategy
wherein participants with FGS were frequency matched with
FGS negative participants. To reduce the risk of selection bias,
we used a random number generator to randomly select controls
and matched on age group. Multiplex bead-based assays have a
precedent for use in CVL (8, 11, 14, 17) and we examined a variety
of soluble immune proteins including chemokines, Th1, Th2, pro-
in!ammatory and regulatory cytokines for a broad overview of the
cervicovaginal immune environment. Another strength is that we
present both crude and adjusted outcomes to facilitate
comparisons in future study settings.
While our study has multiple strengths, there are also some
relevant limitations. The study was conducted in a low-prevalence
area and the number of FGS cases in the main and exploratory
analyses is small. We selected a sub-sample of the cohort for
multiplex bead-based immunoassays. This may limit the
generalizability of the proportions presented for demographic
variables or FGS and schistosomiasis prevalence. Secondly, we
were unable to measure a number of behavioral and biological
factors that also affect cervicovaginal soluble immune protein
expression patterns including the presence of bacterial vaginosis
(13), HSV-2 status (11), intra-vaginal cleansing practices (17),
vaginal pH, menstrual cycle phase (18), body weight (50) and
recent sexual contact (16). It is also undetermined how these same
factors may in!uence Schistosoma DNA concentrations. Thus, we
cannot exclude unmeasured and residual confounding.
Additionally, due to the cross-sectional study design, we were
also unable to assess the long-term impact of the cytokine
expression pro"les or to determine the duration of FGS
infection. Though the cytokines and chemokines we measured
are well-known biomarkers for in!ammation and disease, it is a
limitation that we did not have companion !ow cytometry, biopsy,
or transcriptomic data for a more detailed evaluation of cellular
and histological processes. Additionally, CVL is dilute and the
concentrations of the cytokines and chemokines we measured were
small. This could potentially be ameliorated in future studies with
the use of a menstrual cup to collect genital !uid (51).
FGS is thought to be a chronic infection of the female genital
tissue, with initial infection and the development of genital lesions
occurring during childhood water contact (52) that persist into
adulthood, often even despite treatment with praziquantel (53).
The chronicity of FGS lesions may have an impact on the
cervicovaginal immune environment and a longitudinal study is
needed to document the FGS immune environment in a spectrum
of FGS stages before interventions can be based on our exploratory
observations. Further work investigating the cervicovaginal
immune environment in FGS may impact diagnostic,
preventative, and therapeutic options as well as potentially
providing additional information on HIV-1 vulnerability.
In conclusion, this study does not show a difference in the
cervicovaginal immune environment by Schistosoma PCR-
de"ned FGS status. However, two exploratory analyses suggest
that there may be a relationship between higher genital
Schistosoma DNA concentrations or multiple PCR positive
genital specimens and a Th2 and pro-in!ammatory
modulation of the cervicovaginal immune environment, as
measured by elevated cytokine concentrations. FGS may alter
the female genital tract immune environment, but a larger
longitudinal study in a high FGS prevalence area is needed to
better de"ne the role of FGS in HIV-1 acquisition.
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S1 Table  Crude concentrations of eleven cytokines and six chemokines in the 
cervicovaginal lavage of 212 Zambian women 
 
Analyte  % (n)  
Above LLOQ 
Median (IQR) * 
concentration 






Eotaxin 73.6 (156) 4.83 (3.60  6.64) 5.22 (2.46) 4.0 0.98 
Interferon   84.0 (178) 1.03 (0.70  1.67) 2.03 (4.44) 0.8 0.33 
IL 10 90.1 (191) 1.21 (0.75  2.55) 2.53 (6.00) 1.1 0.33 
IL 13 32.6 (69) 0.76 (0.49  1.35) 1.10 (1.09) 1.3 0.31 
IL 15 47.2 (100) 0.75 (0.48  1.24) 1.09 (1.10) 1.2 0.34 
IL 17A 93.4 (198) 1.52 (0.92  3.04) 4.32 (14.64) 0.7 0.26 
IL1 D 99.5 (211) 50.00 (19.89  164.86) 225.99 (551.30) 9.4 0.97 
IL1 E 93.4 (198) 13.05 (2.88  72.83) 161.49 (414.08) 0.8 0.35 
IL 4  96.2 (204) 2.87 (1.63  5.03) 3.86 (3.49) 4.5 0.31 
IL 5 17.0 (36) 0.50 (0.38  0.72) 0.64 (0.54) 0.5 0.32 
IL 6 87.7 (186) 4.09 (1.56  13.66) 13.54 (43.36) 0.9 0.32 
IL 8 100.0 (212) 531.22 (230.01  1268.70) 1034.25 (1261.70) 0.4 5.66 
IP 10 100.0 (212) 101.74 (32.66  276.30) 393.23 (1143.74) 8.6 1.37 
MCP 1 100.0 (212) 27.84 (8.15  72.09) 76.83 (191.26) 1.9 1.03 
MIP1 D 98.1 (208) 4.27 (2.12  15.04) 13.18 (27.32) 2.9 0.55 
MIP1 E 83.5 (177) 2.02 (0.85  5.44) 6.59 (19.29) 3.0 0.28 
TNF D 41.0 (87) 1.18 (0.53  3.77) 4.99 (13.04) 0.7 0.32 
 
Abbreviations: IQR  interquartile range, LLOQ  lower limit of quantification, SD  
standard deviation, CVL  cervicovaginal lavage 
 
* Concentrations are reported in pg/mL 
 
This table shows the concentrations of soluble immune proteins prior to imputation for those 
analytes below the limit of quantification. 
 
S2 Table  Principal component analysis on data from log-transformed cytokines and chemokines 
 
 Comp1  Comp2 Comp3 Comp4 Comp5 Comp6 Comp7 Comp8 Comp9 Comp10 Comp11 Comp12 Comp13 Comp14 Comp15 Comp16 Comp17 
Eotaxin 0.099 0.597 -0.123 0.295 -0.343 0.423 0.214 -0.098 -0.132 0.266 0.196 0.011 0.008 0.099 0.012 0.201 0.051 
INF  0.258 0.154 -0.158 -0.234 -0.099 -0.119 -0.585 -0.149 0.147 0.364 0.017 -0.159 -0.241 -0.095 0.432 -0.048 -0.072 
IL 10 0.295 0.026 -0.021 -0.094 -0.232 -0.272 -0.170 -0.023 0.166 -0.110 -0.197 0.038 -0.023 0.049 -0.453 0.652 0.181 
IL 13 0.262 -0.020 -0.262 -0.334 -0.003 0.091 0.228 -0.153 -0.105 -0.285 -0.165 0.200 0.480 -0.066 0.472 0.207 -0.088 
IL 15 0.268 0.284 -0.205 -0.074 0.202 0.366 -0.254 0.026 -0.340 -0.246 -0.074 -0.528 0.063 0.091 -0.330 -0.098 -0.224 
IL 17a 0.248 0.225 -0.076 0.261 0.140 -0.178 -0.257 0.583 -0.370 -0.132 -0.043 0.402 -0.023 -0.086 0.089 -0.089 0.127 
IL1 D 0.206 -0.212 -0.336 0.333 0.430 0.078 -0.044 -0.052 0.349 0.211 0.387 0.106 0.244 -0.265 -0.135 0.129 -0.043 
IL1 E 0.265 -0.284 0.008 0.299 0.182 0.064 0.180 0.102 0.065 0.093 -0.219 -0.287 -0.146 0.466 0.348 0.114 0.407 
IL 4 0.260 0.310 -0.075 0.161 -0.151 -0.075 0.102 -0.003 0.571 -0.293 -0.264 -0.075 0.105 -0.043 -0.087 -0.506 0.050 
IL 5 0.225 0.014 -0.278 -0.437 0.034 -0.083 0.521 0.373 0.046 0.132 0.175 -0.085 -0.420 -0.118 -0.098 -0.037 -0.061 
IL 6 0.246 -0.175 0.367 0.029 -0.076 0.239 0.098 0.155 -0.041 0.478 -0.492 0.029 0.148 -0.381 -0.091 -0.028 -0.169 
IL 8 0.259 0.089 0.143 0.247 0.269 -0.157 0.191 -0.541 -0.211 -0.190 -0.108 0.119 -0.474 -0.218 0.030 0.037 -0.189 
IP 10 0.163 0.395 0.369 -0.221 0.420 -0.351 0.107 -0.072 -0.060 0.262 0.132 -0.111 0.360 0.271 -0.093 -0.053 0.019 
MCP 1 0.190 0.036 0.464 -0.285 0.168 0.535 -0.151 0.051 0.254 -0.250 0.243 0.249 -0.185 0.007 0.033 0.044 0.204 
MIP1 D 0.267 -0.188 0.264 0.196 -0.293 -0.126 0.017 0.188 0.099 -0.118 0.305 -0.010 0.027 0.298 0.126 0.071 -0.649 
MIP1 E 0.266 -0.200 0.198 0.040 -0.344 -0.166 0.051 -0.098 -0.252 -0.103 0.407 -0.288 0.163 -0.374 0.030 -0.157 0.420 
TNF D 0.266 -0.275 -0.179 -0.128 -0.174 0.046 -0.041 -0.286 -0.169 0.222 0.026 0.463 -0.003 0.403 -0.277 -0.385 0.092 
POV 0.519 0.087 0.081 0.062 0.046 0.037 0.027 0.024 0.021 0.018 0.017 0.015 0.013 0.011 0.011 0.007 0.005 
CPOV 0.519 0.606 0.687 0.749 0.795 0.831 0.856 0.882 0.903 0.921 0.939 0.954 0.966 0.977 0.989 0.995 1.000 
 
Abbreviations:  Comp  component, CPOV  cumulative proportion of variance explained, IL interleukin, INF  Interferon- , 
MCP1  monocyte chemoattractant protein-1, MIP1-D  macrophage inflammatory protein 1 D, MIP1-E  macrophage inflammatory 
protein 1-E, POV  proportion of variance explained, TNF-D   Tumor necrosis factor D 
 
 




Shaded items were not measured objectively.  
 
Adapted from Francis SC, et al. Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at 
High Risk for HIV Infection. PloS one (2016) 11(1):e0143109.   
 









S4 Figure  Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six 
chemokines in cervicovaginal lavage of participants with FGS and Probable FGS (n=53) and without female genital 




S4 Figure Caption 
FFGS  Schistosoma PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative  negative 
genital PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging 
p-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.09 
 





S5 Figure  Comparison of the concentration or presence of eleven cytokines and six chemokines 
in cervicovaginal lavage in participants with (FGS + Probable FGS, n=53) and without (negative 




Figure S5 Caption 
A. Concentrations of eotaxin, IFN- , IL-1 , IL-1 , IL-4, IL-6, IL-8, IL-10, MCP-1, MIP-1 , a  MIP-
1  were compared between FGS and FGS negative by linear regression adjusted for age, community of 
residence, education, presence of sexually transmitted infection and hormonal contraceptive use, with 
results shown as geometric mean ratios with 95% CI.  
 
B. Presence/absence of IL-5, IL-13, IL-15 and TNF-  were compared by logistic regression and adjusted 
for age and sexually transmitted infection, with results shown as odds ratio with 95% CI. 
The line at 1 indicates the value at which there is no difference between the FGS and negative FGS 
groups 
 
p-value symbol legend: 
**p<0.05 
 
Ffemale genital schistosomiasis  Schistosoma PCR positive specimen from cervicovaginal lavage, 
vaginal swab or cervical swab; FGS negative  negative genital PCR and negative urine circulating 
anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging 
 
 
 S6 Figure  Sensitivity analysis: Median with interquartile range of the log-transformed concentrations of eleven cytokines 





FFGS  PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative  negative Schistosoma 
PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging 
 
All p-values are greater than 0.1 
 
  
S7 Figure  Median with interquartile range of the log-transformed crude concentrations of eleven cytokines and six 




FFGS  PCR positive specimen from cervicovaginal lavage, vaginal swab or cervical swab; FGS negative  negative Schistosoma 
PCR and negative circulating anodic antigen and negative urine microscopy and negative expert-reviewed colposcopy imaging 
p-value after adjustment for multiple testing with a Monte-Carlo simulation approach, p=0.13 
 




S8 Figure  Median with interquartile range of the log-transformed crude concentrations of seven pro-inflammatory cytokines 
in cervicovaginal lavage by Gardnerella vaginalis status  
 
 
S8 Figure Caption 
p-value symbol legend: 
*p<0.05 , IL-1D, IL-1E, 
IL-1D  Rank-sum p-value <0.001 (for the comparison of concentrations by presence/absence of G. vaginalis); Kruskal Wallis p-
value, p=0.002 (for the comparison of concentrations by G. vaginalis density) 
IL-1E  Rank-sum p-value 0.005 (for the comparison of concentrations by presence/absence of G. vaginalis); Kruskal Wallis p-value, 
p=0.02 (for the comparison of concentrations by G. vaginalis density) 
TNF-D  Rank-sum p-value 0.04 (for the comparison of concentrations by presence/absence of G. vaginalis); Kruskal Wallis p-value, 
p=0.04 (for the comparison of concentrations by G. vaginalis density) 
 
  
S9 Figure  Median with interquartile range of the log-transformed crude concentrations of seven pro-inflammatory cytokines 




S9 Figure Caption 
p-value symbol legend: 
*p<0.05 
IL-1D  Rank-sum p-value <0.001 (for the comparison of concentrations by presence/absence of A. vaginae); Kruskal Wallis p-value, 
p<0.001 (for the comparison of concentrations by A. vaginae density) 
IL-1E  Rank-sum p-value <0.001 (for the comparison of concentrations by presence/absence of A. vaginae); Kruskal Wallis p-value, 
p<0.001 (for the comparison of concentrations by A. vaginae density) 
TNF-D  Rank-sum p-value 0.002 (for the comparison of concentrations by presence/absence of A. vaginae); Kruskal Wallis p-value, 
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Background:   
Female genital schistosomiasis (FGS) has been associated with prevalent HIV-1. We estimated the 
incidence of HIV-1 infection in Zambian women with and without FGS. 
Methods: 
Women (aged 18-31, non-pregnant, sexually active) were invited to participate in this study in 
January-August 2018 at final follow-up of the HPTN 071 (PopART) Population Cohort. HIV-1 
negative participants at enrolment (n=492) were included in this analysis with testing to confirm 
incident HIV-1 performed in HPTN 071 (PopART). Association of incident HIV-1 infection with 
FGS (Schistosoma DNA detected by PCR in any genital specimen) was assessed with exact 
Poisson regression.  
Results:  
Incident HIV-1 infections were observed in 4.1% (20/492) participants. Women with FGS were 
twice as likely to seroconvert as women without FGS but with no statistical evidence for a 
difference (aRR 2.16, 95%CI[0.21 12.30], p=0.33). Exploratory analysis suggested an association 
with HIV-1 acquisition among women with 2 positive genital PCR specimens (RR 6.02, [0.58
34.96]), p=0.13). 
Conclusions:  
Despite higher HIV seroconversion rates in women with FGS, there was no statistical evidence of 
association, possibly due to low power. Further longitudinal studies should investigate this 
association in a setting with higher schistosomiasis endemicity.  
 
Keywords: HIV incidence, female genital schistosomiasis, polymerase chain reaction, PCR, 




In 2019, an estimated 56 million women were living with female genital schistosomiasis (FGS), a 
neglected tropical disease that results when eggs from the parasite Schistosoma (S.) haematobium 
are deposited in reproductive tract tissues [1]. Tissue-entrapped eggs incite a cellular response [2], 
ultimately resulting in FGS-related morbidity, including infertility [3], and distinct cervicovaginal 
manifestations [4, 5]. In sub-Saharan Africa, there is a geographical association between areas of 
high S. haematobium prevalence and HIV-1 infection [6], and FGS has been associated with 
prevalent HIV-1 [7] with biological plausibility for a causal relationship [3, 8]. Despite global 
advances in HIV-1 treatment and prevention, gender related disparities still exist, with particularly 
heightened risk among young women aged 15-24 years [9]. HIV-1 vulnerability in young women 
is multifactorial, including biological, behavioural, demographic, social, and structural 
components [10]. The potential role of FGS as an underreported and preventable co-factor in HIV-
1 vulnerability needs further investigation. 
 
Disruption of the protective vaginal and cervical epithelium by FGS-associated lesions may 
increase HIV-1 susceptibility by providing a portal for viral entry [3, 11]. Additionally, the 
environment created by S. haematobium eggs is more vascular [12], with an increased density of 
CD4+ lymphocytes [8] compared to non-egg containing tissue. Thus, tissue-entrapped S. 
haematobium eggs create a cellular milieu which may promote HIV-1 infection. Both S. 
haematobium and S. mansoni infection have been associated with prevalent HIV-1 [11]. A cross-
sectional study of women with FGS, defined as parasite eggs detected in genital tissue, describes 
a strong association with prevalent HIV-1 but no evidence of an association between urinary 
schistosomiasis and HIV-1 [7]. Studies primarily evaluating urinary S. haematobium (without 
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universal evaluation for genital involvement) and prevalent HIV-1 have been mixed, with evidence 
of an association with prevalent HIV-1 in a study of Tanzanian women [13], some evidence of an 
association with prevalent HIV-1 in a study of Zimbabwean women [14], but with no evidence of 
an association with prevalent HIV-1 in men and women with urinary S. haematobium in Congo 
[15]. While S. haematobium seropositivity in women has been associated with HIV-1 acquisition 
[16], the association of FGS with incident HIV-1 has not been described.  
 
FGS diagnosis is challenging and its burden is likely underreported. The presence of parasite eggs 
or DNA in cervicovaginal tissue is diagnostic of FGS, [17, 18], and, historically, biopsy is used as 
a reference standard [4, 19]. However, theoretical concerns regarding post-biopsy HIV-1 
acquisition has limited its acceptance in research settings [17]. Polymerase chain reaction (PCR) 
on cervicovaginal lavage (CVL) is a less-invasive means of FGS diagnosis, albeit with imperfect 
sensitivity [17, 18]. Well-defined clinical manifestations have been associated with FGS [5, 20] 
but are variably correlated with the presence of S. haematobium eggs [19, 20] or DNA [17] in 
genital tissue. The identification of clinical lesions, such as homogenous yellow sandy patches and 
abnormal blood vessels, with colposcopy is observer-dependent and subject to low specificity [21]. 
Indeed, homogeneous yellow sandy patches have also been associated with herpes simplex virus-
2 and human papillomavirus, and abnormal blood vessels may be associated with cervical 
intraepithelial neoplasia [5]. Urine microscopy and circulating anodic antigen (CAA) can be used 
to detect active schistosome infection [18, 22], but do not assess involvement of genital tissue. 
While either S. haematobium and S. mansoni can cause FGS, the majority of cases are attributed 
to S. haematobium [23, 24] and the current study focuses on S. haematobium. We conducted an 
array of diagnostic tests for S. haematobium infection (CAA and urine microscopy) and FGS 
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(portable colposcopy, cervical swabs, vaginal swabs, and cervicovaginal lavage), and have 
previously demonstrated that self-collected genital swabs had comparable sensitivity to clinic-
based, midwife-collected CVL for the detection of Schistosoma DNA by real-time PCR [18]. 
 
The longitudinal follow-up of women in the HPTN 071 (PopART) trial in two schistosomiasis-
endemic communities in Zambia provided an opportunity for a nested study exploring the 
association of FGS with HIV-1 incidence.  
 
Methods 
Study setting and participants 
The cross-sectional bilharzia and HIV (BILHIV) study was nested in HPTN 071 (PopART), a 
cluster randomized trial assessing the impact of an HIV-1 combination prevention package 
including universal testing and treatment  [25]. HIV-1 incidence was measured in a Population 
Cohort (PC) comprised of one randomly selected adult (18 to 44 years of age) from a random 
sample of households in each community who provided data and blood samples at baseline, 12, 
24, and 36 months [25]. Between January and August 2018, after the 36-month HPTN 071 
(PopART) PC visit, trained community workers conducted home visits to women who had 
expressed interest in the BILHIV study [18]. Women in Livingstone, Zambia were eligible if they 
were 18-31 years old, not pregnant, sexually active, and residing in one of the two urban S. 
haematobium endemic communities that participated in one of two HPTN 071 (PopART) 




Following written informed consent, the BILHIV study home visit included a questionnaire, 
genital self-sampling (cervical and vaginal), and a urine specimen, as previously described [18]. 
Within days of self-sampling, non-menstruating participants were invited to attend Livingstone 
Central Hospital for cervicovaginal lavage (CVL) [18]. Cervicovaginal images were captured with 
a portable colposcope (MobileODT, Tel Aviv, Israel) and evaluated by one author (EFK) for the 
presence of any of the four accepted FGS cervicovaginal manifestations: homogenous yellow 
sandy patches, grainy sandy patches, rubbery papules, and abnormal blood vessels [26]. Women 
with evidence of schistosome infection by colposcopy [26] or any positive urine or genital 
diagnostic were treated free of charge with 40 mg/kg praziquantel. Routine testing for sexually 
transmitted infections (STI) was not performed. Participants with suspected STI were offered 
syndromic management, as per local guidelines [27].  
 
HIV-1 
Laboratory-based fourth-generation HIV-1 testing (Abbott Architect HIV Ag/Ab ComboAssay, 
Wiesbaden, Germany) was performed for HPTN 071 (PopART) PC participants at each study visit 
[25]. Additional testing using antigen/antibody screening tests, a discriminatory test, and an HIV-
1 RNA test was used to confirm incident HIV-1 infection, as previously described [28].  
 
Circulating Anodic Antigen 
CAA levels reflect the burden of live schistosomes and decline after successful treatment with 
praziquantel [22, 29]. An up-converting reporter particle lateral flow assay for the quantification 
of CAA in urine was performed at the Leiden University Medical Center (LUMC), as previously 
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described [18, 30]. Analysing the equivalent of 417 PL urine, a CAA value of >0.6 pg/mL was 
considered positive [22]. 
 
PCR for detection of Schistosoma DNA 
DNA extraction and PCR was performed at LUMC as previously described, using a custom 
automated liquid handling station (Hamilton, Switzerland) [20, 31]. DNA was extracted from 
200PL of specimen (cervical swab, vaginal swab, CVL) with QIAamp spin columns (QIAGEN 
Benelux; Venlo, The Netherlands). Detection of the schistosome-specific internal-transcribed-
spacer-2 (ITS2) target was performed by real-time PCR as previously described [18, 31]. This 
PCR does not differentiate between Schistosoma species. DNA amplification and detection were 
performed with the CFX96 Real Time PCR Detection System (BioRad, California, USA). The 
output in threshold cycles (Ct), reflecting the parasite-specific DNA load in the tested sample, was 
analysed using BioRad CFX software. Parasite DNA loads were categorized by the following pre-
specified Ct thresholds: high (Ct<30), moderate (30 Ct<35), low (35  Ct <50) and negative (no Ct 
detected), as previously described [32].  
 
Patient Consent Statement 
The study was approved by the University of Zambia Biomedical Research Ethics Committee 
(reference 011-08-17), the Zambia National Health Research Authority and the London School of 
Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to conduct the 
study was given by Livingstone District Health Office and the Livingstone Central Hospital 





Comparison groups were defined by the results of four investigations: genital PCR, colposcopy 
image review, urine CAA, and urine microscopy. Participants were grouped by the outcomes of 
their diagnostic tests into three mutually exclusive categories. FGS was defined as at least one 
positive genital PCR (cervical swab, vaginal swab or CVL) (Figure 1). Probable/possible FGS 
was defined as the presence of either a positive urine diagnostic (CAA or microscopy) or one of 
four cervicovaginal manifestations suggestive of FGS on portable colposcopy, or both, with 
negative genital PCR (Figure 1). FGS negative was defined as negative results on all diagnostics. 
 
Statistical Methods 
Characteristics of study participants were summarized by frequency and percentage. Women 
living with HIV-1 (WLHIV) at HPTN 071 (PopART) baseline were excluded from further 
analyses. HIV-1 incidence was calculated as the number of seroconversions per 1000 person-years 
of follow up. Participants contributed person-time for the calculation of HIV-1 incidence starting 
with their first HIV-1 test and ending at date of HIV-1 seroconversion for those who seroconverted, 
or at the date of last follow-up or the end of scheduled follow-up (whichever occurred earliest) for 
women who did not seroconvert. HIV-1 seroconversion was assumed to occur at the midpoint 
between the last negative and the first positive HIV-1 test. We assumed that FGS acquisition 
occurred prior to HPTN 071 (PopART) enrolment [33]. BILHIV study participants were 
consecutively recruited from the PC, providing the opportunity to compare the rate of incident 
HIV-1 infection in women with and without FGS, with power determined by the number of HIV-
1 seroconversions and FGS prevalence. Data on HIV-1 outcomes were not available until after 
BILHIV study closure. 
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Associations of risk factors with incident HIV-1 infection were calculated as rate ratios and 95% 
confidence intervals, estimated using exact Poisson regression in univariable and multivariable 
analysis. We used a causal conceptual framework to inform our choice of potential confounders. 
A priori, we included age as a confounding variable. Due to loss of precision with further 
adjustment for potential confounding variables, no additional parameters were included in the 
multivariable model. To assess the primary exposure of interest, women with FGS (n=26) were 
compared with an FGS negative comparison group comprising those who were negative on all 
diagnostic investigations (n=218). Participants who were negative on all diagnostic investigations 
but missing colposcopy images (n=82) were excluded from the primary analysis. 
To evaluate the association of schistosome infection intensity with HIV-1 seroconversion, two ad 
hoc exploratory analyses were performed. One compared participants with FGS and a 
moderate/high Schistosoma DNA concentration (Ct <35) with those in the FGS negative group. 
The second compared participants with FGS with 2 positive genital PCR specimens with those 
in the FGS negative group. Data were analysed using STATA 15.1 (Stata Corporation, College 
Station, TX).  
Results 
A total of 603 eligible women from the HPTN 071 Population Cohort were enrolled in the BILHIV 
study. WLHIV at HPTN 071 (PopART) trial entry (n=107, 17.7%) were excluded, with 492 
(82.1%) included in this analysis (Figure 2). Of the included participants, 14% (69/492) did not 
attend clinic for CVL.  
 
Baseline characteristics  
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The majority of participants had received at least secondary education, were not working, and 
reported being currently sexually active. A small proportion of women reported current water 
contact, but more than half reported childhood water contact. Active schistosome infection, 
defined as either a positive urine microscopy (5.5%, 27/492) or detectable CAA (15.1%, 74/492), 
was detected in 15.7% (77/492) of participants.  
 
HIV incidence  
The 492 women without HIV-1 at HPTN 071 (PopART) study entry provided a total of 1,164 
person-years of follow-up, during which time, 20 (4.1%) incident HIV-1 infections were 
measured, for an overall rate of 17.2 (95% CI 11.1 26.6) seroconversions per 1000 person-years. 
HIV-1 incidence rates are shown by baseline characteristics in Table 1.  
 
HIV-1 incidence rates were 23.6 (14.2  39.2) in women aged 18-24 years compared with 9.5 (3.9
22.7) in women aged 25-31, (RR 0.40 [0.15 1.10]), p=0.06 (Table 1)). The HIV-1 seroconversion 
rate decreased as the household size increased (p=0.007, test for trend) and increased as the number 
of lifetime sexual partners increased (p=0.01, test for trend). Women self-reporting a history of 
STI were more likely to seroconvert than women without self-reported STI (RR 5.76 [1.92 17.22], 
p=0.009) (Table 1). No other sociodemographic or behavioural characteristics were associated 
with HIV-1 incidence. After adjusting for age, there remained strong evidence that a higher number 
of people residing in a household (p=0.008, test for trend), a higher number of lifetime sexual 
partners (p=0.01, test for trend), and self-reported history of STI (aRR 6.05 [2.02 18.12], p=0.008) 
were associated with HIV-1 seroconversion. Additionally, there was no evidence for an association 
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between urinary schistosome infection (as defined by urine CAA and/or microscopy) and HIV-1 
seroconversion (Table 2). 
 
Association between FGS and HIV-1 seroconversion  
FGS was identified in 5.3% of women (26/492), defined as any positive genital PCR (cervical 
swab 3.5%, [17/492]; vaginal swab 2.4%, [12/492]; or CVL 3.1%, [13/423]). Among women with 
a negative genital PCR, results from both urine and colposcopy imaging were positive in 4.5% 
(21/466) of participants and results from either urine or colposcopy imaging were positive in 
31.1% (145/466). Of the participants with probable/possible FGS, 63.8% (106/166) had 
colposcopy changes in isolation (Figure 1), of whom 62.3% (66/106) had abnormal blood vessels 
and 37.7% (40/106) had grainy or homogenous yellow sandy patches on colposcopy. There were 
218 (44.3%) participants who were negative on all diagnostic tests. The rate of HIV-1 
seroconversion (per 1000 person/year) in women with FGS (31.0 [7.8  123.9]) was higher than 
in the FGS negative group (11.3[5.1 25.1]) (Table 2) but without statistical evidence of a 
difference between these rates in either univariable or multivariable analyses (crude RR 2.75 
[0.27 15.36], p=0.26; aRR 2.16 (0.21 12.30), p=0.33) (Table 2).  
 
Exploratory analyses: Schistosoma DNA concentrations and disease burden  
In the ad hoc exploratory analysis of women (n=13) with FGS and moderate/high Schistosoma 
DNA concentrations the IRR for HIV-1 acquisition after adjusting for age was 4.73 (0.46 27.05), 
p=0.19) compared to FGS negative participants (Table 2). In an ad hoc exploratory analysis of 
women (n=13) with 2 positive genital PCR specimens compared to FGS negative participants, 
the IRR for HIV-1 acquisition after adjusting for age was 6.02 (0.58 34.96, p=0.13) (Table 2). In 
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these groups, n=9 of the women overlapped and the same two participants contributed 
seroconversions in both groups. There were no HIV-1 seroconversions in participants with one 
positive genital PCR.  
 
Discussion 
This study is the first to examine the association of PCR-defined FGS with HIV-1 incidence. While 
barriers to implementation still exist, PCR for Schistosoma DNA detection in FGS diagnosis is 
reproducible, has high specificity, and can be performed on self-collected genital specimens [18]. 
We found that women with FGS were twice as likely to seroconvert than women in the comparison 
group albeit with wide confidence intervals and no statistical evidence for a difference.  
 
While some cross-sectional studies show an association between schistosomiasis and prevalent 
HIV-1 infection [13, 23], this association is not universally reported [34, 35]. The association 
between schistosomiasis and HIV-1 is complex and cross-study comparisons require the 
consideration of many aspects, including schistosome species (S. haematobium versus S. mansoni), 
diagnostic tests used, assessment of genital involvement, and presentation of subgroup analyses 
e.g. b  participant s se . Our findings, while limited by power, show a point estimate consistent 
with increased risk of incident HIV-1, but with a wide confidence interval. Recently, two case-
control studies nested within longitudinal African cohorts have retrospectively assessed the 
association between schistosome infection status and HIV-1 seroconversion with conflicting 
results [16, 36]. A Zambian study showed an increased risk of HIV-1 acquisition in S. 
haematobium antibody positive women (aHR=1.4, p<0.05), but not men [16]. Similar to our 
results, the study from Kenya and Uganda did not show an association between active schistosome 
 
 14 
infection and HIV-1 seroconversion, including in subgroup analyses by sex, schistosome species, 
and infection intensity [36]. Notably, however, neither of these nested case-control studies 
evaluated genital infection status. FGS may enhance HIV-1 vulnerability, with proposed 
mechanisms including cervicovaginal barrier dysfunction [37], local recruitment or activation of 
HIV-1 target cells [3], and Schistosoma-related alterations in integrin [38] or co-receptor [39] 
expression. 
 
Schistosomiasis and FGS are preventable and current WHO control measures recommend 
praziquantel preventive chemotherapy [40]. However, current control programmes do not 
universally achieve 75% coverage of school-aged children, representing substantial missed 
opportunities for prevention [41, 42]. The 2025 AIDS targets place communities at risk for HIV-
1 in the centre of societal, system, and service enablers with a call for between sector integration 
and synergy to advance the HIV-1 response [43]. Programmatic synergy including integrated 
sexual and reproductive health programmes could leverage and scale-up existing HIV-1 treatment 
and prevention resources to include FGS screening and treatment programs.  
 
We carried out two ad hoc exploratory analyses. The intensity of schistosome infection, defined 
by serum CAA concentration, has been strongly correlated with HIV-1 prevalence [13]. Thus, first, 
we investigated whether Schistosoma DNA concentrations might be associated with HIV-1 
infection in an analysis of 13 participants with FGS and moderate/high Schistosoma DNA 
concentrations. We found no evidence of an association between FGS and HIV-1 acquisition, 
albeit with wide confidence intervals. Additionally, participants with moderate to high intensity 
seminal egg excretion have higher seminal cytokine concentrations than S. haematobium negative 
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participants [44]. Thus secondly, we investigated the association between multiple positive genital 
PCR specimens as a potential proxy marker of higher FGS burden and HIV-1 seroconversion in 
13 women with 2 positive genital specimens for Schistosoma DNA. We found weak evidence of 
an association between FGS and HIV-1 acquisition, which was less pronounced in the age-adjusted 
estimates. These findings are hypothesis generating for the association between FGS 
cervicovaginal disease burden or Schistosoma DNA concentrations and HIV-1.  
 
This study was nested within a large population-based HIV-1 prevention trial and is the first 
prospective study to document FGS in Zambia, but also had some relevant limitations. Similar to 
other FGS studies using imperfect available diagnostics, there is the risk of potential diagnostic 
misclassification, especially in this low-prevalence setting. We defined FGS by PCR positivity 
based on its semi-quantitative nature and precedent in FGS diagnosis [17, 18, 45]. However, S. 
haematobium eggs in semen from a male sex partner could potentially be detected by PCR of 
vaginal specimens. We were unable to adjust for potential confounders beyond age and are thus 
unable to exclude unmeasured and residual confounding. This was related to the low number of 
HIV-1 seroconversions and FGS cases, which also resulted in a loss of power. Overall, the effect 
sizes suggest the possibility of a relationship we were not sufficiently powered to detect. While 
the prevalence of HIV-1 in the study population was high at 17.9%, the two participating 
communities were enrolled in HPTN 071 (PopART) as intervention sites, potentially reducing the 
number of HIV-1 seroconversions [25]. The prevalence of urinary S. haematobium infection in 
this study was 5.5% (27/492), lower than anticipated, defined by the World Health Organization 
as a low prevalence area (<10% S. haematobium prevalence) [46]. Indeed, a 2013 survey done by 
the Zambian Ministry of Health reported a wide range of egg-patent prevalence in Livingstone, 
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ranging from of 3.3  73.3% (median 15.0%, mean 23.3%) in school-aged children, highlighting 
its focal distribution [47]. In addition, while schistosomiasis is endemic in all of Zambia s 10 
provinces [48], and can be found in urban locations , it is generally considered to be a focal disease 
of rural areas [49]. For all the above reasons, the presented estimates, obtained in a peri-urban 
setting, are subject to a high degree of imprecision and may not be generalizable to rural 
communities. Lastly, vaginal and cervical swabs were self-collected by participants, raising the 
potential for false negative genital swabs. In future work, this could be addressed by measuring E-
globin PCR as a positive control to confirm the presence of human DNA [50]. This study was 
developed based on a conceptual framework which describes a potentially causal relationship 
between FGS and HIV-1, with FGS as a potentially preventable and modifiable risk factor. In the 
literature, albeit in cross-sectional studies, there is evidence for biological plausibility [3, 8, 12] 
and large effect sizes for the association [7] between FGS and HIV-1. One of our study limitations 
was the temporality of HIV-1 and FGS diagnostics. HIV-1 seroconversion was measured in HPTN 
071 (PopART) up to three years prior to participant enrolment in the study and subsequent FGS 
diagnosis. This sequencing assumes that FGS status and demographic descriptors at the time of 
genital PCR sampling are similar to those at the time of HPTN 071 (PopART) study entry and/or 
HIV-1 seroconversion. This assumption is reasonable given that FGS is thought to develop after 
childhood water exposure [33] and persist into adulthood with chronic genital lesions, often 
persisting despite treatment with praziquantel [51]. A large, prospective, longitudinal study in 
areas of higher S. haematobium endemicity is needed to evaluate incident HIV-1 infection in 
women with known S. haematobium and FGS status at study baseline. In future work, it will be 
important to continue to analyse HIV-1 outcomes by both S. haematobium infection status and 




In conclusion, this analysis does not show evidence of association between FGS and HIV-1 
incidence. The hypothesis generating observations that FGS, and in particular higher FGS 
cervicovaginal disease burden or Schistosoma DNA concentrations, may be associated with HIV-
1 acquisition should be investigated in a larger longitudinal study in a high FGS prevalence area 
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Rate of HIV 
Seroconversion 
per 1000 p/y 
 





Age in years 18-24 289 (58.7) 15 23.6 (14.2  39.2) Reference 0.06 
 25-31 203 (41.3) 5 9.5 (3.9  22.7) 0.40 (0.15  1.10)  
Marital status Single 219 (44.5) 12 23.0 (13.1  40.5) Reference 0.35 
 Married or Cohabitating 255 (51.8) 7 11.8 (5.6  24.7) 0.51 (0.20  1.30)  
 Widowed, Divorced, or 
Separated 
18 (3.7) 1 21.2 (3.0  150.6) 0.92 (0.12  7.10)  
Education (highest level) None or Any Primary School 137 (27.9) 5 15.7 (6.5  37.6) Reference 0.57 
 Any Secondary School 297 (60.4) 11 15.5 (8.6  28.0) 0.99 (0.34  2.85)  
 Trade, Degree or higher 58 (11.8) 4 29.4 (11.0  78.4) 1.88 (0.50  7.00)  
District Community A 260 (52.9) 11 15.5 (8.6  28.0) Reference 0.60 
 Community B 232 (47.2) 9 19.8 (10.3  38.0) 1.27 (0.53  3.07)  
Household members 1-3 141 (28.7) 12 38.4 (21.8  67.6) Reference 0.007I 
 4-5 201 (40.9) 4 8.2 (3.1  21.7) 0.21 (0.07  0.66)  
 6+ 150 (30.5) 4 11.1 (4.2  29.5) 0.29 (0.09  0.90)  
Employment status Not Working 327 (66.5) 13 17.1 (10.0  29.5) Reference 0.99 
 Working 165 (33.5) 7 17.3 (8.2  36.2) 1.01 (0.40  2.52)  
Sexual behaviour characteristics        
Age at sexual debut (years) 8-16 197 (40.0) 9 20.6 (10.7  39.5) Reference 0.79 
 17-19 220 (44.7) 8 14.9 (7.5  29.9) 0.73 (0.28  1.88)  





Lifetime sexual partners 1 149 (30.3) 2 5.7 (1.4  22.9) Reference 0.01I 
 2 134 (27.2) 5 15.9 (6.6  38.3) 2.78 (0.54  14.34)  
 3 103 (20.9) 5 18.7 (7.8  45.0) 3.27 (0.63  16.85)  
 4+ 106 (21.5) 8 34.1 (17.1  68.2) 5.95 (1.26  28.02)  
Currently sexually active**,  No 63 (12.9) 3 20.1 (6.5  62.4) Reference 0.78 
 Yes 427 (87.1) 17 16.9 (10.5  27.1) 0.84 (0.25  2.86)  
STI history  No 466 (94.9) 16 14.4 (8.8  23.5) Reference 0.009 
 Yes 25 (5.1) 4 82.8 (31.1  220.5) 5.76 (1.92  17.22)  
Condom use with last sex  No 367 (75.8) 12 13.8 (7.9  24.3) Reference 0.11 
 Yes 117 (24.2) 8 29.2 (14.6  58.3) 2.11 (0.86  5.16)  
Contraceptive Use       
Condoms No 407 (82.7) 14 14.8 (8.8  25.0) Reference 0.23 
 Yes 85 (17.3) 6 27.5 (12.4  61.2) 1.86 (0.71  4.83)  
OCP No 440 (89.4) 18 17.3 (10.9  27.4) Reference 0.96 
 Yes 52 (10.6) 2 16.6 (4.1  66.3) 0.96 (0.22  4.14)  
Injectable No 225 (45.7) 14 22.5 (13.4  38.1) Reference 0.13 
 Yes 267 (54.3) 6 11.1 (5.0  24.6) 0.49 (0.19  1.28)  
Implant No 466 (94.7) 18 16.3 (10.3  25.9) Reference 0.37 
 Yes 26 (5.3) 2 34.0 (8.5  135.8) 2.10 (0.48  8.99)  
       
I test for trend p-value  
**Any sexual activity in the last 6 months 
Participants ho responded ith no ans er  (n=2) are not sho n in the table (HIV seroconversions =0) 
 STI history was self-reported, participants ho responded ith no ans er  (n=1) are not sho n (HIV serocon ersions =0) 
Participants ho responded ith no ans er  (n=8) are not sho n in the table (HIV serocon ersions =0)  
Table 7.2  HIV-1 incidence by FGS status and schistosomiasis-related factors  
 




Rate per 1000 PY 
(95% CI) 
IRR (95% CI) p-value aRR* p-value 
FGS Negative** 218 (53.2) 6 532.0 11.3 (5.1  25.1) Reference 0.26# Reference 0.33# 
Probable/possible FGS 166 (40.5) 7 372.2 18.8 (9.0  39.5) 1.67 (0.48  6.01)  1.73 (0.50  6.22)  
FGS  26 (6.3) 2 64.5 31.0 (7.8  123.9) 2.75 (0.27  15.36)  2.16 (0.21  12.30)  
Exploratory Analysis of Participants with FGS      
FGS Negative 218  6 532.0 11.3 (5.1  25.1) Reference 0.09 Reference 0.13 
FGS and 2-3 PCR Positive## 13  2 24.9 80.4 (20.1  321.7) 7.13 (0.70  39.89)  6.02 (0.58  34.96)  
FGS Negative 218  6 532.0 11.3 (5.1  25.1) Reference 0.15 Reference 0.19 
FGS and PCR Ct<35  13  2 32.6 61.31 (15.33  245.14) 5.44 (0.54  30.40)  4.73 (0.46  27.05)  
Schistosomiasis-related factors         
Urine Microscopy                  Negative 465 (94.5) 18 1,102.4 16.3 (10.3  25.9) Reference 0.40 Reference 0.47 
Positive 27 (5.5) 2 61.6 32.5 (8.1  129.9) 1.98 (0.46  8.58)  1.78 (0.41  7.71)  
Urine CAA                    Not detectable 416 (84.9) 16 993.5 16.1 (9.9  26.3) Reference 0.86 Reference 0.78 
Detectable 74 (15.1) 3 166.6 18.0 (5.8  55.8) 1.12 (0.33  3.84)  1.19 (0.35  4.10)  
Active Infection ,             Not Present 413 (84.3) 16 985.0 16.2 (10.0  26.5) Reference 0.93 Reference 0.85 






**82 participants who were negative on all diagnostic tests but missing portable colposcopy images were excluded from this analysis 
*Adjusted for age  
#Test for trend p-value (RR per unit of the exposure variable [FGS Negative, Probable/Possible FGS and FGS] treated as a continuous variable) 
##n=13 excluded (one genital PCR specimen positive) 
 n=13 excluded (Ct>35) 
 n=492, unless otherwise specified 
n=490, 2 vials arrived at the laboratory empty, HIV-1 seroconversion occurred in (n=1) of these participants 
defined as detectable urine CAA or positive urine microscopy 
 
 
Abbreviations: aRR  adjusted rate ratio, CAA  circulating anodic antigen, Ct  cycle threshold, FGS  female genital schistosomiasis, IRR  incidence rate 






Figure 7.1  Female Genital Schistosomiasis categories and Venn diagram illustrating results 







Figure 7.1 Legend: 
A. Female Genital Schistosomiasis diagnostic categories 
B. Participants in the diagnostic categories by test result 











Figure 7.2 Legend:  
Not visited (n=189)  the participant was not visited before the study closed for enrolment 
Visited but not contacted (n=110)  a visit was made to the study household, but the 
participant could not be located (70), had relocated (39), or died (1) 
Contacted & not immediately enrolled (n=120)  visited but not recruited (42), out of town 
(18), declined to participate (60) 










FGS is a preventable, albeit neglected, tropical gynaecologic condition. Women in endemic 
countries lack access to adequate diagnostics, curative treatment, and effective prevention 
[2]. Many even struggle to access adequate water, sanitation and hygiene measures [122]. To 
develop improved treatment, prevention, and diagnostic efforts, the scientific community 
needs to better understand FGS pathophysiology and epidemiology. This thesis provides the 
foundation to leverage additional clinical and laboratory research needed to make concepts 
translatable to the patient experience.  
 
This chapter outlines the main findings and interpretation of the original research papers, 
strengths and limitations of the methods, generalisability, and outlines implications for policy 
and further research. This PhD thesis is comprised of a narrative review and three original 
research papers. The overall aim of this PhD thesis was to describe the cervicovaginal 
microbiota (including STIs) and the cervicovaginal immune environment in Zambian women 
with and without PCR-defined FGS  and to explore the association of PCR-defined FGS  
with HIV-1 incidence. There is a well-described association between both STIs and non-
optimal  cer ico aginal microbiota and HIV-1 acquisition [100, 123]. Thus, this PhD thesis 
tests the hypothesis that PCR-defined FGS  would be associated with STIs and the 
cer ico aginal microbiota in their non-optimal  state and that PCR-defined FGS  would be 
associated with incident HIV-1 infection. This PhD thesis also proposed that PCR-defined 
FGS  might act as a risk factor for HIV-1 acquisition by promoting elevated concentrations 
of chemokines associated with HIV-1 acquisition and contributing to a change in 






Figure 8.1  Conceptual pathway describing the potential association of FGS with epithelial 
disruption, STI, vaginal inflammation, non-optimal  cer ico aginal microbiota, and HIV-1 




*adapted from [14] 
 
As outlined in Chapter 1, FGS studies are challenging to contextualize and compare, due to 
heterogeneity in study methodologies and FGS definitions. Much research has been 
performed in participants ith isual FGS  or urogenital schistosomiasis . This PhD thesis 
adds to the current FGS literature by using PCR, a semi-quantitative method, to define FGS. 
Data regarding this emerging standard in FGS research, including work contributed in this 
PhD thesis, is contextualized with what is currently known regarding other schistosomiasis 
categories, including urogenital schistosomiasis , isual FGS , tissue FGS , and 
unspecified/mi ed/S. man oni  infections. Data contributed by this PhD thesis are shown in 







Figure 8.2  Schistosoma infection categories and supporting literature describing the 
cervicovaginal environment, the cervicovaginal microbiota, HIV-1 prevalence and HIV-1 
incidence, including work from this PhD thesis 
 
 
Abbreviations: Ab  antibody, Assoc   association, Ca  Candida albicans, CAA  
circulating anodic antigen, Ct  Chlamydia trachomatis, BV  bacterial vaginosis, diff  
difference, HPV  human papillomavirus, HSV-2  herpes simplex virus-2, HYSP  
homogeneous yellow sandy patch, IL  interleukin, FGS  female genital schistosomiasis, 
RPR  rapid plasma reagin, SG  subgroup, Sh  S. haematobium, Sm  S. mansoni, SP  
sandy patch, STI  sexually transmitted infection, Th2  T-helper 2, Tp  Treponema 
pallidum, Tv  Trichomonas vaginalis 
 
8.2 Main findings and Interpretation 
 
8.2.1 Research Paper 2 (Chapter 5): FGS, the cervicovaginal microbiota and STIs   
Main Findings 
Compared to negative FGS women, there was no evidence of a difference in the presence or 
concentration of cervicovaginal L. crispatus, L. iners, A. vaginae, G. vaginalis or Candida 
spp. in participants ith PCR-defined FGS . There as some e idence that T. vaginalis was 
present in a higher proportion of participants ith PCR-defined FGS  (p=0.08) and this 
association remained after adjusting for age. A secondary analysis combined participants 
from the PCR-defined FGS  and probable FGS groups. Participants ith PCR-defined 
FGS /probable FGS likewise had a higher proportions of T. vaginalis compared to negative 






In an e plorator  anal sis, si teen participants ith a higher burden of PCR-defined FGS  
( 2 Schistosoma PCR positive genital specimens) had an increased prevalence of T. vaginalis 
compared to negative FGS participants (p=0.01). In si teen participants ith PCR-defined 
FGS  and moderate/high genital Schistosoma DNA concentrations, the presence of T. 
vaginalis was higher in the participants with moderate/high Schistosoma DNA concentration 
compared with negative FGS participants (p=0.01).  
 
8.2.2 Research Paper 2 (Chapter 5): FGS, the cervicovaginal microbiota and STIs  
Interpretation  
 
Molecular characterization of the cervicovaginal microbiota has consistently revealed a 
variety of bacterial communities that vary in diversity and composition [104, 124]. Low-
diversity communities, dominated by lactobacilli have been associated with a lower risk of 
HIV-1 acquisition compared to higher-diversity anaerobic communities [104]. Additionally, 
specific cervicovaginal microbiota have been associated with increased risk of HIV-1 
acquisition [101]. Thus, at the outset of this ork, m  h pothesis as that PCR-defined 
FGS  ould be associated ith STIs and the cer ico aginal microbiota in their non-
optimal  state. 
 
The findings presented in Chapter 5 regarding the cervicovaginal microbiota in women with 
and ithout PCR-defined FGS  harmonise ith recentl  published data from Tan ania. 
Although using different techniques, 16s rRNA sequencing in Tanzanian women with urinary 
S. haematobium infection showed no difference in cervicovaginal microbiota diversity, 
compared to uninfected women [59]. Contrary to the original hypothesis, there was no 
association between the presence and concentration of key species of the cervicovaginal 
microbiota (L. crispatus, L. iners, A. vaginae, G. vaginalis, and Candida spp.) ith PCR-
defined FGS  (Figure 8.3). This PhD thesis did not evaluate the association of concentrations 
of cervicovaginal microbiota known to be associated with HIV-1 such as Parvimonas species 
types 1 and 2, G. asaccharolytica, M. hominis, Leptotrichia/Sneathia, Eggerthella species 







Figure 8.3  Conceptual pathway describing the potential association of FGS with epithelial 
disruption, STI, vaginal inflammation, non-optimal  cer ico aginal microbiota, and HIV-1 




Despite not finding strong evidence of an association between the presence and concentration 
of cervicovaginal key species, data regarding T. vaginalis and FGS co-infection presented in 
this PhD thesis are thought-provoking. Although there was no association between the STI 
pathogens C. trachomatis, N. gonorrhoeae, and M. genitalium and PCR-defined FGS , there 
was weak evidence that the proportion of participants with T. vaginalis was higher in 
participants ith PCR-defined FGS  compared ith negative FGS participants (Figure 8.3). 
The evidence of association between T. vaginalis and FGS was strengthened by combining 
PCR-defined FGS  and probable FGS participants, due to an increase in po er (the point 
estimate did not change, but the confidence intervals narrowed). Additionally, the association 
between T. vaginalis and FGS was seen across both exploratory analyses of higher FGS 
burden. This PhD research adds to the growing literature regarding an association between S. 
haematobium infection and T. vaginalis [74, 77]. Notably, the association between S. 
haematobium infection and T. vaginalis presence has been previously identified across 





isual FGS  in aried geographical locations with both small and large sample sizes [74, 
77]. 
 
The association between T. vaginalis  and FGS raises salient questions regarding the role of 
the cervicovaginal immunologic environment in FGS pathogenesis. In Chapter 6, participants 
ith a higher clinical disease burden of PCR-defined FGS  had ele ated concentrations of 
the Th2 cytokines (IL-4 and IL-5) in their CVL. A mouse model of S. haematobium infection 
and urinary tract infection suggested that a Th2 environment may be associated with delayed 
urinary pathogen clearance [125]. If this finding can be extended to the genital tract, future 
ork could e aluate hether PCR-defined FGS  ma  be associated ith dela ed T. 
vaginalis clearance.  
 
Chapter 6 describes a Th2 biased cervicovaginal environment in participants with a higher 
FGS clinical disease burden. Another potential role of the Th2 immune environment in FGS 
may involve alternative macrophage activation. Often classically activated macrophages 
(M1) are selected by pro-inflammatory T-helper (Th) 1 cytokines and alternative macrophage 
activation (M2) is selected by Th2 cytokines [126]. M2 macrophages are often associated 
with tissue-repair or fibrosis and can have anti-inflammatory effects [126, 127]. T. 
vaginalis has been implicated in alternative macrophage activation. Macrophage polarization 
can be also influenced by the local immune environment and schistosome infection, 
illustrating the complex interplay between the cervicovaginal immune environment and the 
cervicovaginal microbiota [126, 128].  
 
In a recent meta-analysis, the WHO reports that worldwide prevalence of T. vaginalis  is 
5.3% among women age 15-49, making this parasitic infection the most prevalent non-viral 
STI [129]. Trichomoniasis is a risk factor for HIV-1 acquisition [130] and the highest global 
incidence rates have been reported in Africa [129] where increased incident T. vaginalis  may 
manifest as a substantial number of new HIV-1 infections in women. Thus, further work is 
needed to understand how T. vaginalis and S. haematobium might influence the 
cervicovaginal environment. As parasites, both T. vaginalis and S. haematobium require a 
living host for survival. The unicellular protozoa, T. vaginalis is strictly extra-cellular, 
adhering to cervicovaginal epithelial cells and interacting with host cell galectins to modulate 
the cervicovaginal immune environment [131-133]. Both S. haematobium and T. 





asymptomatic infections and re-infection are common to both parasites, possibly suggesting 
immune evasion or a less effective adaptive immune response [131]. Examining the 
mechanisms of T. vaginalis pathogenesis may provide insights into the association between 
the parasites. Broadly, T. vaginalis influences the local environment first, via attachment to 
the cervicovaginal epithelium causing disruption of tight junctions and alterations in 
cellular permeability [134, 135] , second through subversion of innate immunity, via decrease 
in secretory leukocyte peptidase inhibitor and both direct and soluble-
factor lymphotoxic effects on B and T cells [132, 136]; third, through a reduction in epithelia-
associated Lactobacilli [137] and finally, through haemolysis [138]. The local immune 
system then counters T. vaginalis infection with a pro-inflammatory cytokine and chemokine 
response. Overlapping synergies between T. vaginalis and S. haematobium cervicovaginal 
pathogenesis may begin with, but are not limited to, disruption to the cervicovaginal 
epithelium, with both infections associated with well-defined clinical manifestations [26, 
139]. This breach in the protective cervicovaginal defences provides a plausible mechanism 
for the HIV-1 vulnerability demonstrated in women with prevalent T. vaginalis [123] or S. 
haematobium infection  [17].   
 
8.2.3 Research Paper 3 (Chapter 6): FGS and cervicovaginal immune activation   
Main Findings 
 
Compared to negative FGS women, there was no difference in the concentrations of 
cytokines and chemokines in participants with PCR-defined FGS , after adjusting for 
potential confounders and multiple testing. This includes chemokines (MIP-1a [CCL-3], 
MIP-1b [CCL-4], IL-8 [CXCL-8], and IP-10 [CXCL-10]) that predicted HIV-1 acquisition 
risk in a South African study [118]. Using a Principal Components Analysis to reduce the 
dimensionality of the data, a comparison of the mean scores for the first two Principal 
Components by PCR-defined FGS  status, likewise showed no difference between groups. 
 
In exploratory analyses, fifteen participants with a higher PCR-defined FGS  burden ( 2 
Schistosoma PCR positive genital specimens) had elevated concentrations of IL-4 and IL-5 
compared to negative FGS participants, after adjusting for potential confounders and multiple 
comparisons. Compared to negative FGS participants, fifteen participants with PCR-defined 
FGS  and moderate/high genital Schistosoma DNA concentrations had elevated 







8.2.4 Research Paper 3 (Chapter 6): FGS and cervicovaginal immune activation  
Interpretation  
 
The mechanism behind HIV-1 susceptibility in FGS is still largely unknown. Thus, one of the 
objectives of this PhD thesis was to evaluate whether FGS might be associated with HIV-1 
through the promotion of increased concentrations of HIV-1 acquisition associated cytokines. 
At the outset of this work, my hypothesis was that FGS would act as a risk factor for HIV-1 
acquisition by promoting elevated concentrations of chemokines associated with HIV-1 
acquisition and contributing to changes in cervicovaginal immune protein concentrations. As 
presented in Chapter 6, PCR-defined FGS  and negative FGS women had similar 
expression profiles of chemokines and cytokines, including those that predicted HIV-1 
acquisition risk in a South African study (MIP-1a [CCL-3], MIP-1b [CCL-4], IL-8 [CXCL-
8], and IP-10 [CXCL-10]) [118]. Thus, PCR-defined FGS  this thesis suggests that the 
cytokine and chemokine environment in PCR-defined FGS  is not likel  to increase HIV-1 
acquisition risk.  
 
An important finding reported in this thesis is that women with FGS and a high burden of 
clinical disease displayed a cervicovaginal Th2 environment. Previous work has suggested that 
HIV-1 strains using the CCR5 co-receptor are primarily responsible for sexual HIV-1 
transmission and that the cytokine and chemokine environment can regulate T cell HIV-1 
susceptibility [140, 141]. While IL-4 and IL-5 reflect the canonical Th2 cytokines, the presence 
of mixed Th1 and Th2 immune responses in S. haematobium exposure or infection are often 
reported [142-144]. HIV-1 preferentially replicates in different T cell phenotypes, with a Th17 
phenotype supporting CCR5-using HIV-1 replication and a Th2 phenotype supporting only a 
low to undetectable HIV-1 replication level [140]. Additionally, a Th2 phenotype is associated 
with replication of CXCR-4 using HIV-1 replication, a co-receptor often associated with 
chronic HIV-1 infection [140]. While cellular populations were not evaluated in this PhD 
thesis, overall, the finding of a cervicovaginal Th2-biased immune environment would not 
support a hypothesis of enhanced HIV-1 susceptibility in FGS [63]. Thus, FGS may instead 
increase HIV-1 acquisition risk through other mechanisms (Figure 8.4). The HIV-1 
vulnerability in S. mansoni infection has been seen in women, but not men [56, 57] suggesting 
that a non-cytokine based response involving the cervicovaginal mucosa may be associated 





higher proportions of mucosal-homing integrin 4 7 expressing cells in the blood [63, 70]. 
While eggs are primarily deposited in the urogenital tract in S. haematobium infection, autopsy 
studies show that S. haematobium eggs can also be found in the colon and small intestine [62], 
suggesting that further work will need to explore the role of integrin 4 7 in S. haematobium 
infection. 
 
Figure 8.4  Conceptual pathway describing the potential association of FGS with epithelial 
disruption, STI, vaginal inflammation, non-optimal  cer ico aginal microbiota, and HIV-1 




Another objective of this PhD thesis was to describe the cervicovaginal cytokine and 
chemokine signature in women with and without FGS, focusing on the Th1 and Th2 immune 
responses. After adjusting for potential confounders and multiple comparisons, there was no 
difference in the concentrations of the evaluated chemokines and cytokines between 
participants ho had PCR-defined FGS  and those ho ere negative FGS. However, in two 
exploratory analysis there was a difference in Th2 cytokine concentrations (IL-4 and IL-5) 
between groups when women with a higher clinical burden of infection and in Th2 and pro-





Schistosoma DNA concentrations were compared with negative FGS participants. There was 
no difference in the canonical Th1 cytokine, IFN-  between these groups. 
 
This thesis adds to the literature b  reporting no el c tokine data in humans ith PCR-defined 
FGS . Alterations in IL-4 and IL-5 concentrations in women with FGS and a higher clinical 
disease burden and IL-5 and TNF𝛼 concentrations in women with moderate/high genital 
Schistosoma DNA concentrations (reported in Chapter 6) harmonise with findings from human 
and murine research [143-146]. The immunologic response to Schistosoma infection is 
complex and may reflect the interaction of the Th1 and Th2 immune responses [143]. Tissue-
lodged Schistosoma eggs are accompanied by an influx of T- cells [147]. Indeed, murine 
Schistosoma models report a shift from a Th1 to a Th2 biased immune environment at 
oviposition and the commencement of egg-patent infection [148]. A tissue-based innate 
immune response is thought to generate Th2 cells, with IL-4 production supporting granuloma 
formation, IL-5 production recruiting neutrophils, and IL-13 promoting fibrosis [147]. 
Conversely, a Th1 and Th17 response may be largely suppressed after oviposition. Schistosoma 
egg antigen as well as Th1 and T regulatory cells induce a regulatory IL-10 response [149]. 
The Th2 and regulatory responses provide a means for helminths to evade unabated host pro-
inflammatory responses [63]. Many such data come from murine models, and while data 
providing a time course for the cytokine response in human S. haematobium infection are 
lacking, cross-sectional and longitudinal data in human populations have documented that S. 
haematobium infection is associated with altered levels of systemic [144, 150], seminal fluid 
[151] and cervicovaginal [60] cytokine concentrations.  
 
Notably, Th2 and pro-inflammatory cytokines were present in the CVL of women with a 
moderate/high concentration of Schistosoma DNA. As a marker of schistosomiasis morbidity, 
TNF-D may be an important mediator of granuloma formation and fibrosis. Morbidity may 
potentiall  be correlated ith the host s inflammator  response to tissue-lodged ova [146]. 
While TNF-D expression is not universally reported in S. haematobium infection [152], TNF-
D production in children with S. haematobium infection has been associated with urinary 
bladder morbidity [146]. Additionally, in vitro models of infection with T. vaginalis and 
cervicovaginal anaerobic bacteria have been associated with cellular tight junction disruption, 
paracellular permeability, and TNF-D production [135]. The subsequent cervicovaginal barrier 





of action brings together work from Chapter 5 and Chapter 6 to explain a potential mechanism 
that may influence HIV-1 susceptibility. TNF-D is a pro-inflammatory cytokine and is 
produced by cells from both the innate and adaptive immune system [153]. While TNF-D is 
produced by Th1 cells, it can also be produced by Th2 cells [154]. Thus, in this thesis TNF-D 
is referred to as pro-inflammatory rather than a Th1 or Th2 cytokine.  
 
The cytokine work presented in Chapter 6 illustrates the importance of defining and reporting 
infection intensit  in FGS research. The finding that omen ith PCR-defined FGS  and 
moderate/high genital Schistosoma DNA concentrations had higher concentrations of Th2 (IL-
4) and pro-inflammatory (TNF-D) cytokines than negative FGS women, harmonise with 
research in male genital schistosomiasis. In male genital schistosomiasis, infection intensity 
has been defined by semen egg count. A study evaluating semen cytokine levels in Madagascan 
participants (n=116) with male genital schistosomiasis found that men with a moderate/high 
seminal egg excretion had higher levels of seminal Th2 (IL-4), regulatory (IL-10), Th1 (IFN-
J) and pro-inflammatory (TNF-D) cytokines compared to egg-negative men [151]. Only one 
study has evaluated cervicovaginal immune proteins in women with schistosomiasis. This 
study, done in Tanzania, found lower CVL IL-15 concentrations in women with urinary S. 
haematobium infection (n=20, urine microscopy and CAA positive) who had not been 
e aluated for PCR-defined FGS . This PhD thesis describes higher concentrations of IL-15 
in participants in both exploratory analyses of infection intensity, but there was not strong 
evidence of a difference between FGS and negative FGS groups after adjusting for multiple 
testing. 
 
The finding that both Th2 and pro-inflammatory cytokines in participants with FGS and a high 
burden of clinical disease and moderate/high Schistosoma DNA concentrations is intriguing 
and further work will be needed to make these immunologic findings relevant to participants.  
In the future, immunologic markers of PCR-defined FGS  could impact FGS diagnostic 
pathways, may assist in evaluating therapeutics, or could function as markers of treatment 
success.  
 







Incident HIV-1 infections were observed in 20 (4.1%) of 492 women, who provided 1,164 
person-years of follow-up. The overall rate of HIV-1 seroconversions per 1,000 person-years 
was 17.2 (95% CI 11.1  26.6). In women with PCR-defined FGS , the HIV-1 
seroconversion rate was 31.0 [7.8  123.9) per 1,000 person-years. This rate of HIV-1 
seroconversion was higher than among negative FGS participants, albeit without statistical 
evidence of a difference in both crude and adjusted analyses (crude RR 2.75 [0.27  15.36, 
p=0.26; aRR 2.16 [0.21  12.30), p=0.33). 
 
In exploratory analyses, thirteen participants with a higher PCR-defined FGS  burden ( 2 
Schistosoma PCR positive genital specimens) acquired HIV-1 with an incidence rate ratio of 
6.02 (0.58  34.96, p=0.13), compared to negative FGS participants, after adjusting for age. 
Compared to negative FGS participants, thirteen participants with PCR-defined FGS  and 
moderate/high genital Schistosoma DNA concentrations acquired HIV-1 with an incidence 
rate ratio 4.73 (0.46  27.05), p=0.19). 
 
8.2.6 Research Paper 4 (Chapter 7): FGS and HIV-1 Incidence   
Interpretation  
 
At the outset of this ork, m  h pothesis as that PCR-defined FGS  ould be associated 
with incident HIV-1 infection. The work presented in Chapter 7 did not show an association 
bet een PCR-defined FGS  and incident HIV-1. In the exploratory analyses of 
moderate/high Schistosoma DNA concentrations, there was no evidence of a difference in 
HIV-1 seroconversion when comparing participants with a moderate/high Schistosoma DNA 
concentration and negative FGS participants. In comparing participants with a higher clinical 
FGS burden, there was weak evidence of an association with HIV-1 seroconversion, which 
was less pronounced in the age-adjusted estimates.  
 
Due to low power in the work described in Chapter 7, there may have been a difference in 
HIV-1 seroconversion bet een PCR-defined FGS  and negative FGS groups that we were 
unable to detect. The low power makes it challenging to rule out an association between FGS 
and HIV-1. However, one possible hypothesis is that there may not be an association between 
FGS and incident HIV-1 and pre ious ork sho ing an association bet een tissue FGS  
and HIV-1 [17] may have been influenced by residual or unmeasured confounding. As 





participants with FGS in both the primary and exploratory analyses were small. Thus, the 
po er to detect a difference bet een PCR-defined FGS  and negative FGS groups was 
limited. However, as discussed in Chapter 1, the literature on incident HIV-1 in schistosome 
infection is conflicting, with an increased risk of HIV-1 acquisition in Zambian S. 
haematobium antibody positive women, but not men [47] and no association between active 
schistosome infection and HIV-1 seroconversion in a study from Kenya and Uganda, despite 
sub-analyses by sex, schistosome species, and infection intensity [45]. However, neither of 
these important studies evaluated for genital involvement [45, 47].  
 
In fa our of a causal association bet een PCR-defined FGS  and pre alent or incident HIV-
1, the work presented in Chapter 7 identifies a possible dose-response relationship between 
FGS and HIV-1 acquisition and also shows strong effect sizes for this association, albeit with 
wide confidence intervals [155]. Although the literature on the association between prevalent 
HIV-1 and FGS are conflicting [83], studies that do show an association between FGS and 
HIV-1 show a moderate [82] or strong effect size [17]. Also supportive of a potentially causal 
relationship between FGS and HIV-1 is the hypothesis for biological plausibility. As 
described in Chapter 1 and Chapter 2, the biological plausibility for an association between 
FGS and HIV-1 includes FGS characteristics such as mechanical FGS-related cervicovaginal 
barrier dysfunction [15], the vascular and target cell composition of the granuloma 
environment [76, 78], enhanced CD4+ T cell trafficking to genital sites through integrin 4 7 




This work is the first to describe the cervicovaginal immune environment and the 
cervicovaginal microbiota in young, sexually active, non-pregnant Zambian women in the 
context of high HIV-1 prevalence. There are limited data regarding the cervicovaginal 
immune environment and the microbiota in women with S. haematobium infection [59, 60]. 
This PhD thesis fills a gap in the literature and extends these existing results by evaluating a 
patient population ith PCR-defined FGS . Pre ious studies ha e e aluated HIV-1 
acquisition in schistosome infection, however due to the study design, they were not able to 
evaluate for genital involvement [45, 47]. Thus, a strength of the evaluation of the association 
of FGS with HIV-1 incidence is the thorough e aluation for PCR-defined FGS  and isual 






Many studies use 16s rRNA sequencing to evaluate the relative abundance of cervicovaginal 
microbial communities; however, targeted PCR was chosen for this study. In 16s rRNA 
approaches, the relative abundance of operational taxonomic units in an individual patient 
specimen describes the proportion of an operational taxonomic unit of interest within a 
sample, compared with all other taxa [156]. However, this method does not allow 
determination of concentrations of individual microbiota, as in PCR. An additional strength 
of this approach was that it allowed us to define concentrations of the species as interest, as 
well as identifying a protozoan (T. vaginalis) and yeast (Candida spp.) that cannot be 
detected by 16s rRNA sequencing. Another strength is that the immunology work 
investigated a range of chemokines as well as Th1, Th2, proinflammatory, and regulatory 
cytokines. 
 
Another strength of this PhD thesis is the strides taken towards filling a number of gaps in the 
FGS literature. FGS prevalence is likely under documented and we are the first study group 
to prospectively document FGS in Zambia. The use of biopsy in FGS research has been 
limited by theoretical concerns regarding HIV-1 vulnerability in the setting of diagnostic 
biopsy for FGS. Thus, characteristic clinical manifestations of the cervix and vagina have 
been put forward as a means of FGS diagnosis, but these lesions lack specificity [157]. The 
use of a semi-quantitative diagnostic with high specificity to define the FGS group enhances 
the reproducibility of the results [25]. Thus, a strength of this PhD thesis is the use of PCR 
testing to define the FGS group. Across the three studies presented in Chapter 5, Chapter 6, 
and Chapter 7, participants are also classified by FGS burden in order to evaluate differences 
in desired outcomes by clinical burden of disease and moderate/high concentrations of 
Schistosoma DNA. Another strength of the PhD thesis is the ability to classify participants 
into mutually exclusive categories based on the results of a number of different diagnostics to 
evaluate for Schistosoma infection (urine microscopy and CAA) and FGS (mobile phone 
colposcopy and Schistosoma PCR).  
 
This PhD thesis was based on work performed in the BILHIV study, a cross-sectional study 
performed among participants previously enrolled in the HPTN 071 (PopART) trial, after the 
final 36-month visit. The study retention in the BILHIV study was high, with 87.4% 





incidence in HPTN 071 (PopART) provided a unique opportunity to explore the association 
of FGS with HIV-1 incidence.  
 
The BILHIV study is one of the largest FGS studies to date, with a total of 603 participants 
enrolled and evaluated by a comprehensive array of diagnostics: genital PCR, portable 
colposcopy, CAA and urine microscopy [25]. To maximise resources in the studies of the 
cervicovaginal microbiota and the cervicovaginal immune environment, all PCR-defined 
FGS  cases were frequency matched to a subset of negative FGS participants. To reduce the 
risk of selection bias for the negative FGS participants in these studies, a random number 
generator was used to randomly select negative FGS participants matched with PCR-defined 




Schistosomiasis often affects impoverished areas, lacking in clean water and adequate 
sanitation [158, 159]. A pre-study survey of school-aged children in the Livingstone area 
showed a urinary S. haematobium prevalence of 20%. Despite this, the prevalence of S. 
haematobium infection by urine microscopy in the BILHIV study was 5.5% (33/603), with 
8.2% (26/319) and 2.5% (7/284) prevalence in Community A and B, respectively. Thus, by 
WHO definitions, Livingstone is a low prevalence area for S. haematobium infection [37]. 
Overall, the prevalence of FGS was 5.7% (30/529). Thus, there were small numbers of FGS 
cases in both the main and exploratory analyses. The communities enrolled in the BILHIV 
study had been previously enrolled in intervention arms of the HPTN 071 (PopART) trial 
[105]. Although HIV-1 prevalence was high (17.9%), the number of HIV-1 seroconversions 
may have been further reduced due to participants in both Community-A and Community-B 
receiving trial interventions. Overall, the low prevalence of PCR-defined FGS  and HIV-1 
seroconversion translated into a lack of precision in the HIV-1 incidence study presented in 
Chapter 7. Additionally, in Chapter 6, the concentrations of immune proteins measured in 
CVL were low, despite the use of a protease inhibitor to decrease immune protein 
degradation. Thus, to reduce the dilution of immune protein concentrations in saline-based 
CVL in future work, cervicovaginal secretions could be collected in a menstrual cup [160]. 
 
The sensitivity of Schistosoma PCR is imperfect and varies by the chosen reference standard 





low-prevalence settings [158]. Although not unique to this study, a limitation when using 
schistosomiasis diagnostics is the potential risk of diagnostic misclassification. Additionally, 
women self-collected cervical and vaginal swabs in their homes, raising the possibility of 
false negative genital swabs. Future work could employ E-globin PCR to assess for the 
presence of human DNA [161]. This study did not measure prostate specific antigen (PSA) or 
Y-chromosome to assess for recent penile-vaginal sex [61, 162] and thus cannot preclude that 
a positive genital specimen may have detected DNA from Schistosoma eggs in a male 
partner s semen. 
 
Another potential limitation is the temporality of HIV-1 and FGS diagnosis. In the HPTN 071 
(PopART) trial, HIV-1 ma  ha e been diagnosed up to three ears prior to the participant s 
FGS diagnosis. S. haematobium infection, and subsequent FGS, likely occurs in childhood 
and may persist despite treatment with praziquantel [163, 164]. Thus, FGS likely preceded 
the participant s HIV-1 diagnosis. Ideally, this would be confirmed with the presence of 
species-specific Schistosoma antibodies from HPTN 071 (PopART) banked blood samples. 
 
The BILHIV study was a pilot study comparing the operating characteristics of home-based, 
self-collected cervical and vaginal swabs with provider performed cervicovaginal lavage 
[25]. The BILHIV study questionnaire focused on demographics, HIV-1 risk factors, and the 
acceptability of study procedures and did not enquire regarding menstrual cycle phase, 
frequency of penile-vaginal sex or intravaginal practices. Additionally, the BILHIV study 
clinic visit did not assess some behavioural and biological factors that could influence the 
outcomes of interest in this PhD thesis (cervicovaginal microbiota and the concentration of 
cytokines and chemokines) such as body weight, PSA or Y-chromosome status, vaginal pH, 
Nugent score, herpes simplex virus-2, and human papillomavirus status. Additionally, due to 
the small numbers of outcomes in some analyses, it was not possible to fully adjust for 
confounding. Thus, we cannot exclude unmeasured or residual confounding. In the studies of 
the cervicovaginal microbiota and the immunologic environment, we compared multiple key 
species and 17 cytokines and chemokines. Since these analyses involved multiple statistical 
comparisons, we adjusted for multiple testing and prioritized results that showed a consistent 
pattern of association across analyses and species. We also employed two exploratory 






The cervicovaginal microbiota are dynamic with fluctuations in response to menstrual blood 
[165], the presence of semen [166], and other behavioural and biological factors. Some 
cervicovaginal cytokine concentrations may also vary by menstrual cycle phase [107]. The 
cross-sectional study design limited the ability to characterize the impact of, trends in, and 
stability of the cervicovaginal microbiota and the immune environment in participants with 
and without FGS over time. Longitudinal participant follow-up in this cohort would also help 
minimize inter-individual variability. In this PhD thesis, we measured well-known immune 
proteins and key species of the cervicovaginal microbiota. However, study results could be 
expanded by the inclusion of additional specimen types, particularly endocervical 
cytobrushes for cells for flow cytometry. Due to budgetary and ethical constraints, multi 
omics were not conducted, nor was cellular processing for flow cytometry performed, or 




The data presented in this PhD thesis may be generalisable to other sub-Saharan African 
populations. The BILHIV study population was selected from a representative sample of two 
communities in Livingstone, Zambia that participated in the HPTN 071 (PopART) trial. A 
census was performed in each community prior to the HPTN 071 (PopART) trial onset. The 
household listing was used to select a random sample of households, and each adult in the 
household was numbered. At the enrolment visit, one adult (age 18  44 years) was selected 
with a random number generator [167]. The BILHIV study population was then selected 
consecutively from women aged 18  31 within the trial population, suggesting a 
representative sample that should be generalisable to other Zambian communities [25]. We 
enrolled a population of sexually active, young women from communities with a high HIV-1 
prevalence and this population sub-group may be generalisable across sub-Saharan Africa.  
 
Although an estimated 82 million women in sub-Saharan African are living with Schistosoma 
infection [7], FGS prevalence is underreported, with only approximately 10,000 FGS cases 
described in the published literature [12]. In addition, few studies use PCR-based methods to 
define FGS [29, 79, 88, 90]. Thus, much progress is needed to ensure the generalisability of 
the methods employed in this work across sub-Saharan Africa. Schistosoma infection is 
endemic in all of Zambia s 10 provinces [168]. Although often considered a focal disease of 





locations [25, 170]. The BILHIV study was performed in an urban community in 
Livingstone, Zambia and thus the results may not be generalisable to rural locations and other 
locations with a higher S. haematobium prevalence. In a higher prevalence community, 
ideally there would have been a higher pre alence of PCR-defined FGS , allo ing greater 
power for study endpoints. 
 
In the studies of the cervicovaginal microbiota and immune environments presented in 
Chapters 5 and 6, we selected all the participants with PCR-defined FGS  and probable 
FGS. The negative FGS cases were then frequency matched (on age) to the participants with 
FGS. Thus, the proportions of demographic and diagnostic variables presented in Chapter 5 
and 6 may not be generalisable to the study population as a whole. 
 
8.6 Implications for further research 
 
This PhD describes higher HIV-1 seroconversion rates in women with PCR-defined FGS , 
without statistical evidence of a difference. Evidence of an association between HIV-1 and 
FGS could fundamentally influence HIV-1 prevention in sub-Saharan Africa. Thus, 
clarifying the association between HIV-1 and FGS must continue to be a research priority 
going forward. Evidence of an association between FGS and HIV-1 would likely stimulate 
the political and societal will to leverage funding needed for expanded praziquantel treatment 
programmes for FGS-prevention, the integration of FGS into the existing HIV-1 care cascade 
as well as water, sanitation and hygiene efforts. Clear evidence of an association between 
FGS and HIV-1 would also likely enhance a funding environment amenable to supporting 
larger treatment, prevention, and randomised controlled trials testing different treatment 
interventions. Ideally, further work evaluating HIV-1 incidence in women with PCR-defined 
FGS  would be continued with a study design that correctly ascertains the temporality of 
FGS and HIV-1 seroconversion. In this future work, female HIV-1 negative participants 
would be evaluated at baseline for PCR-defined FGS  and visual FGS , as well as 
urogenital schistosomiasis  and followed longitudinally to evaluate HIV-1 seroconversion. 
Ideally, this work would be performed in a high HIV-1 and high S. haematobium prevalence 
setting. Since the risk profile of both isual FGS  and PCR-defined FGS  are relati el  






Chapter 5 discusses a cross-sectional approach to the immunologic environment in women 
ith PCR-defined FGS . However, this format leaves open future possibilities to integrate 
the subject matter of Chapter 5 and Chapter 6 in one combined work. Future work could 
evaluate the impact of praziquantel treatment on cervicovaginal microbiota, cytokines and 
chemokines in women with FGS followed longitudinally. Additionally, it would be important 
to evaluate different levels of schistosome infection as the exposure, including PCR-defined 
FGS , isual FGS , and urogenital schistosomiasis , also including women with high-
burden infections. In this prospective cohort Th17 responses could be evaluated in addition to 
Th1 and Th2 responses both before and after praziquantel treatment. Little is known about 
the natural history of the human cervicovaginal immune response at different phases of FGS 
infection (both acute and chronic). Ideally future work could address this knowledge gap. 
Furthermore, little is known regarding FGS prevalence and intensity in adolescent girls and 
young women and future efforts in FGS prevention, diagnosis, and treatment could be 
expanded to include women younger than 18 years of age. The BILHIV study showed that 
vaginal and cervical self-sampling was acceptable in women 18-31 [171] (Appendix 2), and 
future work could extend this finding to adolescent girls and young women both before and 
after their sexual debut.  
 
Currently, there are no data using 16s rRNA sequencing to evaluate the abundance and 
diversity of the cervicovaginal microbiota in omen ith PCR-defined FGS . Future work 
should evaluate the abundance and diversity of the cervicovaginal microbiota in a prospective 
cohort both before and after treatment with praziquantel. Additionally, to further evaluate the 
association of cervicovaginal microbiota with HIV-1 acquisition risk in participants with 
FGS, future work could evaluate the association of concentrations of cervicovaginal 
microbiota known to be associated with HIV-1 (Parvimonas species types 1 and 2, G. 
asaccharolytica, M. hominis, Leptotrichia/Sneathia, Eggerthella species type 1, and 
Megasphaera) ith PCR-defined FGS  [101].  
 
This PhD describes an association between high burden FGS and the presence of T. 
vaginalis. In addition to aiming to achieve a larger sample size and additional geographically 
diverse study populations, the next step in evaluating the association between FGS and T. 
vaginalis is to evaluate incident T. vaginalis infection in women by differing schistosomiasis 
definitions ( urogenital schistosomiasis , isual FGS  and PCR-defined FGS ). Additional 





to define pathogenic mechanisms. Both parasites are known to polarize the macrophage 
response toward alternative activation [126, 128], which may contribute to T. vaginalis 
persistence. Thus, further research regarding macrophage phenotypes in FGS is indicated. 
Participants in the sub-studies presented in this PhD thesis were not evaluated for HSV-2 and 
HPV. A Th2-biased cervicovaginal environment is hypothesized to compromise effective 
Th1 responses, necessary to control intracellular HPV. Additionally, considering the 
association between S. haematobium and squamous cell carcinoma of the bladder [172], 
further evaluation between the prevalence and persistence of high and low risk HPV in 
women with FGS and their cervicovaginal clinical endpoints is also indicated. 
 
The mucosal immune environment contributes substantially to HIV-1 acquisition risk [173]. 
The immunologic impact of FGS on the female reproductive tract requires additional 
clarification. In women with PCR-defined FGS , further work is needed to study human 
cervicovaginal genes, proteins, and metabolites associated with FGS with the goal of 
improving FGS prevention, diagnosis, and treatment. Future work needs to focus on 
establishing links between FGS-related genes, proteins, and metabolites and vaginal 
immunity and HIV-1 vulnerability. This could be addressed using multi omic methods 
(transcriptomics, proteomics, metabolomics) in women with PCR-defined FGS  both before 
and after treatment with praziquantel. Additionally, flow cytometry has not yet been used to 
characterize the cellular populations present in women with PCR-defined FGS , especially 
those cellular populations that are HIV-1 susceptible such as CCR5+ CD4 T-cells and Th17 
cells, both before and after treatment with praziquantel [64]. 
 
This literature review in Chapter 1 illustrates the challenges inherent in performing cross-
study comparisons in urogenital schistosomiasis and female genital schistosomiasis research. 
When evaluating schistosomiasis research, multiple components need to be considered 
including schistosome species, assessment of genital involvement, diagnostics used, 
reference standard, and analytic strategies (e.g. subgroup analyses by participant sex or 
intensity). Heterogeneity within these components makes study interpretation and 
contextualization complex. As evidenced by this PhD thesis, the research community could 
benefit from consensus definitions that could be applied in research to aid in cross-study 
comparisons and diagnostic evaluations. Similar classification systems for research purposes 
are currently in use for challenging to diagnose invasive fungal infections, where a biopsy-





literature is cross-sectional, reporting small numbers of affected women, occasionally 
requiring composite endpoints to assess study outcomes. Further FGS research could be 
strengthened by evaluating a longitudinal cohort of women, followed over time in 
communities with varying S. haematobium prevalence. Additionall , fe  tissue FGS  and 
isual FGS  data ha e been associated ith HIV-1, cervicovaginal microbiota, and STI 
outcomes. These research gaps highlight the opportunity for larger future longitudinal 
studies.  
 
The WHO definition for FGS includes both the presence of parasite eggs in genital tissue as 
ell as a characteristic clinical patholog  [24]. However, these findings may represent 
different ends of a spectrum of Schistosoma infection chronicity. Broadly, this spectrum 
ranges from acti e infection ith genital DNA detection to isual FGS  ith non-viable S. 
haematobium eggs. This PhD thesis employs PCR for Schistosoma DNA as a surrogate 
marker for DNA-containing parasite eggs in genital tissue, however this  PCR-based 
approach misses DNA negati e isual FGS . While the full temporality of viable, egg-
producing blood schistosome infection with the de elopment of isual FGS  manifestations 
has not yet been described in humans, theoretically, Schistosoma egg deposition in genital 
tissue leads to the development of isual FGS . However, the relevance of Schistosoma 
DNA positive versus DNA negative isual FGS  is unknown. Thus, further work could 
address the DNA status of S. haematobium cervicovaginal manifestations and the risk of 
HIV-1 acquisition. 
 
8.7 Implications for policy 
 
This PhD thesis describes a population of women with urogenital schistosomiasis  and 
PCR-defined FGS . Regardless of whether an association is present between FGS and HIV-
1, schistosomiasis and FGS are preventable. Schistosomiasis causes urogenital and intestinal 
morbidity in all ages [6], with negative cognitive and growth implications for infected 
children [175, 176]. Preventive chemotherapy for schistosomiasis is currently recommended 
based on the subject s age and the communit  schistosomiasis pre alence [37, 158]. 
Traditionally school age children (age 6-15) and adults from special at-risk groups in 
moderate-high prevalence areas are targeted for mass drug administration [37, 158], but 
current control programmes frequently do not meet the target of 75% preventive 






Additionally, this PhD thesis illustrates that women aged 18-31, particularly in the sub-group 
with high intensity infection, experience changes in the cervicovaginal immune environment 
related to FGS. While this PhD thesis does not provide substantial evidence to change policy, 
it contributes to the descriptive lexicon regarding the findings and effects of FGS in 
populations not universally eligible for mass-drug administration [179].  
 
Foundational to this PhD thesis, the BILHIV study illustrates how FGS diagnosis and 
treatment can be integrated into pre-e isting omen s health platforms in sub-Saharan 
Africa, such as cervical cancer screening, to leverage limited human and financial resources 
[12, 180]. The 2025 joint United Nations Programme on HIV/AIDS (UNAIDS) targets call 
for between section integration and synergy to advance the HIV-1 response, and the BILHIV 
study is an example of such integration and synergy [181]. Additionally, the BILHIV 
community workers were enthusiastic teachers, depicting the how the empowerment of 




To achie e the United Nations Sustainable De elopment Goal of good health and ell-
being  man  countries ha e focused initiatives around sexual and reproductive health. In 
achieving this goal, the data presented in this PhD thesis provide a framework from which to 
approach and leverage funding for future female genital schistosomiasis research. While this 
thesis represents a modicum of progress, it simultaneously identifies profound deficiencies in 
the FGS care cascade. Substantial engagement in furthering the FGS research platform is 
especially needed with regards to FGS epidemiology, treatment, diagnostics, and prevention.  
 
To allow the design and roll-out of effective diagnostic, prevention, and treatment strategies, 
we need an improved understanding of FGS epidemiology and pathophysiology. Of the 
utmost importance is resolving the persistent question of whether FGS is associated with 
HIV-1 acquisition. A definitive answer is urgently needed and will require an adequately 
powered, longitudinal study in areas of high S. haematobium and HIV-1 endemicity. In 
addition to providing data on the association between FGS and incident HIV-1, longitudinal 
data will fill critical knowledge gaps regarding FGS epidemiology and the effect of 






The ASSURED criteria declare that diagnostics for infectious tropical diseases should be 
affordable, sensitive, specific, user-friendly, rapid, equipment free, and delivered at all levels 
of the healthcare system [182]. Current FGS diagnostics fall profoundly short of the 
ASSURED criteria. Thus, substantial effort must be invested in the further development 
point-of-care ASSURED molecular assays, such as the recombinase polymerase assay (RPA) 
which has been piloted in urogenital schistosomiasis [183]. The RPA must be further 
evaluated in FGS, ideally in combination with genital self-sampling [25]. Combining RPA 
and genital self-sampling for community FGS diagnosis should be investigated in areas of 
varying S. haematobium endemicity with the aim to map, define, and evaluate FGS 
prevalence and burden. Additionally, with ASSURED diagnostics, FGS diagnosis and 
management could be seamlessly integrated into pre-existing comprehensive sexual and 
reproductive health services for cervical cancer, STIs, and HIV-1 [184]. An additional 
challenge in the field is the absence of a reference standard for FGS research initiatives. 
Future work must thoughtfully and sensitively address bias around the use of cervicovaginal 
biopsy in FGS [185] and strive to unite the FGS community around meaningful, 
reproducible, and consistent diagnostic research endpoints.  
 
In addition to sensitive point-of-care FGS diagnostics, women in S. haematobium endemic 
areas require improved access to curative FGS treatment. Currently, praziquantel is 
recommended for FGS treatment. Though studies vary by use of biopsy, lesion type, duration 
of follow-up, and praziquantel dose, a proportion of FGS lesions (ranging from 29  100%) 
are not reversible after a single praziquantel treatment [14, 164]. This highlights both the 
urgent need for improved FGS treatment modalities and effective prevention strategies in 
girls and young women prior to the development of clinical FGS manifestations.  
 
This PhD thesis is the first research to describe the immunologic environment and the 
presence and concentrations of key cervicovaginal key species and STIs among women with 
PCR-defined FGS  (Figure 8.5). The cervicovaginal environment is an important 
determinant of sexual and reproductive health and influences the risk of HIV-1 acquisition 
[91, 118, 186]. HIV-1 incidence was evaluated in the context of a cross-sectional study of 
young, sexually active Zambian women ith PCR-defined FGS . The findings in this PhD 





concentrations or number of positive clinical specimens, is an important variable to consider 
in FGS research.  
 
Figure 8.5  Evidence from this PhD thesis regarding PCR-defined FGS  and the 





Abbreviations: FGS  female genital schistosomiasis, HIV-1  human immunodeficiency 
virus, PCR  polymerase chain reaction, SG  sub-group, STI  sexually transmitted 
infection, Th2  T helper 2 
 
Women with moderate to high concentrations of Schistosoma DNA and higher clinical 
burden PCR-defined FGS  have higher concentrations of pro-inflammatory/Th2 and Th2 
cytokines, respectively, present in their cervicovaginal lavage compared to negative FGS 
women. Work presented in this PhD thesis also describes that women in these sub-groups, 
whether assessed by clinical burden or DNA concentration, were more likely to have 
cervicovaginal T. vaginalis present than negative FGS participants. While there was no 
evidence of a difference in the rates of HIV-1 acquisition between women with and without 
PCR-defined FGS , there may be a dose-response relationship between higher burden 
genital Schistosoma DNA concentrations or multiple positive specimens and HIV-1 
seroconversion. 
 
This thesis evaluates the cervicovaginal environment in Zambian women with and without 
FGS and evaluates the association of FGS with HIV-1 incidence. Further work investigating 
the cervicovaginal environment and HIV-1 risk in FGS will be needed to impact diagnostic, 
preventative, and therapeutic options for women with FGS. Additionally, prospective studies 
of the cer ico aginal microbiome, multi omics, and flo  c tometr  in omen focusing on 
epithelial disruption and target cell recruitment in women with FGS will help define and 
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Given the potentially causal association of female genital schistosomiasis (FGS) with HIV-1
infection, improved diagnostics are urgently needed to scale-up FGS surveillance. The BIL-
HIV (bilharzia and HIV) study assessed the performance of home-based self-collection
methods (cervical and vaginal swabs) compared to cervicovaginal lavage (CVL) for the
detection of Schistosoma DNA by real-time polymerase chain reaction (PCR).
Methods
Between January and August 2018, a consecutive series of female participants from the
Population-Cohort of the previous HIV prevention trial HPTN 071 (PopART), resident in Liv-
ingstone, Zambia were invited to take part in BILHIV if they were 18–31 years old, non-preg-
nant and sexually active. Genital self-collected swabs and a urine specimen were obtained
and a questionnaire completed at home visits. CVL was obtained at clinic follow-up.
Results
603 women self-collected genital swabs. Of these, 527 women had CVL performed by a
mid-wife during clinic follow-up. Schistosoma DNA was more frequently detected in genital
self-collected specimens (24/603, 4.0%) compared to CVL (14/527, 2.7%). Overall, 5.0%
(30/603) women had female genital schistosomiasis, defined as a positive PCR by any geni-
tal sampling method (cervical swab PCR, vaginal swab PCR, or CVL PCR) and 95% (573/
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603) did not have a positive genital PCR. The sensitivity of any positive genital self-collected
swab against CVL was 57.1% (95% CI 28.9–82.3%), specificity 97.3% (95.5–98.5%). In a
subset of participants with active schistosome infection, determined by detectable urine Cir-
culating Anodic Antigen (CAA) (15.1%, 91/601), positive PCR (4.3%, 26/601), or positive
microscopy (5.5%, 33/603), the sensitivity of any positive self-collected specimen against
CVL was 88.9% (51.8–99.7%).
Conclusions
Genital self-sampling increased the overall number of PCR-based FGS diagnoses in a field
setting, compared with CVL. Home-based sampling may represent a scalable alternative
method for FGS community-based diagnosis in endemic resource limited settings.
Author summary
Female Genital schistosomiasis (FGS) is a neglected and disabling disease that results
when eggs from the waterborne parasite Schistosoma haematobium are trapped in the
human reproductive tract. Current female genital schistosomiasis (FGS) diagnostic strate-
gies are limited because they require expertise and equipment that may not be readily
available in low income settings. Improved and accessible diagnostics are urgently needed
to scale-up FGS surveillance. This is especially important as FGS has been associated with
HIV-1 infection. The BILHIV (bilharzia and HIV) study assessed the performance of
home-based self-collection methods (cervical and vaginal swabs) compared with a clinic-
based cervicovaginal lavage (CVL) performed by a medical professional. Both methods
used real-time polymerase chain reaction (PCR) to detect Schistosoma DNA. We found
that, in a field setting, self-collected genital and cervical swabs increased the overall num-
ber of PCR-based FGS diagnoses, compared with clinically collected CVL. We report the
sensitivity of self-collected swabs for the diagnosis of FGS, compared with CVL. We found
that the sensitivity of self-collected genital swabs was high in a subset of women with
active schistosome infection. We suggest that home-based self-sampling may represent a
scalable community-based sampling platform for FGS community-based diagnosis in
endemic resource limited settings.
Introduction
An estimated 82 million women in sub-Saharan Africa live with Schistosoma (S.) haematobium
or S. mansoni infections [1] that follow fresh water contact. In Zambia alone, it is estimated
that 3.8 million people (approximately 22% of the population) are infected with Schistosoma
species [2]. After maturation, these trematode parasites commence egg-laying in the host’s
venous system and disease occurs when tissue-entrapped eggs cause both local and systemic
pathology [3]. Female genital schistosomiasis (FGS), defined as the detection of eggs or Schisto-
soma spp. DNA in genital tissue or fluids [4], affects an estimated 20–56 million women world-
wide [5], mostly in sub-Saharan Africa, including Zambia [6]. The presence of eggs or
Schistosoma spp. DNA in urine and stool does not confirm concurrent genital involvement [7,
8].
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Egg deposition in FGS occurs in clusters [9], often at the squamocolumnar junction in the
subepithelial connective tissue [9] and is therefore frequently missed on superficial Papanico-
laou-smear based sampling [8–10]. Often tissue-lodged eggs are accompanied by characteristic
sandy patches (both grainy and homogenous) [11] and rubbery papules [12]. However, in up
to one-quarter of cases, FGS occurs in macroscopically normal appearing cervical tissue [9,
13]. Classically, FGS lesions are visualized colposcopically [8, 12], requiring equipment and
trained clinical expertise that may not be available in low income settings [4]. Also, concern
that tissue biopsy, the proposed reference standard, may provide a means of entry for HIV-1
infection [4] has limited its use in FGS research. Given this theoretical risk, the use of polymer-
ase chain reaction (PCR) on cervicovaginal lavage (CVL) has been advocated as an acceptable
and less-invasive method of FGS diagnosis in research settings [8, 12, 14, 15]. However,
because CVL sampling requires a trained health professional, vaginal speculum insertion, and
an intact cold chain, it is not likely scalable for population–based FGS surveillance.
FGS has been associated with adverse reproductive health outcomes, such as infertility [16],
ectopic pregnancy [17, 18], and abortion [17]. Eggs deposited in reproductive tissues release
immunogenic antigens [19], resulting in granulomatous reaction and fibrosis [18]. There is
also increasing evidence on the association of FGS with prevalent HIV-1 infection [10, 20], a
relationship that may be causal. Accurate, accessible, and affordable diagnostics are urgently
needed to scale-up FGS surveillance and treatment. Schistosome infection is associated with a
continuum of disease co-morbidities and post-infection complications [21]. FGS can occur
along this continuum and there is currently not a diagnostic test that captures the entire range
of FGS clinical presentations [21].
Self-sampling has been used for diagnosis of reproductive tract infections, including
human papillomavirus (HPV) [22]. Compared with clinician collected specimens, self-col-
lected PCR-based HPV testing is acceptable to participants [23], increases screening coverage
[22, 24], and is as sensitive as clinician collected samples [25]. A home-based diagnostic option
for FGS with decreased reliance on medical professionals would have high field applicability.
This study was designed to compare the performance of two home-based self-collection meth-
ods (cervical and vaginal swabs), to clinic-based, midwife-collected CVL for the detection of
Schistosoma DNA by Nucleic Acid Amplification Tests (NAATs).
Methods
Study site and subjects
Between January and August 2018, participants from the Population Cohort (PC) of HPTN
071 (PopART), a trial to measure the impact of an HIV combination prevention package,
including universal HIV test and treat [26], were recruited to participate in the cross-sectional
bilharzia and HIV (BILHIV) study. Women were eligible to participate if they were 18–31
years old, non-pregnant, sexually active, and resident in one of the two communities (desig-
nated Community-A and Community-B) that participated in HPTN 071 (PopART) in Living-
stone, Zambia. Central Livingstone is located within 5–10 kilometres of the Zambezi River,
with a tributary flowing in close proximity to Community A. HPTN 071 (PopART) is a cluster
randomized trial including 21 participating communities. At the community level, the Popula-
tion Cohort included one randomly selected adult 18 to 44 years of age from a random sample
of households in each community [26]. BILHIV study participants were then selected as a con-
secutive sample from the HPTN 071 (PopART) Population Cohort. A 2013 survey of school
aged children in Livingstone reported prevalence ranges for urinary S. haematobium infection
between 3.3% and 73.3% (median 15.0%, mean 23.3%) [27].
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Home-based sample collection and questionnaire
Trained community workers provided home visits to women who gave an “expression of
interest” in the BILHIV study at the HPTN 071 (PopART) PC 36-month visit. The home visit
included assessment of eligibility, a questionnaire, genital self-sampling (cervical and vaginal),
and a single urine specimen. Trained field workers provided study information in the partici-
pant’s preferred language. Following written informed consent, a questionnaire containing
questions regarding demographics, water contact, sexual behaviour, and genital symptoms
was administered. There were no restrictions on the timing of urine sample self-collection,
and 69.5% (419/603) were performed between 9:00 and 14:00. The community worker pro-
vided participating women with instructions for urine collection and cervical and vaginal self-
sampling. Participants were instructed to hold a 6-inch PrimeSwab (Longhorn Diagnostics,
Texas, USA) at the 2 3/8-inch score mark, insert the swab vaginally until their fingers touched
the labia minora, and rotate the swab against the vaginal walls (minimum 15 repetitions) (Fig
1). Similarly, for the cervical swab, participants were instructed to hold a 6 3/4-inch flocked
swab (Miraclean, Shenzen, China) with a quadrilateral kite-shaped tip at the non-flocked end,
insert the swab until their fingers touched the labia minora and/or encountered resistance, and
rotate the swab against the place of resistance (minimum 15 repetitions). Each flocked swab
head was placed in individual screw cap microtubes (STARLAB, Hamburg, Germany) by the
participant after the swab shaft was broken. Both swab specimens and urine were placed in
cool boxes for transportation to the laboratory for further processing (see Supplementary
Material). Women with evidence of active schistosome infection, defined by any positive urine
examination (microscopy, Circulating Anodic Antigen (CAA) or PCR), or women with clini-
cal evidence of FGS as determined by the midwife’s clinical examination [28], were treated free
of charge with 40 mg/kg praziquantel, either at the clinic visit, or via community workers.
Fig 1. Genital Self-sampling in the BILHIV Study. A) Participants held a 6-inch vaginal swab at the 2 3/8-inch score
mark, inserted the swab vaginally until their fingers touched the labia minora, and rotated the swab against the vaginal
walls (minimum 15 repetitions). B) Participants held the 6 3/4-inch cervical swab at the non-flocked end, inserted the
swab until their fingers touched the labia minora and/or encountered resistance, and rotated the swab against the place
of resistance (minimum 15 repetitions).
https://doi.org/10.1371/journal.pntd.0008337.g001
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Clinic-based sample collection
Enrolled women who were not currently menstruating were invited to attend Livingstone
Central Hospital cervical cancer screening clinic within days of self-sampling, where one of
two trained midwives performed a cervicovaginal lavage (CVL). After speculum insertion,
normal saline (10mL) was flushed continuously with a bulb syringe across the cervix and vagi-
nal walls for one minute and collected from the posterior fornices. Images of the vagina and
cervix were captured with a point-of-care colposcope (MobileODT, Tel Aviv, Israel). Partici-
pants with suspected reproductive tract infections were offered syndromic management, as
per the Ministry of Health [29]. Routine testing for reproductive tract infections was not per-
formed in this study.
Laboratory analysis
Urine aliquoting for quantification of CAA, PCR, and urinalysis were performed on the day of
specimen arrival at the laboratory (see S1 Text). The remaining urine, up to 60mL per partici-
pant, was centrifuged in 15mL aliquots and examined by microscopy within 24 hours. The pel-
let from each 15mL urine aliquot (5 maximum) was evaluated for S. haematobium eggs. When
a pellet contained at least one terminal-spined ovum, the participant was considered positive
and the total number of counted eggs in the pellet was reported. Review of all positive and 10%
of the negative specimens was conducted blinded by an expert for quality control. Dipsticks
were used for analysis of hematuria and proteinuria (Multistix, Siemens, Germany). An up-
converting reporter particle (UCP) lateral flow (LF) assay for the quantification of CAA in
urine (0.4 mL) was performed at the Leiden University Medical Center (LUMC) (see S1 Text)
[30]. Urine CAA antigen levels are known to reflect adult worm burden and decline after suc-
cessful treatment with praziquantel [31, 32].
PCR for Schistosoma spp
Pre-treatment and DNA isolation of CVL, genital swabs, and urine samples were performed
(see S1 Text) in different sites at the LUMC, hence minor differences in the laboratory proce-
dures. Briefly, genital swabs were suspended in PBS and vortexed, and thereafter handled as
lavages, by pre-treating using a proteinase K heating step and isolating DNA using QIAamp
spin columns (QIAGEN Benelux, Venlo, The Netherlands) [8, 12, 33]. Two hundred !L of
urine sample per participant were pretreated using Precellys Soil grinding SK38 (Bertin tech-
nology, Montigny-le-Bretonneux, France) and DNA was isolated using MagNA Pure 96 tech-
nology (Roche Diagnostics, Penzberg, Germany). Internal transcribed spacer 2-based real-
time PCR was performed as previously described [33], with slight modifications (see S1 Text).
DNA amplification and detection were performed with the CFX96 Real Time PCR Detection
System (BioRad, California, USA). The output in threshold cycles (Ct) was analysed using
BioRad CFX software. Negative and positive control samples were included in each amplifica-
tion run. Parasite DNA load is categorized by the following pre-specified Ct threshold for all
specimens processed by PCR (urine, cervical swab, vaginal swab, and CVL): any Ct-value
observed means positive and no Ct-value observed means negative (S1 Text) [34]. All speci-
mens tested by PCR at LUMC were blinded for clinical and microscopy data.
Ethical considerations
The study was approved by the University of Zambia Biomedical Research Ethics Committee
(reference 011-08-17), the Zambia National Health Research Authority and the London School
of Hygiene and Tropical Medicine Ethics Committee (reference 14506). Permission to
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conduct the study was given by Livingstone District health office and the superintendent of
Livingstone Central Hospital. All the human subjects in this study were adults.
Statistical methods
We anticipated that the prevalence of S. haematobium infection would be 30% and that PCR
performed on self-collected specimens would have sensitivity of 70% and specificity of 85%.
Under these assumptions a sample size of 600 women would allow us to detect these target val-
ues with 95% confidence intervals of 63%-77% and 81%-88%, respectively.
Data were entered on hand-held electronic data capture devices using Open Data Kit and
analysed using STATA 15.1 (Stata Corporation, College Station, TX). Continuous variables
were summarized by median and interquartile range (IQR), and categorical variables by fre-
quency and percentage. Differences in participant characteristics between the two communi-
ties were evaluated using Fisher’s exact, chi-squared, and Wilcoxon-Mann-Whitney tests. The
association between age group and positive test result was assessed using the test for trend. For
the comparison of home-based self-collection methods with clinic based CVL, we calculated
sensitivity and specificity. There weren’t indeterminate PCR results or missing data for genital
self-collected swabs (the index test). “Definite” FGS was defined as any positive genital PCR
(cervical swab, vaginal swab or CVL). The presence of either CAA or S. haematobium eggs in
clinical specimens indicates the presence of infection with viable worms [30]. Thus, in this
study, “active” schistosome infection refers to participants with a positive urine PCR, CAA, or
microscopy. To evaluate if sequential use of FGS diagnostics might be beneficial, an ad-hoc
secondary analysis was performed in which calculation of the diagnostic performance was
restricted to those with an active schistosome infection according to positive urine PCR, CAA,
or microscopy. CVL was chosen as the a priori reference standard for the BILHIV study. In the
absence of a universally recognized reference standard for FGS, a composite FGS outcome was
constructed, defined as a positive result on any genital PCR specimen (swab or CVL).
Results
Overall, 1105 women in the study communities from the HPTN 071 (PopART) Population
Cohort met the inclusion criteria. A total of 603 (54.5%) eligible women were enrolled with
527 (87.0%) completing clinic follow up (Fig 2). Women from both communities reported reg-
ular water contact in childhood (p = 0.22) (Table 1). Overall, an active schistosome infection
was diagnosed in 15.6% (94/601) (Table 2), of which 33 were urine microscopy positive and an
additional 61 cases were diagnosed by urine CAA. Urine PCR confirmed the presence of schis-
tosome infection in 26 participants and did not detect any additional cases. Overall, 15.6% (94/
601) had schistosome infection (Table 2). The prevalence of S. haematobium infection was
5.5% (33/603) based on urine microscopy, 15.1% (91/601) by urine CAA, and 4.3% (26/601)
by urine PCR (Table 2).
There were 30 women (5.0%) with definite FGS, defined as any positive genital PCR (cervi-
cal swab, vaginal swab or CVL), 22/291 (7.6%) in Community-A and 8/238 (3.4%) in Commu-
nity-B (p = 0.04) and 95% (573/603) did not have definite FGS. The proportion of participants
testing positive decreased with increasing age for all tests except urine CAA and CVL PCR
(urine microscopy p-trend = 0.004, urine PCR p-trend = 0.003, any PCR-positive genital speci-
men p-trend<0.001, cervical swab PCR p-trend<0.001, vaginal swab PCR p-trend<0.001)
(Fig 3 & S1 Table). In the 30 women with FGS, the prevalence of active schistosome infection
was 70.0% (21/30). Of the 94 women with an active schistosome infection, 22.3% (21/94) had
FGS and of the 507 women without active schistosome infection 1.8% (9/507) had FGS
(p<0.001), these numbers include women who did not attend clinic follow-up. Fig 4 illustrates
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FGS diagnosis based on PCR positivity for each of the three genital sampling methods. No
adverse events were reported in either group related to use of the index or reference test.
The sensitivity of a positive result from any positive self-collected specimen (cervical or vag-
inal swab) against CVL was 57.1% (28.9–82.3) with specificity of 97.3% (95.5–98.5%)
(Table 3). Compared with CVL, the sensitivity of self-collected cervical swabs (42.9% [17.7–
71.1%]) was somewhat higher than for vaginal swabs (35.7% [12.8–64.9]), albeit with wide
confidence intervals. The specificity of PCR in self-collected specimens versus CVL was high
regardless of sampling technique (cervical 97.7% [95.9–98.8%], vaginal 98.2% [96.7–99.2%])
(Table 3). Self-collected genital swabs were also evaluated as the reference standard (Table 3).
Of these comparisons, the highest sensitivity (80% [61.4–92.3] was achieved using combined
swab results compared with the composite FGS diagnosis (Table 3).
In a secondary analysis of those participants diagnosed with an active schistosome infec-
tion, the sensitivity of PCR from any positive self-collected swab specimen (cervical or vaginal)
against CVL was marginally higher than in the primary analysis, albeit with wide confidence
intervals (Table 4). The gain in sensitivity when evaluating those participants diagnosed with
an active schistosome infection was accompanied by a decline in specificity (Table 4).
Discussion
The BILHIV study is the first to examine the performance of self-collected genital swabs (vaginal
and cervical) for the diagnosis of FGS. Self-collected swabs were compared with provider-
Fig 2. BILHIV study flow diagram. Not visited - the participant was not visited before the study closed for enrollment
(189) Visited but not contacted - a visit was made to the study household, but the participant could not be located (70), had
relocated (39), or died (1) Contacted & not immediately enrolled - (42), out of town (18), declined to participate (60)
Contacted & ineligible - virgin (16), pregnant (17), over 31 (8)
https://doi.org/10.1371/journal.pntd.0008337.g002
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collected CVL, an accepted, non-invasive standard for FGS diagnosis in research settings [12, 14].
The addition of self-collected swabs to CVL increased the number of FGS diagnoses. The sensitiv-
ity of any self-collected genital specimen compared with CVL improved when only those diag-
nosed with an active infection (i.e. positive urine CAA, urine PCR, or urine microscopy) were
considered. Using a composite definition of FGS (any PCR positive genital specimen) as the refer-
ence standard also improved the sensitivity of self-collected genital specimens. In the absence of a
reference standard for FGS [21], the specificity of genital swabs is limited by comparison with
CVL alone. CVL for FGS diagnosis has imperfect sensitivity and may not identify all true posi-
tives. In this analysis, the sensitivity of CVL as the index test compared to self-sampling as the ref-
erence was similar to that of self-sampling as the index test with CVL as reference standard.
A sub-analysis of the BILHIV data also suggests that sensitivity of PCR-based testing of geni-
tal self-samples is high in the subgroup of participants with active infection. The cost of genital
swabs (0.50$/vaginal swab and 0.30$/cervical swab) and molecular testing (6.68$/test) may be
Table 1. Baseline characteristics of 603 Zambian women living in S. haematobium endemic areas near the Zambezi river by district.
Characteristics Overall (n = 603) Community A (n = 319) Community B (n = 284) p-value⇤
Age in years–Median (IQR) 24 (22–28) 26 (23–29) 24 (21–27) <0.001
Marital Status Single 258 (42.8%) 110 (34.5%) 148 (52.1%) <0.001
Married or Cohabitating 320 (53.1%) 193 (60.5%) 127 (44.7%)
Divorced or Separated 23 (3.8%) 15 (4.7%) 8 (2.8%)
Widowed 2 (0.3%) 1 (0.3%) 1 (0.4%)
Education (highest level) Any Primary School 167 (27.7%) 117 (36.7%) 50 (17.6%) <0.001
Any Secondary School 364 (60.4%) 173 (54.2%) 191 (67.3%)
Training in a Trade 59 (9.8%) 20 (6.3%) 39 (13.7%)
Degree or Higher 3 (0.5%) 3 (0.9%) 0 (0.0%)
None 10 (1.7%) 6 (1.9%) 4 (1.4%)
Employment Status Working 408 (67.7%) 200 (62.7%) 208 (73.2%) 0.006
Not Working 195 (32.3%) 119 (37.3%) 76 (26.8%)
Current Water Contact None 512 (84.9%) 263 (82.5%) 249 (87.7%) 0.02
At Least Weekly 18 (3.0%) 11 (3.5%) 7 (2.5%)
Every 1–2 Months 30 (5.0%) 24 (7.5%) 6 (2.1%)
Every 6–12 Months 43 (7.1%) 21 (6.6%) 22 (7.8%)
Childhood Water Contact None 186 (30.9%) 96 (30.1%) 90 (31.7%) 0.22
At Least Weekly 381 (63.2%) 208 (65.2%) 173 (60.9%)
Every 1–2 Months 24 (4.0%) 12 (3.8%) 12 (4.2%)
Every 6–12 Months 12 (2.0%) 3 (0.9%) 9 (3.2%)
Self-reported History of Schistosomiasis No 572 (94.8%) 294 (92.2%) 278 (97.9%) 0.006
Yes 25 (4.2%) 20 (6.3%) 5 (1.8%)
Maybe 6 (1.0%) 5 (1.6%) 1 (0.4%)
Self- reported Treatment with Praziquantel No 523 (86.7%) 270 (84.6%) 253 (89.1%) 0.11
Yes 61 (10.1%) 40 (12.5%) 21 (7.4%)
Maybe 19 (3.2%) 9 (2.8%) 10 (3.5%)
⇤ comparison of Community-A vs Community-B
https://doi.org/10.1371/journal.pntd.0008337.t001
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affordable in some research settings, but more field-appropriate and scalable NAAT methods
should be investigated. Given the cost of FGS diagnostics, an algorithm which advocates FGS
screening in resource-limited settings among women with positive CAA or urine microscopy
could assist in conserving resources, labour, reagents, and other costs. Applying this algorithm
to the BILHIV study identifies 70.0% of FGS cases identified in a relatively low-prevalence area.
However, an important limitation of restricting genital self-sampling to a sub-group with active
infection is a decreased ability to detect FGS cases in the population, as FGS would not be iden-
tified in women without active infection. This decrement in the overall sensitivity of screening
must be balanced against the availability of resources. Other practical limitations to this strategy
include low prevalence populations, the imperfect sensitivity of Schistosoma PCR in genital self-
sampling, and the current availability of PCR and CAA as research tools that do not yet allow
individual rapid diagnosis at the point-of-care [35]. To maximally leverage resources, FGS self-
sampling would be integrated into other reproductive health platforms, ideally those that also
utilize self-sampling in the diagnosis of reproductive tract infections, such as HPV [22, 25].
Table 2. Diagnostic test results and FGS prevalence in 603 Zambian women living in S. haematobium endemic areas near the Zambezi river.
Characteristics Overall (n = 603)
% (n)
Community-A (n = 319)
% (n)
Community-B (n = 284)
% (n)
p-value
Hematuria 28.7 (173) 31.0 (99) 26.1 (74) 0.2
Urine Microscopy 5.5 (33/603) 8.2 (26/319) 2.5 (7/284) 0.002
Median egg count per 15mL‡ 18 17.5 18
IQR 5–35 5–35 8–90
Urine CAA⇤ 15.1 (91/601) 20.5 (65/317) 9.2 (26/284) <0.001
Median pg/mL‡ 9.10 11.46 5.93
IQR 2.2–58.6 2.3–42.1 2.2–112.0
Urine PCR⇤ 4.3 (26/601) 6.3 (20/317) 2.1 (6/284) 0.012
Median Ct‡ 29.6 30.2 29.3
IQR 27.8–33.5 26.4–34.9 29.0–32.7
Active schistosome Infection⇤
[any urine test positive]
15.6 (94/601) 21.1 (67/317) 9.5 (27/284) <0.001
PCR–CVL† 2.7 (14/527) 3.8 (11/290) 1.3 (3/237) 0.06⇤⇤
Median Ct‡ 34.6 35.3 33.2
IQR 33.0–37.0 33.0–37.0 21.0–38.0
PCR–Cervical Swab 3.3 (20/603) 4.4 (14/319) 2.1 (6/284) 0.12
Median Ct‡ 35.3 35.8 33.3
IQR 29.6–37.1 29.4–37.2 29.7–36.3
PCR–Vaginal Swab 2.5 (15/603) 2.5 (8/319) 2.5 (7/284) 0.97
Median Ct‡ 34.3 35.4 32.2
IQR 23.6–37.1 30.6–37.2 23.2–35.2
Any PCR Positive Sample†† 5.7 (30/529) 7.6 (22/291) 3.4 (8/238) 0.02
PCR positive–Vaginal or Cervical Swab 4.0 (24/603) 5.3 (17/319) 2.5 (7/284) 0.07
⇤2 urine vials arrived at LUMC empty (n = 601)
⇤⇤ Calculated by Fisher’s exact (otherwise by chi-squared)
† 527 women presented for CVL– 290 Community-A and 237 Community-B
‡ Median egg count, CAA concentrations and PCR Ct-value restricted to positive tests
††One participant from each of Site-1 and Site-2 had positive self-collected PCR specimens but did not present to clinic (n = 529)
Abbreviations: CAA—Circulating Anodic Antigen, CVL–Cervicovaginal Lavage, PCR–Polymerase Chain Reaction for the detection of Schistosoma DNA
https://doi.org/10.1371/journal.pntd.0008337.t002
PLOS NEGLECTED TROPICAL DISEASES Genital self-sampling for FGS diagnosis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008337 July 14, 2020 9 / 18
Fig 3. Distribution of positive diagnostic test results by age group. A. Distribution of positive urine CAA, urine
microscopy, and urine PCR results by age group
⇤
B. Distribution of positive genital PCR results by age group
⇤
C.
Distribution of any positive genital PCR result by age group⇤ ⇤Please see S1 Table for further details of the numbers
of women tested per time point
https://doi.org/10.1371/journal.pntd.0008337.g003
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Scalable, affordable, and field-acceptable diagnostics are necessary to improve our understand-
ing of the current population prevalence of FGS and to limit the negative health impact of HIV-1,
infertility, and gynaecologic symptoms. After repeated fresh-water exposures, girls living in
endemic areas may develop the genital changes associated with FGS prior to sexual debut or the
onset of menstruation [36]. A single dose treatment of praziquantel will decrease egg production.
but will only kill a proportion of living schistosomes [3]. Data on the effect of praziquantel treat-
ment in FGS are limited, with small numbers and heterogeneous methods, but do suggest a pro-
portion of FGS lesions remain despite praziquantel treatment [37–39]. Thus, early identification of
FGS and subsequent praziquantel treatment prior to the age of 21 is associated with beneficial out-
comes, such as lower prevalence of contact bleeding, lower odds of sandy patches [40], and lower
rates of sub-fertility [41]. Prevention efforts cannot be underestimated, and young women should
be prioritized to obtain the maximum benefit from the roll-out of FGS diagnosis and treatment.
To date, no previous studies of FGS diagnostics have used CVL as a reference standard and
cross-study comparisons are limited due to heterogeneity of methods [8, 12, 14, 21]. Previously
published work has reported low sensitivity and high specificity of Schistosoma CVL PCR for
FGS diagnosis in African populations [8, 14, 21]. In adult Zimbabwean women (ages 15–49),
CVL PCR sensitivity was 53% and specificity 79% compared with cervical visualization and
histopathology [14]. The study had some limitations relating to loss of specimens due to cold
chain malfunctions, and extended specimen storage time (10 years), potentially affecting PCR
outcomes. In an adolescent South African population (age range 15–23), CVL PCR was com-
pared with urine microscopy, cervical visualization, and urogenital symptoms by latent class
analysis with a sensitivity of 52.4% (33.2–73.6) and specificity of 42.4% (37.9–47.0) [21].
Fig 4. Venn Diagram of 28⇤ Positive PCR-based Self-Collected Specimens (paired with CVL) for Schistosoma by
Collection Type ⇤2 participants with positive genital self-collected specimens did not follow up in clinic for
cervicovaginal lavage.
https://doi.org/10.1371/journal.pntd.0008337.g004
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Together, these studies further illustrate the limited performance of Schistosoma PCR in the
absence of a reliable FGS reference standard [15].
The performance of diagnostic tests for schistosome infection can vary by background par-
asite prevalence [42]. Important information regarding disease stage, intensity and morbidity
may be missed in the absence of appropriate diagnostics [31]. No one test captures all charac-
teristics of infection simultaneously and with perfect sensitivity. Conventional diagnostic tests
(reagent strips and urine microscopy) are insensitive, especially in low-prevalence areas, where
light intensity infections can be underestimated [42]. The overall prevalence of schistosome
infection in our study population was 5.5% by single urine microscopy, meeting the WHO
classification of a low-risk community [43]. Egg detection in urine microscopy may increase
slightly with serial urine collections [7, 44]. The prevalence of FGS, as diagnosed by a positive
PCR in any genital specimen, was 5.0% with site variations (2.8%-6.9%). Our study took place
in two communities within Livingstone. Community-A is closer to a water source and women
in Community-A had a higher overall prevalence of schistosome infection and FGS. The sensi-
tivity of microscopy, urine PCR, and CAA diminish in areas of low parasite prevalence [42], or
after treatment with praziquantel [44]. Sensitivity of CAA can be increased by using a larger
sample volume [45]. Our results confirm previous findings that urine CAA has higher sensitiv-
ity than microscopy in low-endemic settings [42] and further illustrates that schistosome infec-
tion is focal and prevalence can vary within neighbouring communities.
When comparing the performance of sampling techniques for parasite DNA retrieval, cer-
vical swabs detected 5 cases of FGS not detected by vaginal swabs and CVL. This was also true
Table 3. Sensitivity and specificity of genital specimens for the detection of Schistosoma DNA by PCR.
Reference Standard Index test Sensitivity (%) Specificity (%)
















































Abbreviations: CAA–Circulating Anodic Antigen, CS–Cervical Swab, CVL–Cervicovaginal Lavage, PCR–Polymerase Chain Reaction for the detection of Schistosoma
DNA, VS–Vaginal Swab
⇤Composite FGS Diagnosis–any positive PCR result on a genital specimen (CVL, vaginal swab or cervical swab)
https://doi.org/10.1371/journal.pntd.0008337.t003
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for vaginal swabs (2 FGS cases) and CVL (6 FGS cases) that were not detected in other sites
examined by PCR-based methods (Fig 4). In the absence of self-collecting cervical cytology, it
is not possible to confirm if the participants self-sampled from the cervix. However, the longer
swab and collection techniques likely allowed a high cervicovaginal specimen that contributed
to a greater number of PCR positive samples than vaginal swabs. Studies of FGS histopathol-
ogy report the most common location for egg deposition is the cervix [6], which may explain
the higher proportion of positive specimens in specimens detecting DNA from this site. Geni-
tal swabs are also field-appropriate, acceptable to participants, and scalable, while CVL
requires vaginal speculum insertion and is performed by trained health workers.
The BILHIV study was conducted in a low prevalence area, therefore the presented esti-
mates of sensitivity are subject to a high degree of imprecision due to the small numbers of
total FGS cases. There was excellent retention with 87.4% (527/603) of participants presenting
to the clinic for CVL, with very little missing data. The women self-collected vaginal and cervi-
cal specimens privately in their own homes. This raises the question of false negative genital
swabs, which could be addressed by measuring B-globin PCR as a positive control to confirm
the presence of human DNA [22]. BILHIV data confirm previous findings that Schistosoma
DNA can be detected in the genital tract in the absence of egg excretion [7, 8], and in partici-
pants with negative CAA. While these specimens may appear as false positives, the reported
specificity of PCR for detecting Schistosoma DNA is near 100% [14, 21]. S. haematobium eggs
Table 4. Sub-analysis of sensitivity and specificity of self-collected genital swabs compared with cervicovaginal lavage for the detection of Schistosoma DNA in par-
ticipants with positive urine specimens: CAA(n = 78), microscopy (n = 32), PCR (n = 26).
Reference test Index test Sensitivity (%) Specificity (%)
Urine CAA
Cervicovaginal lavage PCR
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can be detected in semen [46] and our study did not objectively evaluate for PSA or other
markers of recent sexual contact.
Overall, the relatively high concordance of DNA detection in genital self-collected speci-
mens and CVL suggest that self-collection methods for the diagnosis of FGS are feasible in
resource limited areas. Drawing on the experience of HPV, self-sampling has been shown to
be scalable and effective in real-world settings [47]. As the focus in schistosomiasis shifts from
morbidity control to elimination, data on the performance of diagnostic tests for infection and
morbidity in low-prevalence settings becomes increasingly applicable [48]. To achieve elimina-
tion of both infection and chronic disease such as FGS, low-prevalence areas require novel and
innovative interventions and diagnostic strategies to provide site-appropriate, accurate preva-
lence estimates [48].
Conclusion
Genital self-sampling increased the overall number of PCR-based FGS diagnoses in a field set-
ting, compared with cervicovaginal lavage. Schistosomiasis is focal and background parasite
prevalence may impact test sensitivity. Home-based self-sampling may represent a scalable
alternative method for FGS community-based diagnosis in endemic resource limited setting.
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Human schistosomiasis is a waterborne parasitic disease caused 
by blood flukes of the genus Schistosoma1,2. It constitutes a sig-
nificant public health problem causing the loss of 1,440 million 
years of full health worldwide, with approximately 659 million 
people at risk of acquiring infection2,3. More specifically, 
Schistosoma haematobium affects both the urinary as well as the 
genital tract. In female genital schistosomiasis (FGS)1, parasite 
egg deposition occurs in the genital tract and it is characterized 
by histologic vaginal or cervical mucosal inflammation4 and 
unique clinical findings5. FGS has been associated with infertility, 
a condition associated with negative social and psychological 
impacts in many low-income countries6. In addition, observational 
studies have suggested an association between FGS and 
prevalent HIV infection7,8, and HIV transmission and acquisition9.
Genital self-sampling has been described in the diagnosis of 
reproductive tract infections (RTI)10–12 in both adults and 
adolescents13 and has enhanced access to health services among 
hard-to-reach populations such as adolescents/young people14, 
and those who do not regularly access health screening 
services15,16. A high proportion of women, including those from 
resource-limited settings have been found to prefer vaginal 
specimen self-collection10,17 compared with clinic-based 
sampling. In addition to acceptability, two other factors make 
genital self-sampling advantageous; 1) the availability of vagi-
nal self-sampling is effective for improving participation in 
specific RTI screening programmes and 2) the sensitivity of 
PCR-based assays on self-collected specimens compares 
favourably with physician-performed sampling16,18.
The Bilharzia and HIV (BILHIV) study’s primary aim was to 
validate home-based self-sampling for the detection of 
Schistosoma DNA with vaginal and cervical swabs against provider 
obtained cervicovaginal lavage in a clinic setting in an endemic 
area in Zambia. The BILHIV study previously found that 
Schistosoma DNA was more frequently detected in genital self- 
collected specimens compared to clinic-collected cervicovaginal 
lavage19. Here, we describe the acceptability and feasibility of 
genital self-sampling for the detection of Schistosoma DNA in 
the BILHIV study. In addition, this study also analyses the 
demographic predictors for participant’s preference of home- 
based self-sampling over clinic-based sampling.
Methods
Study setting and participants
The Bilharzia and HIV (BILHIV) study was a cross-sectional 
study nested within two of the 12 HPTN 071 (PopART) 
communities in Livingstone, southern province of Zambia20. 
HPTN 071 (PopART) was a trial to measure the impact of an HIV 
combination prevention package, including universal test and 
treat20. Non-pregnant, sexually active women aged 18–31 who had 
previously been recruited for the HPTN 071 (PopART) population 
cohort were eligible for inclusion in BILHIV.
Sample collection and questionnaire
Between January and August 2018, specially trained population 
cohort research assistants visited women during the population 
cohort 36-month end of study follow up and enquired regarding 
an “expression of interest” in the BILHIV study. At a subsequent 
home visit, BILHIV Community Workers (BCW) evaluated 
study eligibility, provided participants with study information 
in the language of their choice, along with FGS education, and 
obtained written informed consent.
At the home visit, conducted in each participant’s household, 
the BCW provided participating women with instructions for 
urine collection and cervical and vaginal self-swabs using 
educational materials including an information sheet with 
diagrams of the female anatomy, model vagina, and test 
swabs. Photos in the World Health Organization’s “Female 
Genital Schistosomiasis Pocket Atlas” were also displayed as a 
visual aid. As shown in Figure 1, these educational materials were 
used to explain and demonstrate the procedure of self-collection 
of genital specimens. For swab self-collection, participants were 
instructed to hold a 6-inch vaginal swab (PrimeSwab, Longhorn 
Diagnostics, Texas, USA) at the 2 3/8-inch score mark and insert 
the swab vaginally until their fingers touched the labia minora. 
Participants moved the swab in a circular motion against the 
vaginal walls for a minimum of 15 repetitions. Similarly, for the 
cervical swab, participants were instructed to hold a 6 3/4-inch 
flocked swab (Miraclean, Shenzen, China) with a quadrilateral 
kite-shaped tip at the non-flocked end of the swab body and 
insert the swab vaginally until they met noticeable resistance. The 
participant then performed swab rotation as described above. The 
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Figure 1. (A) The Bilharzia and HIV Community Workers (BCWs) demonstrating the use of genital self-swabs by using a 3D model; (B) BCWs 
teaching by using the WHO female genital schistosomiasis atlas; (C) BCWs delivering questionnaires in hand-held tablets. Photo credit: A. 
Bustinduy; oral permission was obtained from subjects to publish these images. Images have also been edited (pixelated and cropped) to 
keep the identity of the subjects anonymous.
participant broke the shaft of each swab and placed the vaginal 
and cervical swabs in separate screw-capped microtubes 
(STARLAB, Hamburg, Germany). Both swab specimens and 
urine were placed in cool boxes for transportation to the laboratory.
Following written informed consent and specimen collection, 
the participants completed a non-anonymous questionnaire, 
with responses captured on hand-held tablets. The questionnaire 
assessed basic demographics, information regarding genital 
symptoms, sexual behaviour and also the participant’s assess-
ment of the acceptability of self-sampling, through their 
responses to 15 questions each measured on a five-point Likert 
scale (Extended data21; Table 1).
At a later date, participating women who were not currently 
menstruating attended Livingstone Central Hospital (LCH) cervical 
cancer screening clinic where a trained midwife performed 
a cervicovaginal lavage and images of the vagina and cervix 
were captured with a point-of-care colposcope (MobileODT, Tel 
Aviv Israel)19
Ethics and informed consent
All eligible participants providing written consent were recruited 
into the study. Participants who were unable to provide written 
informed consent were recruited in the presence of a witness 
with the participant placing their thumbprint on the consent 
form. The study was approved by the University of Zambia 
Biomedical Research Ethics Committee (reference number: 
011-08-17), the Zambia National Health Research Authority and 
the London School of Hygiene and Tropical Medicine research 
ethics committee (reference number: 14506). Permission to 
conduct the study was given by the Livingstone District health 
office and the superintendent of the Livingstone Central Hospital.
Data management and statistical methods
Acceptability in our study was measured by the following outcomes: 
the proportion of women who rated home based self-sampling to 
be “easy” or “very easy” (for each of urine, vaginal, cervical 
self-sampling), the proportion who didn’t experience “pain” while 
self-sampling (for each of vaginal, cervical self-sampling), the 
proportion who were willing to self-sample again “in the 
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Table 1. Baseline characteristics of 603 Zambian women living in Schistosoma haematobium endemic 






Age in years – Median (IQR) 24 (22-28) 26 (23-29) 24 (21-27) <0.001
Marital Status Single 258 (42.8%) 110 (34.5%) 148 (52.1%) <0.001
Married or 
Cohabitating
320 (53.1%) 193 (60.5%) 127 (44.7%)
Divorced or 
Separated
23 (3.8%) 15 (4.7%) 8 (2.8%)
Widowed 2 (0.3%) 1 (0.3%) 1 (0.4%)
Education (highest level) Any Primary School 167 (27.7%) 117 (36.7%) 50 (17.6%) <0.001
Any Secondary 
School
364 (60.4%) 173 (54.2%) 191 (67.3%)
Training in a Trade 59 (9.8%) 20 (6.3%) 39 (13.7%)
Degree or Higher 3 (0.5%) 3 (0.9%) 0 (0.0%)
None 10 (1.7%) 6 (1.9%) 4 (1.4%)
Employment status Working 408 (67.7%) 200 (62.7%) 208 (73.2%) 0.006
Not Working 195 (32.3%) 119 (37.3%) 76 (26.8%)
Current water contact None 512 (84.9%) 263 (82.5%) 249 (87.7%) 0.02
At Least Weekly 18 (3.0%) 11 (3.5%) 7 (2.5%)
Every 1–2 Months 30 (5.0%) 24 (7.5%) 6 (2.1%)
Every 6–12 Months 43 (7.1%) 21 (6.6%) 22 (7.8%)
Childhood water contact None 186 (30.9%) 96 (30.1%) 90 (31.7%) 0.22
At Least Weekly 381 (63.2%) 208 (65.2%) 173 (60.9%)
Every 1–2 Months 24 (4.0%) 12 (3.8%) 12 (4.2%)
Every 6–12 Months 12 (2.0%) 3 (0.9%) 9 (3.2%)
No 572 (94.8%) 294 (92.2%) 278 (97.9%) 0.006
Self-reported history of 
schistosomiasis
Yes 25 (4.2%) 20 (6.3%) 5 (1.8%)
Maybe 6 (1.0%) 5 (1.6%) 1 (0.4%)
*comparison of Community-A vs Community-B
future” (for each of urine, vaginal, cervical self-sampling), and 
the proportion who would prefer to “sample at home” (versus 
sampling in the clinic).
Participant data were entered using Open Data Kit Collect22. 
Continuous variables were summarized by mean and interquar-
tile range (IQR), and categorical variables by frequency and per-
centage. Participant characteristics were compared between the 
two communities using Wilcoxon-Mann-Whitney, chi-squared, 
and Fisher’s exact tests. The Mantel-Haenszel approach was used 
to obtain crude and age-adjusted odds ratios for the association 
of demographic variables with a participant’s preference for 
home-based versus clinic-based sampling.
Results
Of 1104 women screened for BILHIV eligibility, 54.5% 
(603/1105) were enrolled and all completed an initial home-based 
visit. Of those completing the initial home visit, 87.4% (527/603) 
completed clinic follow up visit (Figure 2). Unless otherwise 
stated, the denominator for the results presented reflects the 
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Figure 2. The Bilharzia and HIV study enrolment and sampling flow chart.
total study enrolment of 603. The median age was 24 years 
(IQR 22-28). More than half of participants, 60.4% (364/603), 
completed secondary school education and 59% (356/603) 
spoke primarily Nyanja (Table 1). Active schistosome infection 
was determined by detectable urine Circulating Anodic Antigen 
(CAA) (15.1%, 91/601) or microscopy (5.5%, 33/603), as 
previously described18. Compared to clinic-collected CVL 
(14/527, 2.7%), Schistosoma DNA was more frequently detected 
in genital self-collected specimens (24/603, 4.0%)19.
Acceptability and feasibility
Out of 603 women recruited, a high proportion indicated that 
self-collection of genital specimens was “easy” or “very easy” 
on a 5-point Likert scale for urine collection (96.2%; 580/603), 
vaginal swab (94.9%; 572/603), and cervical swab (86.6%; 
522/603) (Figure 3; Table 2). Most participants indicated that 
they would be willing to self-collect again in the future: urine 
97.0% (585/603), vaginal swab 96.7% (583/603) and cervical 
swab 96.5% (582/603). Substantially less than half of participants 
reported that it was “painful” to self-collect vaginal specimens 
(3.3%; 20/603) and cervical specimens (6.8%; 41/603) (Table 2). 
A high proportion of women (95.7%; 577/603) indicated that 
they would ‘recommend self-sampling to my friends’. Overall, 
most women preferred to collect specimens at home (90.0%; 
543/603), compared with clinic-based sampling (10.0%; 60/603), 
(Table 3). Women from both communities preferred to self-collect 
specimens from home (Community A: 89.3%, 285/319; 
Community B: 90.9%, 258/284; p=0.5) compared with attending 
the health facility. Participants preferred “self-sampling at home” 
over provider-based sampling in the clinic due to greater privacy 
(65.0%, 353/543), convenience (51.4%, 279/543) and lack 
of transportation (17.7%, 96/543) (Table 3). Participants in 
Community B were more confident (99.3%; 282/284) than par-
ticipants in Community A (91.5%; 292/319) (p<0.001) that they 
collected the specimens correctly.
Overall, there was little evidence that education, marital status, 
community of residence, employment status, language spoken, 
and age were associated with a participant’s preference for home- 
based sampling over clinic-based sampling (Table 4). Given 
that the preference for self-sampling was universal across the 
groups examined in the crude analysis, we did not undertake 
multivariable analysis.
Discussion
Vulnerable women and girls in sub-Saharan Africa are afflicted 
by FGS, a chronic gynaecologic condition. Current diagnostic 
strategies are limited as they rely on resources that are seldom 
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Figure 3. Ease of self-sampling in 603 Zambian women by specimen type.
Table 2. Acceptability of genital self-sampling for women from the BILHIV study (n=603).











I found vaginal self-sampling to be 34.5 (208) 60.4 (364) 2.0 (12) 3.2 (19) 0 (0)
I found cervical self-sampling to be 26.2 (158) 60.4 (364) 5.0 (30) 8.5 (51) 0 (0)
I found collecting my own urine sample to be 56.2 (339) 40.0 (241) 1.7 (10) 2.0 (12) 0.2 (1)
Question Strong yes Yes Maybe No Strong no
I would be willing to take a vaginal self-sample 
in the future.
42.1 (254) 54.6 (329) 2.2 (13) 1.2 (7) 0 (0)
I would be willing to take a cervical self-sample 
in the future.
37.0 (223) 60.0 (359) 2.5 (15) 1.0 (6) 0 (0)
I would be willing to takes a urine self-sample 
in the future.
38.6 (233) 58.4 (352) 2.3 (14) 0.7 (4) 0 (0)
I would recommend self-sampling to my 
friends.
29.0 (175) 66.7 (402) 1.8 (11) 2.0 (12) 0.5 (3)
Self-collecting a vaginal swab was painful. 0.33 (2) 3.0 (18) 3.7 (22) 77.1 (465) 15.9 (96)
Self-collecting a cervical swab was painful. 0 (0) 6.8 (41) 9.6 (58) 71.3 (430) 12.3 (74)
I am confident I collected the specimens 
properly.
29.0 (175) 66.2 (399) 2.7 (16) 2.2 (13) 0 (0)
I feel confident I collected a sample from my 
vagina.
25.7 (155) 72.3 (436) 1.3 (8) 0.7 (4) 0 (0)
I feel confident I collected a sample from my 
cervix.
24.5 (148) 71.6 (432) 3.5 (21) 0.3 (2) 0 (0)
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Table 3. Results of the BILHIV study patient experience surveys for 603 
women living in Schistosoma haematobium endemic areas in Livingstone, 
Zambia*.
Question Participant responses % (n)*
Do you prefer to take your samples 
at home, or would you prefer to 
take samples at the clinic?
Clinic 10.0 (60)
Home 90.0 (543)
I prefer doing samples at home 
because** It is more convenient 51.4 (279)
I don’t have transportation 17.7 (96)
I don’t have childcare 2.6 (14)
I need to work 6.2 (34)
I have more privacy at home 65.0 (353)
It is easier to sample at home 66.3 (360)
Other reason 11.4 (62)
I prefer having samples performed 
in clinic because** I don’t have privacy at home 26.7 (16)
I had discomfort with 
collecting my own samples 13.3 (8)
I was unsure if I did the 
sampling properly 30.0 (18)
I’d like more supervision 28.3 (17)
Other 28.3 (17)
*Proportions for home-based testing have a denominator of 543, proportions for clinic-based 
testing have a denominator of 60
**Participants could choose more than one answer
available in low-income settings23. A self-collection method that 
minimises reliance on health care providers would represent a 
scalable alternative method for FGS community-based diagnosis 
in endemic resource limited settings, but only if it is an accept-
able procedure to perform. However, barriers to FGS diagno-
sis still remain, including costs, limited access to point-of-care 
diagnostics, and challenges with maintaining the cold chain. The 
cost of genital swabs (0.50$/vaginal swab and 0.30$/cervical 
swab) and molecular testing (6.68$/test) may be affordable in 
some research settings, but more field-appropriate and scalable 
methods should be investigated. Home based genital self-sam-
pling for the diagnosis of FGS was highly acceptable among 
women aged 18 to 31 years of age enrolled in the BILHIV 
study in Zambia. All participating women provided all three 
self-collected specimens (urine, vaginal and cervical swabs), 
and a high proportion found vaginal self-sampling and cervical 
self-sampling “easy” or “very easy”.
Our study is in agreement with other studies in which self-swabs 
were acceptable to women in geographically and ethnically 
diverse target populations10,18,24. In a study of Haitian immigrants 
living in the USA, the acceptability of unsupervised cervical 
HPV self-sampling using written instructions revealed that self- 
sampling was more acceptable to the majority of the women than 
clinician-administered sampling24,25, and it increased screening 
coverage among female clinic non-attendees15,26. Also in an Italian 
study, cervical self-sampling using either a brush or a self-lavaging 
device was acceptable and both modalities were preferred to 
clinician-sampling (n=117, 68%)27. A systematic review on the 
acceptability of self-sampled screening for HPV DNA reported 
that self-sampling was highly acceptable among study participants 
in 37 studies from 24 countries across five continents25. Despite 
heterogeneity in study design, the studies in this meta-analysis 
suggest that self-sampling is well accepted by participants 
regardless of education, marital status, community of residence, 
employment status, language spoken, and age. Supported by these 
data we can conclude that our findings are likely generalizable 
across geographic areas and among women of varying educational 
background, cultures, and ethnic groups.
Substantially over half of the women in the BILHIV study 
reported that self-collection of specimens was “easy” or “very 
3DJHRI
:HOOFRPH2SHQ5HVHDUFK/DVWXSGDWHG2&7
Table 4. Factors associated with the choice of home-based sampling over clinic-based sampling, adjusted for age.
Exposure n (home-based sampling)/N (%) Crude OR 95% CI aOR 95% CI p-value
Education None or any primary 
school
166/177 (94%) reference reference 0.31
Any secondary 
school
323/364 (89%) 0.52 0.26 – 1.05 0.45 0.22 – 0.91
Trade training or a 
degree
54/62 (87%) 0.45 0.17 – 1.18 0.47 0.17 – 1.27
Language* Nyanja 328/356 (92%) reference reference 0.11
Tonga 114/127 (90%) 0.75 0.37 – 1.50 0.75 0.38 – 1.52
Lozi 72/86 (84%) 0.44 0.22 – 0.88 0.44 0.22 – 0.88
Bemba 26/30 (87%) 0.55 0.18 – 1.71 0.55 0.18 – 1.70
Marital status Single 228/258 (88%) reference reference 0.49
Married 292/320 (91%) 1.37 0.79 – 2.37 1.58 0.85 – 2.95
Divorced or widowed 23/25 (92%) 1.51 0.34 – 6.77 1.61 0.31 – 8.34
District Community A 285/319 (89%) reference reference 0.54
Community B 258/284 (91%) 1.18 0.69 – 2.03 1.14 0.66 – 1.97
Employment 
status
Not working 367/408 (90%) reference reference 0.91
Working 176/195 (90%) 1.03 0.58 – 1.84 1.07 0.60 – 0.90
Age (years) 18–22 144/158 (91%) reference -- -- 0.62
23–26 207/228 (91%) 0.96 0.47 – 1.95 -- --
27–31 192/217 (89%) 0.75 0.37 – 1.49 -- --
easy” (urine 96.2%, vaginal swab 94.9% and cervical swab 
86.6%). This is consistent with other studies that showed that study 
participants found genital self-sampling or the use of a self-sam-
pling device easy to use24,25. The proportion with this outcome was 
slightly lower for cervical than vaginal sampling. Swab length 
and more invasive technique may account for the lower propor-
tion of women who found cervical self-sampling “easy” or “very 
easy”, compared with vaginal self-sampling. As another measure 
of acceptability, over 96% of women in the BILHIV study indi-
cated that they were willing to self-collect all three specimens again 
in the future, which is similar to proportions reported in HPV 
self-collection research using cervical swabs24,28 and curable 
STI research using vaginal swabs29. Our study, as others, further 
showed that a high proportion of the women indicated that they 
would recommend self-sampling to a friend25. This shows prom-
ise for the future use of peer-encouragement in the use of genital 
self-sampling procedures.
Our study also revealed that 90.0% of participants preferred 
self-sampling at home over provider-based sampling at the 
clinic. Our findings are similar to studies reporting a high 
preference for home self-sampling25,27,28. However, a recent 
meta-analysis found that the pooled estimate of women who 
preferred self-sampling to clinic based sampling was 59% 
(48 – 69%)25. There are some possible explanations for this. 
While a binary outcome was evaluated in the meta-analysis, the 
individual reasons for preferring home-based self-sampling to 
health-facility sampling vary across studies. In the BILHIV study 
questionnaire, the questions regarding preferences for home vs. 
clinic sampling included a comprehensive range of options that 
included ‘privacy’, ‘convenience’, ‘transportation’, ‘work con-
flicts’, ‘no child-care’, and ‘ease’ among others. Second, other 
work reports that some women preferred clinic sampling to home 
based self-sampling because they were not comfortable with 
touching their genital areas, they were unsure about the safety of 
self-testing, or they were concerned they would perform the test 
incorrectly30.
This study benefited from HPTN 071 (PopART) because HPTN 
071 (PopART) staff introduced the BILHIV study to all prospec-
tive BILHIV participants that enabled them to be familiar with 
the study even before it began. Further, the BILHIV study was 
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implemented in communities that were already familiar with 
the organization and the staff that worked under the HPTN 071 
(PopART) study. In addition, former HPTN 071 (PopART) staff 
in the two study communities continued to work in the same com-
munities under the BILHIV study. This enabled improved study 
performance because of the existing rapport between BILHIV 
staff and the community members. Standardized questionnaires 
were used to reduce observer bias and were performed at the 
time of self-sampling to minimize recall bias. However, it is 
important to note that the participation in the BILHIV study was 
limited to women who took part in the HPTN 071 (PopART) 
population cohort. In this scenario, bias may be related to a 
Hawthorne effect. This observer effect can occur as participants 
in a study alter their behaviour as a result of regular follow-up 
within a cohort31. The HPTN 071 (PopART) population cohort was 
selected through a random sampling of households and random 
selection of one individual within each household31. BILHIV 
study participants were selected by querying eligible members of 
the population cohort for an “expression of interest”. There may 
be selection bias, in that women who expressed an interest in 
participating in the study may not be representative of the popu-
lation as a whole and findings may not be generalizable to other 
sub-Saharan African communities. A larger study of genital 
self-sampling should be performed, preferably in areas of varied 
schistosomiasis endemicity.
Conclusion
We have shown high acceptability and feasibility of genital 
self-sampling for the diagnosis of FGS in young women 
(18–31 years) in a schistosomiases endemic area in Zambia. 
This practice has potential to increase FGS surveillance in other 
endemic populations. The majority of participants reported that 
specimen self-collection was “easy” or “very easy” with high 
willingness to participate in future home-based self-sampling. 




LSHTM Data Compass: BILHIV acceptability dataset, 
https://doi.org/10.17037/DATA.0000161832.
This data is under restricted access due to the assurance given 
to participants that responses would be kept completely 
confidential. This is particularly important due to the sensitivity 
of the data produced. The data set can be accessed by completing 
the Request Form, which requires that the intended use for the 
data is specified. Data available under the LSHTM Data Compass 
Data Sharing Agreement.
Extended data
Figshare: Extended data_Figshare.docx, https://doi.org/10.6084/
m9.figshare.12023382.v121.
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Thank ou for this input. We have added our point regarding performing other 
studies in schistosomiasis endemic communities in different regions to the discussion. 
Lines 67-70 under discussion. 
 
Incl ion c i e ia (e.g age, non-p egnanc ) a e no  a ed in Me hod . 
 
We apologi e for an  confusion. In the BILHIV stud , women were eligible if the  were 
se uall  active aged 18-31 who were not pregnant and had previousl  been recruited 
3DJHRI
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for the HPTN 071 (PopART) population cohort were eligible for inclusion in BILHIV. In 
the on-line version (https://wellcomeopenresearch.org/articles/5-61) the inclusion 
criteria are stated in the first sentence of the abstract methods. In the main 
manuscript, the inclusion criteria are stated in the Methods section in the second 
sentence methods under stud  setting and participants . In the tracked-changes 
manuscript we have highlighted these areas for clarit . 
 
Wh  info m abo  a pending pape  b  S a  e  al.? Mo e in e e ing o kno  abo  a 
p obabl  pending pape  p e en ing he lab finding  (SH DNA). 
 
We agree that the section in question should be modified. In the section Sample 
collection and questionnaire  in the final sentence, we have removed the wording 
Sturt, A e  al. paper under review  and instead we reference the BILHIV stud  
manuscript. As ou have suggested, this manuscript provides the full laborator  
results. 
 
A 5-poin  Like  cale ha  been ed. Thi  info ma ion ho ld be p e en ed in he Me hod  
and no  in he Re l . 
 
We apologi e for an  confusion, the information about the Likert scale was included in 
the methods section in our final submitted manuscript, but it seems not to have been 
uploaded into the online manuscript. We have highlighted this in the accompan ing 
manuscript. 
 
No info ma ion he he  he e ionnai e a  pe fo med anon mo l  o  no , appa en l  
no  if one look  a  he field image. Then he e o ld ha e been a ni e oppo ni  o 
nco e  a io  ea on  fo  epo ed lack of confidence, accep ance, comfo  e c  e en 
onl  epo ed in a mino i  of he omen.  
 
You are correct that the questionnaire was not performed anon mousl . We have 
clarified this in the methods. 
 
I info ma ion abo  he diffe en  dialec  in Table 1 of in e e  fo  he eade ? 
 
Thank ou for this input, although we agree with the reviewer that dialects are not 
directl  of importance to the stud  outcome, we would like to keep them in the table 
as the  contribute to a more holistic appreciation of the stud  participants and their 
background. This ma  be of interest for certain readers.  
 
In e e ing ha  32.3% of omen a e gi en he a  a  No  o king . 
 
We agree that this is interesting. The women were asked the question are ou 
currentl  working?  with es/no answer. These data reflect their self-reported 
response to this question. 
 





We agree that the variable regarding childhood water contact is subject to recall bias. 
However, we thought this information would provide the reader with information 
regarding the participant s perceived level of e posure. 
 
Ho  ha  elf- epo ed hi o  of chi o omia i  been a e ed? 
 
The self-reported histor  of schistosomiasis was not further assessed be ond the 




N=603 a ed 17 ime . Sho ld be ade a e o men ion once, he n mbe  of d  
pa icipan . 
 
Thank ou for this input. We have repeated the total enrollment number to clarif  the 
denominator for man  of the presented proportions. 
 
Conf ing ha  he pe cen age  in Table 3 (I don  ha e an po a ion, I ha e mo e p i ac  
a  home) a e diffe en  f om ho e in he main e  (17.7%  15.9%; 65.0% . 58.5). 
 
Thank ou for catching this! Outcomes for this variable should be divided b  the 
proportion of women in the sampling categor  (prefer to sample at home, n=543). In 
the abstract and the main te t, these proportions were mistakenl  reported out of 





FGS i  a ch ic g aeg gica  c di i  ha  aff ic  e ab e e  Wha  i  mean  b  
lne able ? 
 
In the setting of environmental health emergencies, the WHO describes vulnerabilit  
as the degree to which a population, individual, or organi ation is unable to 
anticipate, cope with, resist, or recover from the impact of disasters . We feel this 
vulnerabilit  also describes well the plight of women in sub-Saharan Africa in 
relationship to FGS, as an underreported neglected ailment. Thus, we suggest that the 
term could be maintained. 
 
C e  diag ic a egie  a e i i ed a  he  e   e ce  ha  a e e d  a ai ab e i  
-i c e e i g . Self- ampling doe  no  con ib e ignifican l  o ol ing hi  p oblem, 
onl  o mino  e en , ha ing he omen o pe fo m he ampling hem el e  in ead of a 
heal h ca e p o ide  (e.g a n e). O he  majo  co  ill emain, incl ding lab echnician , 
e ipmen , eagen  e c. 
 
Thank ou for this input. We agree that man  of the other costs will remain and we 
have attended to this in the manuscript discussion. However a full cost-effective 
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anal sis was be ond this pilot work. 
 
Pa icipan  ho ld al a  be ackno ledged. 
 
Thank ou for bringing this oversight to our attention. We have acknowledged the 
participants.  
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OCCUPATIONAL HEALTH DEPARTMENT 
 
Health Surveillance Assessment 
 





















*Where a baseline blood sample has been taken prior to work commencing, which will be stored at 














The above named employee is: 
 
FIT FOR WORK 
 
 










Appendix 4  LSHTM CL1/2 Summary Protocol and Risk Assessment 
CL1/2 Summary Protocol and Risk Assessment   
Faculty of Infection and Tropical Disease 
BILHIV_CVL03 v1 Page 1 of 9 
Approved by PI: Amaya Bustinduy : 
Effective Date: 27/06/2019   
Review Date: 27/06/2019 
Note: Principal Investigator takes ownership of this document and is responsible for sending a 
COMPLETE signed copy to Health and Safety Department 
Protocol Number BILHIV_CVL03 
Protocol Title 
MAGPIX Assays Using Human Cervicovaginal 
Lavage 
 
Organism Schistosoma haematobium 
Route(s) of Infection  
Cercariae penetrate transdermally after 
hatching from a fresh-water snail. This 
pathogen is not transmitted human – to 
human. 
 
The infectious stage of this organism 
(cercariae) will not be present in this work. 
There may be presence of S. haematobium 




Inner lab (234d) containing a category 2 
hood and microcentrifuge 
Project Supervisor Amaya Bustinduy 
Disinfectants 
10% chloros for solid and liquid waste that has 
been in contact with CVL. 
 
The hood will be used for specimen opening and 
centrifugation. Further work will be performed 
on the bench. A specific area will be set aside for 
specimen handling.  This area will be lined with 
Benchkote, shiny (non-absorbent) side down, 
which will be removed after use. Surfaces will be 
cleaned with 70% ethanol. 
 
Waste Disposal 
Liquid waste will be decontaminated 
overnight in 10% hypochlorite solution. 
 
Solid waste will be autoclaved. 
 
BILHIV_CVL03 v1  Page 2 of 9 
Approved by PI: Amaya Bustinduy  
Effective Date: 27/06/2019   
Review Date: 27/06/2019 
Written by:  Amy Sturt 
Date: June 14, 2019 
I, the undersigned, have reviewed the assessment of the work titled above, and 
declare that any risks will be controlled by the methods stated on this form and 
that the work will be carried out in accordance with laboratory protocols. 
Approved by: 
Faculty Safety Supervisor  




Is work carried out in BSF? ☐ Yes ☒ No 
Approved by:  
BSF Manager 
 
Approved by:  
Principal Investigator 
 
Date Approved:  27Jun2019 
This assessment should be reviewed within 3 years of approval date, or sooner in 
the event of a change in procedure or an incident occurs. 
Date received by H&S Department:   
To be read in conjunction with the appropriate Laboratory and Specific Code of Practices 
 
Summary of Revisions 
No previous versions 
 
I have read and understood this Risk Assessment and will use the control 
methods identified. 
Name Signature Date 
BILHIV_CVL03 v1  Page 3 of 9 
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LABORATORY TECHNIQUE  
Give a brief description of the technique to be used 
In the MAGPIX system, beads pass into an imaging chamber containing a magnet. The beads 
sit in a monolayer on the magnet. LEDs excite the beads and the flourescence is detected by 
a CCD camera. This method is used to detect biomarkers in body fluids.  
 
RISKS/HAZARDS IDENTIFIED:   
Please list the hazards / risks of this procedure.  e.g., use of sharps, use of poisons. 
EMD Millipore Proprietary Reagents 
x Sodium azide or proclin has been added to some reagents (L-SAPE 3-11, L-WB, 
MXHSM, MHX1060-1-3, MSH6060-1/2, MXH8060-1/2) as a preservative. Dispose of 
unused contents and waste in accordance with local regulations. Other agents can 
cause eye or skin irritation. 
 
Sodium Azide 
x Sodium azide is used as a preservative in Merck Millipore’s Human Cytokine Standard. 
This standard is not used neat. It is diluted by five to six serial five-fold dilutions and 
25 microliters is added to 5 wells in the 96 well plate. 
x Sodium azide is highly toxic if swallowed.   
x Potential risk through inhalation of dust and aerosols. 
x Contact with acids liberates toxic gas, but no acids are used in this protocol. 




x Risk of shock from electrical appliance. 




x MAGPIX microbeads are damaging to the environment. 
 
Cervicovaginal lavage that may be infected with human pathogens 
x Risk of infection (e.g. hepatitis B) when working with unscreened CVL. 
 
Bio-Rad Magnetic Plate Washer 
x The handheld washer used to wash to wash plates during the MAGPIX assay has 
minimal magnetic shielding.  
x Dangerous to pacemaker wearers.   
 
Vortex 
BILHIV_CVL03 v1  Page 5 of 9 
Approved by PI: Amaya Bustinduy  
Effective Date: 27/06/2019   
Review Date: 27/06/2019 
x Spills and splash injuries may occur. 
 
Additional Hazards Identified: 
No sharps will be utilized in this work 
 
CONTROL MEASURES IN PLACE: 




x Wear lab coat and gloves throughout the procedure. 
 
EMD Millipore Proprietary Reagents 
x Sodium azide in very low concentrations may be poured down the drain followed by 
large amounts of water to prevent any appreciable build-up of azide metal. 
 
Sodium Azide 
x Read MSDS prior to use 
x Long-sleeved fastened laboratory coat and gloves to be worn.   
x Safety goggles to be worn where splashing is possible. 
x Sodium azide in very low concentrations may be poured down the drain followed by 
large amounts of water to prevent any appreciable build-up of azide metal. 
 
Mini Centrifuge 
x Centrifuge must be PAT tested and carry a certified sticker. 
x All users should be instructed on the safe use of the equipment. 
x Always use rotator lid and balance odd samples with a counter weight, i.e. a similar 
tube containing water.  
 
MAGPIX Microspheres  
x Do not dispose of beads down the sink. The beads should be filtered out of solution 
though a sintered funnel unit and disposed of as hazardous waste.  
x Used plates should be discarded in the autoclave bin 
 
CVL 
x All biological materials should be handled as potentially hazardous. Follow universal 
precautions when handling and disposing of potentially infectious agents. Please see 
CVL02 CVL Risk Assessment for additional details.  
x Samples will be centrifuged and aliquoted prior to use in the MAGPIX machine to limit 
exposure to S. haematobium ova and other potentially infectious agents as detailed in 
CVL02. Centrifugation and specimen lid opening will be performed in a safety hood. 
x Wear lab coat, gloves, mask and safety glasses when using unscreened biological 
materials. 
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x Never work with your own CVL.  
x Ensure that your Hepatitis B vaccination is up to date.  Students and other staff who 
do not have a Hepatitis B vaccination should be made aware that all human bodily 
fluids should be considered infectious and should follow all other recommendations 
within this risk assessment.  
x All staff using this pathogen should report to Occupational Health prior to 
commencing work. 
x Liquid and solid waste will be decontaminated overnight in 10% hypochlorite solution. 
 
Magnetic Plate Washer  
x Pacemaker wearers should use an automated plate washer with a magnetic plate. 
x Set the plate shaker at a speed that will provide the maximum orbital mixing without 
splashing liquid outside of the plate wells (setting 5-7 or 500-800 rpm). 
x Wear eye protection given the risk of splashing with potentially infectious fluids. 
 
Vortex 
x Use an appropriate vessel for the sample (screw cap rings are preferable) 
x Ensure the cap or lid is on tight before vortexing. 
x Grasp the tube with a paper towel, and vortex the tube perpendicularly 
x To avoid spills, wait 1-2 minutes before opening the vessel after vortexing.  
 
 
Summary of Procedures & Precautions 
Procedure  Risks and Control Measures 
Protocol – SOP if appropriate 
 
1. See the risk assessment entitled “Handling 
Previously Collected Human Cervicovaginal 
Lavage (CVL ” for further details regarding 
specimen opening, centrifugation and transfer 
to the bench. 
 
2. Add 200 uL of wash buffer into each well of the 
plate. Seal and mix on a plate shaker for 10 
minutes at room temperature 
 
3. Decant Wash Buffer and remove residual 
amount from all wells by inverting plate and 






Wash buffer can be irritating to 
skin 
 
Control Measure: wear PPE 





Plate shakers can splash liquid. 
 
Control Measure: Set the plate 
shaker at a speed that will provide the 
maximum orbital mixing without 
splashing liquid outside of the plate 
wells (setting 5-7 or 500-800 rpm). 
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4. Add 25uL of each Standard or Control into the 
appropriate wells. Assay Buffer should be used 
for 0 pg/mL standard (Background). 
 
5. Add 25 uL of Assay Buffer to the sample wells. 
 
6. Add another 25uL of Assay Buffer to the 
background, standards, and control wells (in 





7. Add 50uL of CVL into the appropriate wells 
 
8. Vortex mixing bottle and add 25uL of mixed 
beads to each well (during addition of beads, 
shake bottle intermittently to avoid settling). 
 
9. Seal the plate with a plate sealer. Wrap the 
plate with foil and incubate with agitation on a 
plate shaker for 2 hours at room temperature. 
 
10. Gently remove well contents and wash plates 2 
times.  
 
11. WASH STEP: Rest plate on handheld magnet for 
60 seconds. Remove well contents by decanting 
the plate in an appropriate waste receptacle. 
Gently tap on absorbent pad to remove residual 
liquid. Wash plate with 200uL Wash Buffer by 
removing plate from magnet, adding Wash 
Buffer, shaking for 30 seconds, reattaching to 
magnet, letting beads settle for 60 seconds. 
Repeat. 
 
12. Add 25 uL of Detection Antibodies into each 
well 
 
Wear PPE (gloves, lab coat, face and 







Standard contains low 
concentrations of sodium azide 
but can be harmful if swallowed 
and can cause eye damage.  
 
Control Measure: Wear PPE 
(gloves, lab coat, face and eye mask) 
at all times. Use appropriate 
disposal techniques to avoid 
reactions of high concentrations with 
lead and copper plumbing  
 
 
Risk Identified: Some wells will 
contain small amounts of sodium 
azide and other skin/eye irritants. 
 
Control Measure:  
Wear PPE (gloves, lab coat, face and 
eye mask) at all times. 
 
Collect in appropriate waste 
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13. Seal, cover with foil, and incubate with agitation 





14. Add 25uL of Streptavidin-Phycoerythrin to each 
well containing the 25uL of Detection 
Antibodies 
 
15. Seal, cover with foil, and incubate with agitation 
on a plate shaker for 30 minutes at room 
temperature. 
 
16. Gently remove well contents and wash plates 2 
times (see step 11 above). 
 
17. Add 150uL of Drive Fluid to all wells. Resuspend 
the beads on a plate shaker for 5 minutes. 
 





Risk Identified: Human cytokine 
detection antibodies can cause 
eye irritation. 
 
Control Measure: Wear PPE 
(gloves, lab coat, face and eye mask) 





Phycoerythrin can cause eye 
irritation. 
 
Control Measure: Wear PPE 
(gloves, lab coat, face and eye mask) 





10% chloros for solid and liquid waste 
that has been in contact with CVL. 
 
The hood will be used for specimen 
opening and centrifugation. Further 
work will be performed on the bench. 
A specific area will be set aside for 
specimen handling.  This area will be 
lined with Benchkote, shiny (non-
absorbent) side down, which will be 
removed after use. Surfaces will be 
cleaned with 70% ethanol. 
 
 
BSF Procedures & Precautions 
If work is carried out in BSF, please complete table below 
Risks  Control Measures 
Allergen exposure:  
Needlestick/Sharps injury:  
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Transport:  
Pathogen exposure:  
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Appendix 6  University of Zambia biomedical research committee ethical approval 
Sub-studies amendment, reference 011-08-17 
 
UNIVERSITY OF ZAMBIA 
BIOMEDICAL RESEARCH ETHICS COMMITTEE 
Telephone: 260-1-256067                                  Ridgeway Campus 
Telegrams: UNZA, LUSAKA                        P.O. Box 50110 
Telex: UNZALU ZA 44370                        Lusaka, Zambia 
Fax: + 260-1-250753                                                                                                             E-mail:  unzarec@unza.zm 
Federal Assurance No. FWA00000338                                                                    IRB00001131 of IORG0000774 
 
 
2nd August, 2019. 
 
Your Ref:  011-08-17. 
 
Dr. Amaya Bustinduy, 
ZAMBART, 
P.O Box 50697, 
Lusaka. 
 
Dear Dr. Bustinduy, 
 
            RE: AMENDMENTS TO: “VALIDATION OF HOME BASED SAMPLING AND VAGINAL  
                   SELF SAMPLING FOR THE DIAGNOSIS OF FAMALE GENITAL SCHISTOSOMIASIS  
                   (FGS) IN ZAMBIAN WOMEN WITH AND WITHOUT HIV SEROCONVERSION”                            
                   (REF. No. 011-08-17) 
 
We acknowledge receipt of your request for amendments to the aforementioned protocol in which you are 
proposing to investigate the association of cervicovaginal bacteria (in the protocol referred to as 
mic bi a ) a d he  e all  a mi ed i fec i  i h FGS.  
 
The changes were reviewed and approved as follows: 
1. More information has been added to the Secondary Objectives and to the Outcome Measures. 
2.  More information has been added to the literature review.  
3. More information has been added to the methodology in regards to the hospital visits and to the   
Genital samples. 




Sody Mweetwa Munsaka, BSc., MSc., PhD 
CHAIRPERSON 
Tel: +26099925304 
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6DIHW\,QIRUPDWLRQ ./HWWHU)'$$SSURYDO  
,QYHVWLJDWRU&9 $%XVWLQGX\&9B-XO\B 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,QYHVWLJDWRU&9 6WXUWB&9BBB/6+70  
,QIRUPDWLRQ6KHHW %,/+,91\DQMD  
,QIRUPDWLRQ6KHHW %,/+,9%HPED  
,QIRUPDWLRQ6KHHW %,/+,97RQJD  
$GYHUWLVHPHQWV %,/+,96WXG\)O\HU81=$%5(&  
,QIRUPDWLRQ6KHHW %,/+,9&RQVHQW81=$%5(&  
,QIRUPDWLRQ6KHHW %,/+,9,QIRUPDWLRQ6KHHW81=$%5(&  
3URWRFRO3URSRVDO 81=$%5(&3URWRFRO%,/+,99/6+70  
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5  
2WKHU *&3B*&3&HUWLILFDWH5  
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Appendix 9  Associated workshop, meeting, and conference presentations 
 
American Society of Tropical Medicine and Hygiene National Meeting (69th), November 17-
21, 2020. Toronto, Ontario, Canada. Oral Abstract #1565. The role of vaginal inflammation 
in HIV-1      F   .  
 
London School of H giene and Tropical Medicine. Research Degree Student s Poster Day  
March 2020. The role of vaginal inflammation in HIV-1 vulnerability in Zambian women 
   . 
 
London School of Hygiene and Tropical Medicine. International Statistics and Epidemiology 
Monthly Meeting, January 19, 2021. London, United Kingdom. G    
      . 
 
London School of Hygiene and Tropical Medicine. Clinical Research Department Laboratory 
Group Monthly Meeting, March 16, 2021. London, United Kingdom. A    
genital schistosomiasis with the cervicovaginal microbiota and reproductive tract 
   . 
 
